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Abstract
Poorly water-soluble drugs with dissolution as the rate-limiting step in gastrointestinal 
absorption commonly show increased bioavailability when dissolution is improved by 
conversion to the amorphous form. In this study, different techniques were employed 
to convert a model drug, indomethacin, into the amorphous state. The techniques 
involved the use of spray-drying and supercritical carbon dioxide (SC-CO2) as an 
antisolvent and as a solvent. The products were characterised using differential 
scanning calorimetry (DSC) and Powder X-ray diffraction (PXRD).
In the spray drying method, indomethacin was co-spray dried with microcrystalline 
cellulose (MCC) and polyvinylpyrrolidone (PVP) at various proportions. At 20% PVP 
and above, amorphous indomethacin could be produced but MCC had no effect on 
crystallinity. When SC-CO2 was used as an anti solvent, it was not possible to form 
amorphous indomethacin or coprecipitates of indomethacin-PVP. After modification 
of the rig, SC-CO2 was employed as a solvent. Coprecipitated indomethacin at various 
PVP weight fractions were successfully prepared, and amorphous products were 
obtained at PVP weight fraction of 0.80 and above. The dissolution rates of 
indomethacin-PVP mixtures prepared using SC-CO2, physical mixing and solvent 
evaporation methods were compared. PVP enhanced the dissolution of indomethacin 
at low concentration but increase in PVP content above 30% retarded the dissolution 
rate. The dissolution was dependent on the PVP content and the preparation method. 
The stability of indomethacin-PVP mixtures at different temperatures and relative 
humidities was monitored over a 3-month period. Coprecipitation of indomethacin- 
PVP retarded the crystallization process. The coprecipitates where indomethacin 
existed in completely amorphous form did not crystallize after storage at 30, 50 and 
70 °C for 3 months. Similarly, coprecipitation of indomethacin with PVP also retarded 
the crystallization process at 35% RH for 3 months. At 76% and 98% RH, products 
absorbed large quantities of water but did not crystallize.
In summary, a solvent free, porous and rapid dissolution amorphous indomethacin can 
be prepared by SC-CO2 based process. This method could provide a viable and 
practical alternative to spray drying for the production of amorphous material.
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Chapter 1_________________________________________________________________________________Introduction
Solids can either be crystalline or amorphous in their structures. In the case of 
polymers, it is even more common to find a combination of both crystalline and 
amorphous regions within the same polymer structure with one of them available in a 
higher concentration than the other. If this solid is heated, the crystalline part 
undergoes melting whereas the amorphous part undergoes glass transition.
1.1 Crystalline materials
A solid crystal is a mass of ions, atoms or molecules, which are packed in a neat, 
fixed, rigid and orderly fashion; having both short and long range, order. This high 
degree of order results in the development of definite external crystal faces resulting 
in a certain external shape called the crystal habit. The crystals may vary in the 
development of the various faces and size, but the angle between any two adjacent 
faces is a constant value, described by the law of constant interfacial angles, which 
was proposed in 1784 by Hauy (Mullin, 1997).
The basic unit in a crystal is called a unit cell and repetition of this unit cell in three 
dimensions gives the crystal. Depending on the structure of the molecule itself and 
many other factors such as crystallization conditions, different crystal habits can be 
obtained, such as needle, tabular, lamellar, and columnar (Florence and Attwood, 
1998). If a crystalline solid is heated, it undergoes melting at a certain specific 
temperature which is characteristic to the material being heated.
Melting is a first order phase transition which entails a well-known process. 
Specifically, that upon heating a crystalline solid its temperature will start rising up to 
the melting point. Due to latent heat, the temperature will stop rising until all the solid 
mass melts. Once all have melted, the temperature resumes its rise while heating 
continues (FigureI.l). Hence a first order transition involves both a latent heat and a 
change in the heat capacity.
21
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heat
melting
temperature
temperature ►
Figure 1.1 Plot of heat versus temperature for crystalline material.
1.1.1 Crystallization
Crystallization can be considered to pass through three successive phases.
a. Supersaturation of the solution: can be achieved in different ways such as 
solvent evaporation; cooling; a chemical reaction which changes the properties 
of the solute, or by the addition of a precipitant.
b. Formation of crystal nuclei (nucléation): It is not sufficient to have a 
supersaturated system for crystallization to take place. The presence of seeds 
or nuclei, on the surface of which the material can be deposited and 
crystallized, is essential. These nuclei can be obtained through artificially 
seeding of the supersaturated solution with particles of the same compound to 
enhance deposition and precipitation from solution on the surface of these 
seeds. Dust particles, impurities or even container particles can act as seeds 
that enhance deposition of crystals from solution on their surfaces. Nucléation 
can be triggered in different ways such as mechanical shock, application of 
high pressure or friction within the solution and agitation (Mullin, 1997). 
Spontaneous nucléation can sometimes be achieved without the need for
22
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seeding; in this case collision between molecules of the solute in solution takes 
place and leads to nuclei formation. Primary nucléation is a term given to the 
type of nucléation which is either spontaneously triggered or where seeds are 
already present and not added deliberately such as dust particles. On the other 
hand, secondary nucléation is the type of nucléation which is artificially 
induced by deliberately adding seeds of a crystalline material to enhance 
crystallization.
c. Crystal growth: There are many theories which are proposed in order to 
explain crystal growth. These are as follows:
1. Diffusion theories:
Can be looked upon as the reverse process of dissolution. According to 
Noyes-Whitney(1897) and Nemst(1904), matter is continuously deposited 
on the surface of a crystal at a rate that is proportional to the concentration 
gradient between the surface of the crystal and bulk of solution, 
dm/dt = A km (Css-Cs)
Where m: mass of solid deposited on the surface of crystal at time t 
A: surface area of the crystal 
Css: concentration at supersaturation.
Cs: solute concentration at saturation.
km =  D /5
Where D: diffusion coefficient of solute.
Ô: Thickness of diffusion layer.
It should be noted that rapid cooling results in smaller crystals whereas 
a slow cooling rate gives more chance for crystal growth and therefore 
larger crystals are obtained.
2. Surface energy theory
In this case, a growing crystal is compared to an isolated liquid droplet in 
which case the droplet would assume the minimum surface area resulting 
in minimum surface free energy, which is favoured thermodynamically.
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This would mean that the final shape a crystal ends up having depends on 
the surface areas and hence surface free energies of individual faces. This 
theory means that during crystal growth the face with larger surface area 
would grow at faster rate than other faces having smaller surface areas and 
hence smaller surface free energies. Eventually the smaller, faster- 
growing faces will be eliminated.
The handicap of such theories is that they fail to relate solution movement 
and supersaturation to the rate of crystal growth.
3. Adsorption-layer theory
This theory was first suggested by Volmer in 1939 (Mullin, 1997). The 
theory explains crystal growth as a discontinuous process in which 
adsorption on the surface of the crystal takes place layer by layer.
In this case, ions, atoms or molecules of the crystallizing substance in 
solution migrate to the surface of an existing crystal and diffuse on the 
surface. Later, they connect to the surface of the crystal at a position 
where attractive forces are the highest. This type of growth will continue 
step by step until the whole face of the crystal is completed. Once one 
layer is completed, another layer will be formed in the same manner. A 
centre for crystallization or a so-called active site must be formed on the 
face of the crystal for this layer-by-layer deposition to continue.
1.1.2 Polymorphism
The presence of the same chemical entity in different crystal habits or crystalline 
forms is termed as polymorphism. One of the polymorphs will be the most stable 
one, this usually has a higher melting point and a lower solubility that may in turn 
lead to lower bioavailability. These properties are due to higher structural density 
caused by a closer and more stable packing of ions, atoms or molecules in the most 
stable polymorph. Eventually and given a sufficient period of time, the other less 
stable polymorphs (metastable polymorphs) will convert to the most stable form at 
different rates depending on free energy difference between the metastable and the
24
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Stable forms. It is well known that the most stable form is the one with the lowest free 
energy and the lowest entropy levels. It has to be mentioned that the formation of a 
certain form is favoured if it has higher entropy and lower free energy levels 
(Florence and Attwood, 1998).
Presence of different polymorphs can be triggered by one of the following:
1.Change in the crystallization conditions such as:
a. Type of solvent used for crystallization purposes: A certain solvent may 
favour the formation of a certain polymorph over the other. This depends on 
types of interactions between solute and solvent.
b. Change in temperature at which crystallization is performed.
c. Change in cooling rate.
2.Milling
3.Granulation
4.Drying
Polymorphism is a phenomenon demonstrated by compounds that are able to 
crystallize in more than one crystal structure. Due to the different crystal packing 
arrangements, polymorphs display different chemical and physical properties such as 
melting point, solubility, enthalpy of fusion, density. X-ray diffraction patterns and 
refractive index (Rustichelli et al, 2000). Some of these differences can be quite 
serious. If for example the polymorph suffers from low solubility or stability, this can 
have serious biopharmaceutical implications affecting bioavailability or activity.
In three-dimensional crystalline structure, there are seven possible crystal systems 
resulting in seven independent different unit cell shapes (Florence and Attwood, 1998; 
West, 1997). These are: cubic, tetragonal, orthorhombic, hexagonal, trigonal, 
monoclinic, and triclinic (Figure 1.2). A cubic unit cell exhibits the ultimate and 
maximum symmetry (Florence and Attwood, 1998).
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Cubic Tetragonal Monoclinic Triclinic
HexagonalTrigonal Orthorhombic
Figure 1.2 The seven possible primitive unit cells in crystals (Florence and Attwood, 
1998).
1.1.3 Solvates and hydrates
Sometimes referred to as pseudopolymorphism, a solvate is formed when the solvent 
of crystallization gets trapped in the crystalline lattice. When the solvent is water it is 
called a hydrate. Anhydrous forms on the other hand reflect the absence of such 
water trapped in the crystalline structure. The investigation of the presence of 
solvates or hydrates is not by any means less important than investigating the 
presence of different polymorphic forms.
It has been noted that solvates exhibit different solubilities and melting points when 
compared with the non-solvated compound in which case solvates tend to be more 
soluble in water than the non-solvates.
On the other hand, hydrates tend to have lower water solubilities than the anhydrous 
forms. This can be attributed to the fact that when a hydrate was formed interaction 
with water took place during crystallization releasing some energy. Consequently less 
energy was left to enhance the interaction with water later on in order to solubilize the
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drug and as a result the anhydrous form exhibited higher water solubility than the 
hydrated form (Florence and Attwood, 1998).
1.2 Amorphous materials
Amorphous solid, as the name suggests (a=without, morphe=shape), is a solid 
material which is randomly arranged, and lacks the presence of long range three 
dimensional molecular order, although it may have short range molecular order. 
Amorphous solids exist in many industrially important products, such as polymers 
and pharmaceuticals. Currently, interest in this area has been augmented by two 
developments: an increasing attention in the study of pharmaceutical solids especially 
polymorphs and solvates (Trelfall, 1995; Yu et al., 1998) and a revived interest in the 
glasses and in the phenomenon of glass transition (Angell, 1995; Ediger et al., 1996).
1.2.1 Glass transition temperature (Tg)
Glass transition temperature, Tg, is a point at which an amorphous substance changes 
from the glassy state to the rubbery state or vice versa. When an amorphous solid is 
cooled below its glass transition temperature (Tg), it will be in its glassy state. At this 
state, the molecules are held in an unstable kinetically frozen state, i.e. rigidly and 
randomly fixed in place with short-range molecular motion. Amorphous materials in 
this state are high viscosity uhdercooled liquids (r|>10^^ Pa s). Glassy materials are 
vitreous, hard, brittle and transparent. If an amorphous solid is heated above Tg, the 
material converts from the glassy state to the rubbery state. The molecules gain 
energy and therefore the molecular motion is increased. At this stage, the material has 
enough energy to revert to the crystalline form.
Many amorphous materials have a glass transition temperature above room 
temperature. For example, indomethacin, with an onset Tg of 40 °C (Matsumoto and 
Zografi, 1999). As the temperature increases above Tg, the molecular mobility 
increases with a decrease in viscosity. It is known that water can cause a lowering of 
the Tg of materials. Apart from water, there are many other compounds, which act as 
plasticizers, for example, glycerol and liquid paraffin (Andronis and Zografi, 1998).
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1.2.2 Physico-chemical properties
Amorphous solids have higher molecular mobility and energy than the crystal form. 
These properties render the amorphous systems with higher apparent solubility and 
dissolution rate, hence possibly an enhanced bioavailability compared to the 
crystalline form. Usually, drugs, in solid dosage forms, are used in their crystalline 
state. As the amorphous state can improve drug dissolution behaviour (Gil et al, 
1994), its use has attracted interest in the preparation of solid dosage forms 
(Yonemochi et al, 1997). However, this is very difficult to achieve and maintain the 
stability of the amorphous state because this system is thermodynamically unstable. It 
has the tendency to undergo solid-state transformation to lower energy, and more 
stable, crystalline form upon storage. For this reason, the amorphous state of the drugs 
needs to be maintained throughout their shelf-life. It is therefore important to study 
how to form and stabilise the amorphous state and the way that this preparation can 
affect drug dissolution.
1.3 Techniques for preparing amorphous solid materials
Different pharmaceutical processing techniques can lead to an induction of an 
amorphous moiety in a crystalline solid materials. These processes include super 
cooling of a melt (such as quench cooling), grinding, solid dispersion (melting or 
solvent method), rapid precipitation by anti solvent addition, freeze-drying and spray- 
drying.
Egawa et al (1992) reported that amorphous cefalexin could be prepared by 
lyophilization. Grinding could decrease % crystallinity. The longer the grinding time, 
the lower the % crystallinity. However, grinding could not produce a totally 
amorphous cefalexin. According to Yonemochi et al (1997), amorphous ursodeoxy 
cholic acid obtained by grinding and quenching methods, had a more rapid dissolution 
rate than that of the crystalline form.
Another way of turning crystalline materials into the amorphous state is by co­
grinding them with microcrystalline cellulose (Nakai et al, 1978a; 1978b). It has been 
shown that the resulting ground mixtures have various properties, such as rapid 
dissolution and disappearance of melting endotherms on the thermograms (Nakai et
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al, 1978b). These results were explained by the concept that the ground mixture was 
an “entropy frozen solution”, i.e. dissolving in cellulose without limited molecular 
mobility, thus limiting crystallisation.
The physicochemical properties of drugs can be modified by co-precipitation with 
hydrophilic polymers. Co-precipitation, or solid dispersion, is widely employed for 
enhancing the dissolution rate of poorly water-soluble drugs. Polyvinylpyrrolidone 
(PVP) and polyethylene glycol (PEG) are commonly used hydrophilic polymers. The 
enhanced dissolution rate of the drug-polymer complex is due to the formation of 
thermodynamically unstable amorphous drug phase and/or the molecular dispersion 
of the drug (Banakar, 1992).
Doherty and York (1987) prepared frusemide-PVP solid dispersions. The amount of 
PVP used in the preparation of solid dispersions played an important role in 
controlling the degree of crystallinity of the products. At PVP concentrations above 
60%w/w, the product was in the amorphous form, whereas at concentrations below 
10%, the product was in the crystalline form. It was found that solid dispersions had 
higher dissolution rates than the corresponding physical mixtures and unprocessed 
frusemide. The improved dissolution rate of solid dispersions could be attributed to 
the solubilizing effect of PVP and the amorphous drug phase.
Ochoa Machiste et al. (1995) improved the dissolution rate of poorly water-soluble 
carbamazepine using cross-linked polyvinylpyrrolidone (Polyplasdone XL-10). The 
drug-polymer mixtures were prepared by mixing, milling and solvent evaporation 
techniques. It was found that the dissolution rates of carbamazepine were significantly 
enhanced compared to that of the pure drug. The mixing and milling techniques were 
noted to be more effective in enhancing the dissolution rate than the solvent 
evaporation method.
1.3.1 Spray drying
To change the physical state of poorly water soluble drugs and thus to enhance their 
dissolution and potentially improve their bioavailability, the material can be co-spray 
dried with polymers and other glass forming solids (Corrigan et al, 1985; Bootsma et
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al, 1989; Giunchedi and Conte, 1995). Yamaguchi et al. (1992) documented that the 
amorphous 16-membered macrolide compound, prepared by different conditions of 
spray drying, exhibited different dissolution rates. In addition, it was shown that the 
greatest physicochemical stability was achieved when the amorphous powders were 
prepared at temperatures between the recrystallization temperature (Tc) and the glass 
transition temperature (Tg). Corrigan and Timoney (1975) investigated the dissolution 
rates of hydroflumethiazide-PVP co-precipitates and the crystalline drug. Co­
precipitates containing more than 40% PVP were found to be amorphous. The 
apparent solubility of the co-precipitates was found to be four times higher than that 
of the crystalline drug. Corrigan and Holohan (1984) produced amorphous 
hydroflumethiazide-PVP using a spray-drying technique. The apparent solubility of 
the complex increased as the PVP content increased. The complex also exhibited 
higher dissolution rates than those of the physical mixtures.
1.3.1.1 Spray-drying process
Spray drying is a process by which solution, suspension, emulsion, dispersion, slurry 
or paste is converted into a dry particulate system. It is not only a drying process but 
also has a dramatic effect on the product. Particularly in the pharmaceutical industry, 
it has been employed successfully to alter physicochemical properties to improve 
formulation, in as much as to transform crystalline material to an amorphous state, 
and to improve the compressibility of a powder for tabletting. There are four 
sequential steps: atomisation, spray-gas contact, drying of the sprayed droplets and 
separation of dried sample from air. These steps are commented on as follows:-
Atomisation
Atomisation occurs in the atomiser in order to produce fine droplets of equal size. The 
fine droplets are immediately in contact with the gas from outside of the atomiser. 
Subsequently, this dried product is separated from the air stream in a cyclone and 
finally collected from the collecting vessel. Atomisation provides a feed which has a 
high surface area to mass ratio, creating the ideal evaporating conditions. As a result, 
a product with certain characteristics such as density, shape and particle size 
distribution could be obtained. There are many variables to be optimised during the 
process prior to producing the desired product.
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There are three different atomization systems, which are classified by the nozzle 
design-rotary atomization, pressure atomization and pneumatic (two-fluid) 
atomization. A Buchil90 mini spray dryer (Buchi Laboratoriums-Technik AG, 
Flawil, Switzerland) composed of pneumatic atomisation was shown in Figure 1.3.
pump
nozzle tubing 
" liquid feed 
exhaustspray o o o
air flow
cyclone
separatorV
product
collection
temperature
probe
Figure 1.3 Diagram of the Buchi 190 Mini spray dryer (adapted from Hill, 1999).
Spray-gas contact
Spray dryers are designed to perform in one of three manners in the spray-gas contact 
stage. Firstly, a co-current manner; the spray and the hot drying air enter the drying 
chamber in the same direction. Secondly, a counter-current manner; the spray and 
drying air pass through the chamber at opposite ends. Thirdly, a combined co- 
/counter-current manner; the product is sprayed upwards and remains in the hot zone
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then it immediately drops down into the cool zone by gravitational force. The Buchi 
mini spray dryer used throughout the research operates in a co-current manner.
Drying of the sprayed droplets
The removal of solvents from the spray occurs at the drying stage. Heat and mass 
transfer between atomised droplets and drying air are simultaneous. In general, the 
evaporation process during spray drying can be divided into four stages (Figure 1.4). 
The first stage (a) occurs when the droplet immediately comes into contact with air 
evaporation of the solvent. The temperature of the droplet surface increases until 
equilibrium occurs between the droplet surface and the air. The second stage (b) is the 
stage of constant evaporation. The moisture of the droplet migrates from inside to 
outside prior to maintaining saturation at the surface and until a critical point is 
reached. This critical point indicates that the moisture within the droplet can no longer 
maintain surface saturation. The drying rate then dramatically falls at the third stage 
(c), accompanied by a droplet temperature increase. This stage depends on the air 
temperature and the liquid inside the droplet. If the boiling point of liquid inside the 
droplet is lower than the air temperature, the liquid vaporises. The pressure within the 
droplet increases, when the solid phase forms a crust around the surface. If the crust is 
porous, then the vapour will escape, otherwise the powder will break. The shape of 
the final products is determined by the type of crust formed. Figure 1.5 shows the 
types of product that occur during spray drying. In the last stage (d), when the droplet 
becomes absolutely dry, the evaporation rate continues to slowly decrease since the 
droplet surface provides resistance to drying. Eventually, there is an equilibrium of 
moisture content between the droplet and the surrounding air. However, the product is 
usually collected before equilibrium.
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Figure!.4 A drying graph depicting the relationships between drying rate and 
moisture content. Data adapted from Masters (1990).
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Figure!.5. Diagram of the particle features along the drying stage of spray drying 
(taken from Oakley ,1997).
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Separation of dried sample from air
The last stage of the spray-drying process is product recovery, namely, the separation 
of the product from the air stream. The product can be separated from the air by 
cyclonic air flow which occurs in the cyclone separator. Many dryers also allow for 
product collection at the base of the drying chamber. In the Buchi mini spray dryer, 
the product can be collected from a collecting vessel only.
1.3.1.2 Effect of spray-drying experimental parameters on the product
The various settings on the spray-drying device are important in identifying the 
powder properties. There are many variables to be controlled throughout the process. 
These variables are the inlet and outlet temperatures, the aspirator speed, the spray 
flow rate, the feed rate and feed concentration. However, all the parameters are 
interdependent as adjusting one parameter can affect other parameters.
Inlet temperature
The inlet temperature is the temperature of the heated drying air, which is drawn in 
over a heater by an aspirator motor. The impact of inlet temperature on particle size 
depends on the materials being dried (Crosby and Marshall, 1958). It was noted that 
the temperature had little effect on mean particle size of crystalline sodium sulfate, 
whereas the mean particle size of coffee extract was significantly decreased as the 
inlet temperature increased. Conversely, the particle size of certain substances was 
shown to increase by increasing the inlet air temperature (Newton 1966, through 
Broadhead et al, 1992).
Outlet temperature
The outlet temperature is the temperature of the air of the particulate products before 
entering the cyclone. This temperature is not necessarily the product temperature 
because the vaporization of the water removes heat from the product. However, if this 
temperature is too high, the heat sensitive substances can be degraded. Increasing 
outlet temperature causes lower final moisture content. Hence, the bulk density also 
decreases.
34
Chapter 1_________________________________________________________________________________Introduction
Aspirator speed
The aspirator speed setting has influence on the drying performance of the instrument. 
High aspirator speed results in a higher degree of separation in the cyclone. However, 
if the particle size of products is too small, particles may be lost in the air stream 
exhaust.
Spray flow rate
The spray flow rate is different from the aspirator speed. The spray flow rate is the 
amount of compressed air from the main spray dryer, which is required to convert the 
liquid into fine droplets. The higher the spray flow rate, the smaller the particle size of 
the final product.
Feed rate
An increase in feed rate while holding the inlet temperature and aspirator flow rate at 
constant, results in an increase in the final moisture content of the spray-dried 
products. For this reason, the bulk density also increases (Masters, 1990).
Feed concentration
Spray drying of high concentration preparations of hydrophilic substances usually 
results in powder with a low bulk density. On the other hand, spray drying of high 
concentration of non-hydrophilic materials leads to an increase in bulk density. In 
addition, the feed concentration influences the particle size. The more concentrated 
feed mixtures usually produce larger and more porous particles. It is important to 
understand how all the variables interact, and to know how to modify and optimize 
both process and formulation variables in order to manufacture products with the most 
suitable characteristics.
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1.3.2. Supercritical fluid technology
In the pharmaceutical industry, conventional processing of drugs involves extensive 
use of organic solvents as either reaction media in synthesis of drugs, or as so-called 
“antisolvents” for recrystallising drugs. During the last decade, replacement of 
traditional organic solvents with “environmentally benign” solvents, known as 
supercritical fluids (SCFs), in pharmaceutical processing is receiving increased 
attention. More recently, this technology has been commercialised. One such 
company using this technology is Bradford Particle Design (BPD), which was 
established in 1994 by University of Bradford, UK.
1.3.2.1 Supercritical fluids
A substance is termed supercritical when its pressure and temperature is greater than 
its critical pressure (Pc) and critical temperature (Tc), respectively. Near the critical 
point (1-1.2Tc), the density, transport properties (such as viscosity and diffusivity), 
and other physical properties (such as solvent strength and dielectric constant) can be 
varied from gas-like to liquid-like with relatively small changes around the critical 
pressure (0.2-0.9 Pc) (Subramaniam et al, 1997a). Thus, it is possible to realize unique 
fluid properties to suit various processing needs. In other words, small changes in the 
temperature or pressure near the critical point result in large changes in the fluid’s 
density and, hence, its solubilizing power. The supercritical state of a material is 
shown in the pressure-temperature (P-T) diagram in Figure 1.6, and exists above a 
certain pressure and temperature for any substance.
A comparison of the physical properties of supercritical fluid (SCF) with those of 
liquid and gas is shown in Table 1.1. Supercritical carbon dioxide (sc-COz) has been 
found to have particular use as an environmentally acceptable ‘solvent’ alternative 
compared to some conventional hydrocarbon solvents. For this reason, the area of 
supercritical fluids is also better known as “Clean Technology”.
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Figure 1.6 Pressure-Temperature diagram for a pure substance (McCabe et al.
1993).
Table 1.1 Physical properties of gases, supercritical fluids and liquids (Raynie, 1997).
Density Diffusivity V iscosity Surface Tension
(g/cm3) (cm2/s) (cp) (mN m -i)
G as (0.6-2)x 10-3 0.1-0.4 0.01-0.03 0
SCF 0.2-1.0 (2-7)x 10-4 0.01-0.09 0
Liquid 0.6-1.6 (0.2-2)x 10-3 0.2-3.0 30-60
Table 1.2 lists some common supercritical fluids and their critical temperatures and 
pressures (Mchugh and Krukonis, 1986). For pharmaceutical applications, carbon 
dioxide is an ideal processing medium. The critical parameters of carbon dioxide 
(critical pressure Pc = 73.8 bar, critical temperature Tc = 31.1 °C) are both relatively 
low values for T and P compared to many other potentially useful supercritical fluids. 
Carbon dioxide is also non-toxic, relatively inert, non-flammable and recyclable.
Supercritical carbon dioxide is a relatively nonpolar solvent. A common rule of thumb
is that if a substance dissolves in n-hexane, then that substance may also dissolve in
supercritical carbon dioxide. While this rule is valid for many low molecular mass
substances that have appreciable vapour pressures, it fails in the case of many
polymers, which have negligible vapour pressures. sc-CO] has been employed both as
a solvent and as an antisolvent in pharmaceutical applications (Subramaniam et al,
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1997a). The ability to precisely and rapidly vary the solvent strength and thereby the 
rate of supersaturation and nucléation of dissolved compounds, is a unique aspect of 
supercritical fluids for particle formation.
Table 1.2 Critical data for some supercritical solvents
Solvents Critical temperature 
TcCO
Critical pressure 
Pc (atm)
Ethylene 9.3 730.0
Carbon dioxide 31.1 72.8
Ethane 32.3 709.0
Nitrous oxide 36.5 1050.0
Propylene 91.9 45.6
Propane 96.7 41.9
T richlorofluoromethane 198.1 43.5
Ammonia 132.5 111.3
Cyclohexane 280.3 40.2
Isopropanol 235.2 47.0
Benzene 289.0 48.3
Toluene 318.6 40.6
Water 374.2 217.6
1.3.2.2 Precipitation using supercritical carbon dioxide
Conventional processes for producing small drug particles include ball milling, 
recrystallization of drug particles from solution using organic anti solvents, freeze- 
drying and spray-drying from organic solvents and aqueous solutions. These methods 
can require excessive solvent use and a need for solvent disposal. Also thermal and 
chemical degradation of products can occur or sometimes solvent residues will remain 
in the drugs. Particle size control is also sometimes inconsistent. For this reason, the 
production of contaminant-free microparticles with controlled particle size is a major 
challenge. Any desirable method should provide those features identified for an ideal 
particle formation process (Figure 1.7) (York, 1999). Various particle-formation 
techniques have been developed that can take advantages of the properties of 
supercritical fluids. These techniques can be divided into three main topics: (i)
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precipitation using S C - C O 2  as a solvent; (ii) precipitation from gas saturated solutions; 
and (iii) precipitation from saturated solutions using S C - C O 2  as a non-solvent or 
antisolvent. The subject of particle design using supercritical fluids has been reviewed 
previously (Subramaniam et al, 1997a; York, 1999; Reverchon and Perrut, 2000; Jung 
and Perrut, 2001), thus a short summary is given here.
Figure 1.7 Requirements of an ideai particie formation process for pharmaceuticai products 
(taken from York, 1999).
Operates with relatively small quantities of organic solvent(s)
Molecular control of process
Single step, scalable process for solvent-free final product 
Ability to control desired particle properties
Suitable for wide range of chemical types of therapeutic agents and formulation excipients 
Capability for preparing multi-component systems 
GMP compliant process
Rapid Expansion of Supercritical Solution
This process of particle formation has been called Rapid Expansion of Supercritical 
Solution (RESS) (Matson et al, 1987), consisting of dissolving a solute in a 
supercritical fluid, then depressurising this solution through a heated nozzle or 
capillary into a low pressure precipitator in order to cause a rapid nucléation of the 
substrate in the form of contaminant-free microparticles or fibers or films that are 
collected from gaseous stream. A process schematic of RESS is depicted in Figure 
1.8.
Liquid carbon dioxide from a cylinder is pumped to the desired pressure and
preheated to the extraction temperature through a heat exchanger. The supercritical
fluid is then percolated through the extractor filled with one or more substrates. The
supercritical solution is expanded in the precipitator, through a preheated nozzle to
avoid blocking by substrate precipitation. The morphology of the resulting product
depends on several factors such as the material structure (crystalline or amorphous,
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composite or pure) on the RESS parameters (temperature/pressure) in the precipitator, 
distance of impact of the jet against the surface, dimensions of the expansion device, 
nozzle geometry and the RESS time scale (dictated by the expansion trajectory from 
the preheater and the expansion device) (York, 1999; Phillips and Stella, 1993; 
Reverchon et al, 1993).
Carbon
dioxide
Heat exchanger
h-So lu té
Extractor
Extraction Unit
Heated
nozzle
P recip itator
- Particle 
collection
Figure 1.8 RESS equipment
The relationship between process parameters and the resulting particle size has been 
reported previously (Shaube et al, 1995; Reverchon and Pallado, 1996; Reverchon, 
1999; Tom and Debenedetti, 1991; Lele and Shine 1994). Various types of materials 
have been processed by the RESS method, including organics, inorganics, ceramics 
and polymers, and also coprecipitation of polymer/drug systems. The particle 
dimensions obtained using RESS generally range from 0.5 to a few hundred microns 
(Reverchon, 1999; Reverchon and Perrut, 2000). Although in a few cases, particles 
smaller than 0.1 micron have been produced by this single-step process (Matson et al, 
1987).
As S C - C O 2  is nonpolar, those solutes that are also non-polar can be expected to 
dissolve in S C - C O 2  and thus are suitable candidates for RESS method. Examples of 
pharmaceutical drug compounds soluble in SCCO2 include lovastatin (Larson and 
King, 1986), stigmasterol (Ohgaki et al, 1990), salicylic acid and theophylline (Subra
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and Debenedetti, 1996). Expansion of such solutions to pressure conditions above 
ambient temperature, and thereby at lower levels of supersaturation, can result in 
agglomeration of particles. Whereas, increased supersaturation during expansion leads 
to rapid nucléation rates and micron- and submicron-sized particles.
The RESS process is a suitable technique for size reduction. Due to the high degree of 
supersaturation and rapid expansion characteristics of the RESS process, small 
particles with a uniform distribution can be obtained. Various pharmaceutical 
compounds such as ibuprofen (Charoenchaitrakool et al, 2000), griseofulvin (Martin 
et al, 2000; Reverchon, 1995), progesterone (Alessi et al, 1996) have been 
successfully micronised with the RESS technique. Using ibuprofen as an example, 
Charoenchaitrakool et al (2000) showed that the median particle size of the product 
was less than 2.5 pm, compared to the original material, which has highly non- 
uniform particle size distribution, with a median particle size of 42 pm. It was 
reported that the enthalpy of fusion obtained from DSC analysis and the intensity of 
the XRD peaks of the processed ibuprofen were slightly lower compared with the 
original material. These results indicated a reduction in the degree of crystallinity of 
ibuprofen after processing with RESS. Additionally, it was also demonstrated that 
ibuprofen after RESS processing has a powder dissolution rate of five times greater 
than that of the original material. The enhanced dissolution rate of ibuprofen was due 
to the reduction in both the particle size and the degree of crystallinity.
Martin et al (2000) studied the RESS processing of poorly soluble griseofulvin. Using 
trifluoromethane as a cosolvent, nano size griseofulvin particles were produced. 
However, the processed-griseofulvin was agglomerated, forming a spongy-like 
structure. The genuine particle size was approximately 200 nm. From DSC data, it 
was reported that the melting point of the RESS produced griseofulvin was lower than 
that of the crystalline product, which meant a reduction of crystallinity. The 
dissolution rate of the RESS-produced griseofulvin increased 1.6 times compared to 
the original sample. The increase in dissolution rate of griseofulvin was hence due to 
both the reduction in particle size and the degree of crystallinity.
Several polymers of pharmaceutical interest have been processed by RESS technique, 
including biodegradable polymers based on lactic acid (Tom and Debenedetti, 1991;
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Debenedetti, 1994) and polyethylene glycol (Weidner et al, 1996). Likewise, particle 
shape and morphology have been affected for polymer-supercritical fluids systems, 
depending upon the point of saturation in the processing route. Phase separation at the 
pre-entry to the orifice and within the orifice results in formation of polymer fibres or 
elongated particles, respectively.
Tom and Debenedetti (1991) reported that the RESS process is feasible for the 
production of microspheres and microparticles of biodegradable polymers such as 
poly (hydroxy acid) polymers. Microparticles and microspheres of poly (L-lacilcacid) 
(L-PLA) (MW 5,500) in the range of 4 to 25 pm were precipitated from CO2 and 
C02-acetone mixtures. Irregular-sized particles of poly(0,L-lactic acid) (DL-PLA) 
(MW 5,300) ranging from 10 to 20 pm were produced. The precipitation of 
poly(glycolic acid) (PGA) (MW 6,000) from CO2 produced needle particles of 10-40 
pm length and regular shape. The molecular weight of the precipitated polymers was 
found to be lower than that of the commercial polymers, indicated that RESS is 
limited to low molecular weight polymers.
Polymers are polydisperse to some degree and their solubility in supercritical fluids is 
a function of molecular weight, hence the precipitation of polymers by RESS differs 
from that of single molecular weight compounds. As the extraction begins, the 
molecular weight distribution of the polymer changes. Low molecular weight 
polymers with a low glass transition temperature, appeared to be extracted first and 
precipitated as a liquid or waxy paste (McHugh and Krukonis, 1986). Due to the 
polydispersity of polymers, the ability to maintain consistency and reproducibility of 
the product characteristics still remains as a challenge in polymer processing by 
RESS. However, the successful production of polymer microspheres and 
microparticles is a promising step in developing the RESS process as a novel 
technique for polymer processing.
The application of RESS can be extended to microencapsulation. This can be simply 
accomplished by combining the extracted drug and polymer into one stream prior to 
expansion. The intimate drug/polymer mixture can then be precipitated in one 
processing step.
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The formation of microparticles consisting of lovastatin crystals coated with DL-PLA 
polymer can be obtained via the RESS process (Tom and Debenedetti, 1992; Tom et 
al, 1993). A lovastatin concentration > 30% precipitated as a network structure while 
a low concentration precipitated as microparticles and microspheres. In the first case 
the network consisted of intertwining polymer fibres with the drug incorporated in the 
strands. In the latter case the particles consisted of drug needles coated with polymer. 
The production of polymer coated lovastatin needles suggested that lovastatin 
precipitated and grew first, and then acted as neucleating sites for the polymer.
Tom et al (1994) also investigated the coprecipitation of L-PLA (MW 10,000) and 
pyrene by RESS using SC-CO2 -CHCIF2 solutions. Pyrene, a fluorescent compound, 
was selected as a model solute. The uniformity of pyrene distribution in the polymer 
matrix was then assessed via fluorescence microscopy. Results from confocal 
fluorescence microscopy showed a uniform distribution of pyrene microparticles 
within polymer microspheres, which indicated efficient mixing of the solute and 
carrier in the RESS process.
Kim and co-workers (1996) also employed the RESS method in preparing 
coprecipitated naproxen and L-PLA using CO2 . The drug and polymer were premixed 
and loaded in the same extraction vessel. Mixtures of naproxen and L-PLA were 
coprecipitated using a 50 pm diameter capillary over a range of extraction pressures 
from 170 to 200 bar, pre-expansion temperatures of 90-115 C, and extraction 
temperature of 60 C. The distribution of the fluorescent naproxen within the 
precipitates was analysed using confocal laser scanning microscopy with fluorescence 
wand reflected light detection. Composite particles containing microcrystalline 
naproxen particles at the core, with coated polymer on the surface were observed. 
However, the drug loading in the composite precipitates was not reported.
As demonstrated in the above studies, microencapsulation by RESS is achievable. 
However, due to the low solubility of high molecular weight polymers in supercritical 
fluids, low production rates of microencapsulated products are obtained. Different 
modified supercritical fluids are required to obtain the enhanced solubility of high 
molecular weight polymers in supercritical solutions. Preconditioned or synthesized
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polymer, which possesses low polydispersity and molecular weight, would be an ideal 
solute for RESS encapsulation. Microencapsulation by RESS processing also requires 
further refinement in order to produce a high yield of desirable polymer-drug particles 
with uniform drug distributions.
Tablel .3. Solubility of Pharmacuetical compounds in Supercritical Carbondioxide (adapted from Subramaniam et 
al, 1997).
Solute Cosolvent Solubility* Temp(oG) P(bar)
Lovastatin - 4a 40 345
5%Metfianol 10-45a 40 103-379
Efrotomycin - 3a 40 345
Imipenem - Oa 40 345
Lovastatin - 0.09-3.4a 55 125-409
0.1-6a 75 134-409
Digoxin - 0.18b 50 241
7.2 mol%Methanol 0.17b 50 241
Griseofulvin - 1.5b 50 241
3.5 mol%CH2Cl2 1.4b 50 241
3.4 mol7oButyl acetate 6.4b 50 241
Aspirin - 0.12-26b 45 60-228
Salicylic acid - 14b 45 138-241
Testosterone - 0.23-5.0b 35 88-242
- 0.04-7.0b 55 87-242
Progesterone - 0.99-5.9b 35 105-244
- 0.11-7.4b 55 109-243
Chiolesterol - 0.61-28b 55 102-276
Salicylic acid - 10-53b 40 100-350
- 8.3-67b 60 115-325
Ketoprofen - 1.3-8.0b 39.4 100-220
- 0.78-15b 58.4 116-220
Piroxicam - 0.45-4.3b 39.4 100-220
- 0.37-3.9b 58.4 130-220
Nimesulide - 1.9-7.4b 39.4 130-220
- 0.85-9.8b 58.4 130-220
* a , mass fraction (Icy); b, mole fraction (lO^)
Particle formation by the RESS technique offers several elements of the “ideal
particle formation technique” (Figure 1.7). This process is attractive because it
includes a single-step process with reduced organic solvent requirement and
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capability of producing microparticles. Moreover, the gas generated after expansion 
can be recovered and recycled. Unfortunately, at moderate temperatures and pressures 
(<60 °C and 300 bar) many pharmaceutical substrates are not soluble enough into the 
supercritical fluid to lead to a profitable process. As shown in Table 1.3, the solubility 
of drugs is on the order of 0.01 wt % or less (Subramaniam et al, 1997). Hence, 
relatively large amounts of carbon dioxide are required for increased product 
throughput. To solve this problem, co-solvents, such as methanol, may be used to 
enhance this solubility. However, the solvent elimination step from the resulting 
powders is neither simple nor cheap. Other challenges with this method are the 
operational and scale-up issues associated with nozzle design in order to avoid 
particle agglomeration and freezing caused by the rapid expansion.
Precipitation from Gas Saturated Solutions/Suspensions
A more recent application of supercritical fluids to particle formation is the 
precipitation from gas saturated solutions/suspension (PGSS), which was developed 
in 1994 by Weidner et al.
Since the solubility of compressed gases in liquids and some polymers is normally 
high and larger than the solubility of such liquids and solids in the compressed gas 
phase, the process consists of the solubilisation of sc-COi in melted or liquid 
suspended substances, leading to a so-called gas-saturated solution/suspension that is 
then rapidly expanded in an expansion unit. The gas evaporates and the solution is 
cooled down below the solidification temperature of the solute and solid particles are 
formed. The basic scheme of experimental equipment is shown on Figure 1.9.
This process can produce small particles from a variety of substances (inorganic 
powders, polymers, waxes, fat derivatives, natural products and pharmaceutical 
compounds) that need not be soluble in sc-COz, especially with polymers that absorb 
a high concentration (10-40 wt%) of CO2 that either swells the polymer or melts it at a 
temperature much below its glass transition temperature (Jung and Perrut, 2001).
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Saturation
Particle
/  Collection
Figure 1.9 Particle from Gas Saturated Solutions (PGSS) equipment
With this method, even though the polymer is insoluble, SC-CO2 causes it to swell. 
The higher the pressure, the greater the swelling. In this case the Tg of the polymer is 
decreased in the presence of CO2 , which makes it possible to incorporate the softened 
polymer with the insoluble additives added to the vessel. The polymer forms what is, 
in effect, “supercritical foam” with the insoluble additives within the polymer phase 
rather than the SC-CO2 phase. Finally, the mixture is expanded through the nozzle and 
the foam breaks up into a fine powder. This process can also be used with suspensions 
of active substance(s) in polymers or other carrier substances leading to production of 
composite microspheres. The particle size and size distribution of product can be 
tailored to specific requirements by adjusting process parameters such as temperature, 
nozzle size and shape, and the amount of dense gas dissolved.
Moreover, it is possible to form microparticles when a suspension of active drug is 
mixed in a substrate into a carrier that is swollen with sc-CO^ and then atomised. 
Shine and Gelb (1997) patented a process called “Polymer Liquifaction using 
Supercritical Solvation” (PLUSS). The advantage of this method is that the carrier 
(for instance, polymer) and the active substrate (drug), which are both insoluble in the 
supercritical fluid, can be employed. The mixture of the substrate and the polymer is 
mixed with a supercritical fluid capable of swelling the polymer. The pressure is then
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rapidly released, resulting in the solidification of the polymer around the core material 
to form microcapsules.
Sencar-Bozic et al. (1997) prepared solid dispersions of the poorly water soluble 
calcium antagonist nifedipine and polyethylene glycol (PEG) 4000 using Particles 
from Gas Saturated Solution Process (PGSS). In the PGSS process, a sc-COz is 
dissolved under pressure in a mixture of nifedipine and PEG to be micronized. Upon 
expansion of the gas saturated solution, nifedipine and PEG 4000 were coprecipitated 
as microparticles. The DSC profiles of nifedipine/PEG 4000 mixtures showed only a 
melting peak of PEG 4000. It implied that nifedipine dissolved in the PEG 4000 melt. 
The dissolution rate of nifedipine was enhanced significantly compared to that of the 
physical mixtures and unprocessed nifedipine. The enhanced dissolution rate of solid 
dispersions could be due to particle size reduction, interactions between the drug and 
PEG 4000 and the solubilization effect of the hydrophilic polymer.
Kerc et al (1999) also investigated the micronisation of nifedipine, felodipine and 
fenofibrate by PGSS process using sc-COi. It was shown that the mean particle size 
of micronized nifedipine and that of felodipine depended on the pre-expansion 
conditions. On the other hand, the particle size of processed fenofibrate increased due 
to agglomeration. In the DSC profiles of felodipine/ PEG 4000 mixtures, only a 
melting peak of PEG 4000 existed. Coprecipitated nifedipine/PEG 4000 and 
felodipine/PEG 4000 had enhanced dissolution rates. While, the dissolution profile of 
coprecipitated fenofibrate/PEG 4000 did not differ significantly from the dissolution 
profile of fenofibrate, its physical mixture. The mechanism of the rapid dissolution 
rate of felotiipl'^^/PEG 4000 coprecipitate via PGSS could be explained by a 
combination of three factors including particle size reduction, interactions between 
the drug and PEG 4000 and the solubilization effect of the hydrophilic carrier. In 
addition, decrease in % crystallinity or presence of amorphous mixture could have 
also contributed to the enhanced dissolution rate.
With the PGSS process, micronized drug or micronized drug/carrier can be obtained 
in one step without organic solvent. However, the development of the PGSS process 
is hindered because of the lack of data for phase behaviour of solute-dense gas
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systems. In addition, there are two major limitations for this process, the problem of 
nozzle clogging and the relatively high operating temperatures involved. As a result, 
the stability issues of solute in molten form prohibit the use of this method for 
thermally labile pharmaceuticals and biological substrates.
Precipitation Using SC-CO2 as an Antisolvent
Organic liquid anti solvent processes are extensively used in the pharmaceutical 
industry for drug precipitation. The basic concept is the use of two liquid solvents that 
are completely miscible. However, the drug is soluble in the first solvent, but it is 
insoluble in the second solvent. As a result, the addition of the antisolvent to a 
solution induces supersaturation and precipitation of the solute.
Supercritical fluid antisolvent processes have been recently proposed as alternatives to 
liquid antisolvent processes. When SC-CO2 is used as an anti solvent, the solute of 
interest (usually a drug, polymer or both) is dissolved in a conventional solvent to 
form a solution. The preferred ternary phase behaviour is such that the solute is 
insoluble (or weakly soluble) in compressed carbon dioxide whereas the solvent is 
miscible with compressed carbon dioxide at the recrystallisation temperature and 
pressure.
There are some advantages. It is possible to completely remove the antisolvent by a 
pressure reduction to the gas phase. Nevertheless, this step is problematic for liquid 
anti solvents that require post-processing treatments for the complete elimination of 
liquid residues. Moreover, the supercritical fluid anti solvent can diffuse very fast into 
the liquid solvent. Therefore, It can produce the supersaturation of the solute and 
immediately precipitates the micronised particles in an effective fast single step. The 
narrow particle size distributions are also possible with these technologies.
Supercritical anti solvent micronisation has been performed using different process 
arrangements. To indicate the micronization process, different acronyms were also 
employed by the various authors. The process has been referred to as PC A 
(Precipitation by Compressed Antisolvent) (Dixon et al, 1993; Bodmeier et al, 1995), 
GAS (Gas Antisolvent) (Gallagher-Wetmore et al, 1994; Yeo et al, 1993; Randolph et
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al, 1993), ASES (Aerosol Solvent Extraction System) (Bleich et al, 1993), SEDS 
(Solution Enhanced Dispersion by Supercritical Fluids) (Hanna and York, 1994; 
Palakodaty et al, 1998) and SAS (Supercritical Antisolvent) processes (Reverchon et 
al, 1993; Winters et al, 1996). A short description of the various techniques is 
presented as follows.
Batch operation techniques
Batch techniques are essentially ‘one pot’ methods that usually involve injection of an 
antisolvent into a reactor to bring about precipitation. This process has been called gas 
antisolvent (GAS) or supercritical anti-solvent (SAS) recrystallization. A batch of 
solution is expanded several folds by mixing with a dense gas in a vessel. Due to the 
dissolution of the solvent and compressed gas, and low solubility of solute in the 
compressed gas, the mixture becomes supersaturated and the solute precipitates as 
microparticles. The rate of supercritical antisolvent addition can be an important 
parameter in controlling the morphology and the size of the precipitated particles.
Vent
Precipitator
Active substance 
solution
Particles
Expanded
solution
Figure 1.10. Gas antisolvent (GAS) or supercritical antisolvent (SAS) recrystallization 
equipment.
49
Chapter 1__________________________________________________________________________________Introduction
As depicted on Figure 1.10, the precipitator is partially filled with the solution of 
active compounds. Carbon dioxide is then pumped up to the desired pressure and 
introduced into the precipitation vessel. It can be added from the bottom or from the 
top of the vessel. To achieve a better mixing of the solvent and anti-solvent, Carbon 
dioxide should be introduced from the bottom of the vessel. After a holding time, the 
expanded solution is drained under isobaric conditions to wash and clean the 
precipitated particles. This mode of operation can be termed liquid batch operation.
In an alternative arrangement the precipitation vessel contains the antisolvent and the 
solution is then injected into it. This mode of operation can be referred to as gas batch 
operation. The difference between these two operational modes is that in the former 
case the precipitation occurs in a liquid rich phase, in contrast, in the latter case it 
occurs in a supercritical fluid rich phase. Therefore, the result can be very different 
for the two modes of operation.
It is difficult to analyse the effect of the process parameters on the final characteristics 
of the products because in both cases the operation performed is not at steady state. 
Hence, batch operation is not always suitable for industrial production. Factors 
influencing particle properties when prepared by GAS or SAS process are listed in 
Figure 1.11.
Figure 1.11. Factors Influencing particle properties when prepared by the gas antisolvent or 
supercritical antlsolvent recrystalllzatlon. (adapted from York, 1999)
Solute solubility in organic solvent
Solute insolubility in supercritical fluid antisolvent
Degree of expansion of organic solvent in supercritical fluid (liquid batch operation) 
Organic solvent/supercritical antisolvent ratio 
Flow rate of supercritical antisolvent
Critical parameters ( pressure and temperature condition) in reaction vessel 
Phase process path followed during particle nucléation
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At the last step of batch precipitation processes, the vessel is usually washed with the 
anti solvent to remove any residual organic solvent. This step is important for ‘clean’ 
production of particles. Indeed, if washing is not performed afterwards, the residue of 
liquid solvent is released from the supercritical solution mixture during the 
depressurisation of the apparatus and this may resolubilise some of the solutes.
Semicontinuous operation techniques
Semicontinuous techniques differ from batch techniques in that particles are produced 
under approximately steady-state conditions into a precipitation vessel. The liquid 
solution and the supercritical antisolvent are both delivered into the precipitator in co­
current or counter-current fashion. The dissolution of the supercritical fluid into the 
liquid droplets is accompanied by a large volume expansion. As a result, a reduction 
in the liquid solvent power causes a sharp rise in the supersaturation within the liquid 
mixture and the consequent formation of small and uniform particles. In this method, 
the flow rates and the ratio between the solution and the supercritical anti solvent can 
all be controlled independently and are important for controlling the precipitation 
process. Pressure and temperature are also relevant process parameters. This process 
has been termed as Precipitation with Compressed Anti solvents (PGA) (Dixon et al, 
1993) and employs either liquid or supercritical carbon dioxide as antisolvent. When 
using a supercritical anti solvent, the spray process has also been termed Aerosol 
Solvent Extraction System (ASES). A process schematic is shown in Figure 1.12.
The supercritical fluid is pumped to the top of the reaction vessel by a high pressure 
pump. Once the system reaches steady state (desired pressure and temperature), the 
solution of active substance is introduced into the vessel through a nozzle. The liquid 
solution is pumped at a pressure higher (approximately 20 bar) than the vessel 
operating pressure prior to producing small liquid droplets (Jung and Perrut, 2001). 
Precipitation happens when the non-aqueous drug solution mixes with sc-COz. The 
organic solvent can then be removed by the sc-COz from the vessel. Particles are 
collected on a filter at the bottom of the vessel. After formation of sufficient quantity 
of particles, liquid solution pumping is stopped and pure supercritical fluid continues 
to flow through the vessel to eliminate the residual solvent from the particles. At the 
end of the precipitation process, the washing step with supercritical antisolvent is
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required to clean the precipitated particles and avoid the condensation of liquid phase 
otherwise the characteristics of the powder will be changed.
Pump
CO2
Precipitator
Particle
'collection
L#LJ
Active substance 
solution
Vent
Figure 1.12 PC A/ASES equipment.
An important factor in the semi-continuous process is the liquid solution injection
device. The injector is designed to produce liquid jet break-up and the formation of
small droplets which expand in the vessel. The solute is released from solution when
its local concentration exceeds the saturation limit. Different kinds of injectors such as
standard capillary nozzles, ultrasonic atomizers, and coaxial nozzles have been
employed to spray the active substance solution. Reverchon et al (1998) employed an
atomisation method, which involves spraying the solution through a 22 |Lim diameter
stainless steel nozzle in the form of fine droplets into compressed carbon dioxide.
Metal-organic nanoparticles reduced to about 100 nm were successfully obtained at
very large expansion after subsequent heat treatment of the liquid solution. This
process was used to prepare semiconductor particles. Debenedetti et al (1992) and
Yeo et al (1993) proposed the adoption of an atomisation nozzle and tested a variety
of nozzle diameters ranging from 5 to 50 pim. Other authors employed an atomisation
nozzle (Saim et al, 1996; Bleich et al, 1993). Randolph et al (1993) used small internal
diameter capillary (75 pm i.d.), or vibrating orifice nozzle (ultrasonic type). This
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vibrating apparatus produces a spray by superimposing a high frequency vibration on 
the liquid jet that exits from an orifice. Submicron size L -PLA microspheres with a 
narrow size distribution were produced when 0.6 wt% PLA/methylene chloride 
solution was sprayed into supercritical carbon dioxide via both capillary and vibrating 
nozzles. This led researchers to speculate that interphase mass transfer rates, rather 
than initial droplet size, control final particle size. Using 100 pm capillary orifices, 
Bodmeier et al (1995) reported that at higherL-PLA concentrations (> 4 wt %) with 
relatively low flow rates of CO2 , led to fibre formation instead of microspheres.
Coaxial devices have also been employed in which two capillary tubes continuously 
deliver the liquid solution and the supercritical antisolvent (York and Hanna, 1996).
In this case, the high velocity of the supercritical fluid allows break-up of the solution 
into very small droplets. Thus, the formation of droplets depends on the turbulent 
mixing of the two flows. This method is known as Solution Enhanced Dispersion by 
Supercritical fluids (SEDS) (Hanna and York, 1994). In the United Kingdom, 
Bradford University developed this unique process in order to achieve smaller droplet 
size and intense mixing of supercritical fluid and solution for increased transfer rates. 
This process has recently been commercialised and pilot-plant scale-up is in progress 
(www.bpd.co.uk). A process schematic of SEDS is shown in Figure 1.1%. The 
supercritical fluid is used both for its antisolvent properties and as a ‘spray enhancer’ 
by mechanical effect. A nozzle with two coaxial passages allows introducing the 
supercritical fluid and a solution of active substance(s) into the particle formation 
vessel where pressure and temperature are controlled. The high velocity of the 
supercritical fluid flow allows the break-up of the solution into very small droplets. 
Furthermore, the conditions are set up so that the supercritical fluid will effectively 
extract the solvent from the solution at the same time as it meets and disperses the 
solution. Researchers at University of Kansas have recently developed a unique 
nozzle design in which sonic waves were applied to the nozzle leading to 1 pm 
particles being produced (Subramanium et al, 1997b). Robertson et al (1998) 
employed a premixed injector in which the liquid solution is mixed into the flowing 
CO2 before the entrance to the reaction vessel. Other authors have used stirred 
autoclaves in a similar way (Schmitt et al, 1995; Wubbolts et al, 1997). The stirred 
autoclave device shows marked similarities in industrial crystallizers.
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The SEDS process has been employed for several drug formulation applications. It 
has also been developed to process water-soluble materials, including sugars and 
proteins (Hanna and York, 1995). As shown in Figure 1.13, the process is based on a 
nozzle with three coaxial passages into a precipitator, to co-introduce the following;
(i) A solution or suspension of active substance in solvent 1.
(ii) A solvent 2 which is miscible with solvent 1 and soluble in the 
supercritical antisolvent.
(iii)A supercritical antisolvent.
The dispersion of the active substance solution (in solvent 1) and solvent 2, and the 
extraction of these two solvents can occur simultaneously. Both solvents are then 
extracted by the supercritical antisolvent.
Coole
-f----
CO;
Pump) Heat
scCO; (+ cosolvent)
VActive substance solution
\  /
Two coaxial-passage nozzle
Coaxial nozzle
U
Precipitator
, Particle 
collection
Active substance 
solution
"►  Vent
scC O z
Solvent 1
Solution of active 
substance in solvent 1
Three coaxial-passage
Figure 1.13 SEDS equipment concept along with a cross section of the two and three 
coaxial-passages nozzle.
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Recently, Bradford Particle Design also patented the special antisolvent process 
which is suitable for particle formation of lipophilic materials and low polarity 
compounds (Hanna et al, 1999). In conventional GAS or SAS process, the S C - C O 2  
expands an organic solution of active substance, decreasing its solvent power and 
causing the active substance precipitation. In this new method, the S C - C O 2  expands 
another supercritical solvent, in which the active substance is dissolved. Due to the 
second supercritical fluid action, precipitating particles of the active substance occurs. 
Ibuprofen particles were prepared by mixing a supercritical solution of ibuprofen in 
S C - C O 2  with supercritical nitrogen. Other lipophilic drugs, such as salicylic acid, 
ketoprofen, salmeterol xinafoate and nicotinic acid, have also been produced using 
this method.
Various fluid parameters can be used to control particle characteristics in semi­
continuous precipitation processes. The type of injection device used can also strongly 
influence the precipitation process, the size of droplets and the mixing of the different 
fluids. In the ASES and PCA processes, the particle size and morphology are 
dependent on several factors such as the operating temperature, pressure, jet break-up, 
and the mass transfer rates between the supercritical fluid antisolvent phases and the 
sprayed droplet. Jet break up and the sizes of droplet depend on the relative 
magnitudes of the droplet deforming (inertial, external) and reforming (viscous, 
interfacial tension) forces. These forces are determined by the nozzle design, spray 
velocity, physical properties of the droplet and anti solvent phases. The mass transfer 
between the antisolvent phase and the sprayed droplet has two limiting paths. Firstly, 
the solvent evaporation with little carbon dioxide penetration into the droplet phase. 
Secondly, carbon dioxide swelling of the droplet phase with no solvent evaporation.
In the case of polystyrene polymer, various particle morphologies have been obtained 
using this method (Dixon et al, 1993). The rate of particle formation is determined by 
the mass transfer of the antisolvent into the sprayed droplet, whereas particle 
agglomeration and aggregation are affected by the rate of solvent mass transfer into 
the supercritical fluid from the droplet. The mass transfer is influenced by atomisation 
efficiency and depends on dispersing and mixing phenomena between the solution 
droplet and supercritical fluid (Palakodaty and York, 1999). Therefore, an
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understanding of mass-transfer rates is required to minimise particle agglomeration 
and to reduce drying time.
Anti solvent precipitation using sc-COz yields a relatively more rapid precipitation in 
comparison with conventional solvent evaporation process. Surprisingly, many sc- 
processed products exhibit high levels of crystallinity. Micronized budesonide can be 
prepared using ASES (Steckel et al, 1997). Dichloromethane was used as the solvent 
and SC-CO2 was used as the anti solvent. XRD analysis revealed that budesonide 
showed no change in crystallinity. Corrigan and Crgan (2002) reported that 
Hydrocortisone-PVP coprecipitate prepared using gas anti solvent method (GAS) was 
more crystalline than corresponding system prepared by spray drying. Moneghini et al 
(2001) prepared carbamazepine-PEG4000 coprecipitate using gas anti solvent method 
(GAS). From XRD and DSC analysis, the crystalline carbamazepine was still 
detectable in all the coprecipitates.
Versatility of the antisolvent precipitation method has been demonstrated by 
producing a pure polymorphic form. Crystallization of Salmeterol xinafoate was 
prepared using SEDS of acetone and methanol solutions (Beach et al, 1999). Thermal 
analysis revealed that this compound can exist in two different polymorphic forms. 
Varying the temperature and pressure of preparation conditions can control the 
relative composition of the two polymorphs.
In some cases, amorphous products were obtained from the antisolvent precipitation 
method. Jaarmo et al (1997) produced Sodium chromoglycate using the SEDS 
technique employing methanol solution. Nanoparticles of catalyst precursor zinc 
acetate can be prepared using the Supercritical Anti solvent (SAS) method (Reverchon 
et al, 1999). Dimethyl sulfoxide was used as the solvent and SC-CO2 was used as the 
antisolvent. XRD analysis revealed that the SAS-processed product at 150 bar, 40°C 
and 90 mg/ml was amorphous. Recently, Reverchon et al (2000) reported that 
amorphous amoxicillin can be obtained from continuous SAS process. The solution of 
drug in N-methyl pyrrolidone was sprayed using SC-CO2 as anti solvent. However, the 
effect of the storage time on the morphology and the crystalline structure has not been 
assessed.
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As shown in Table 1.4, a significant number of recent publications demonstrates that 
the use of carbon dioxide as an antisolvent can clearly recrystallise many different 
polymers and pharmaceutical particles with a narrow size distribution using fewer 
organic solvents. In particular, Reverchon (1999) has published several reviews 
concerning supercritical antisolvent precipitation applications. Because the semi­
continuous process (PCA, ASES and SEDS) permits faster depletion of the solvent 
relative to the GAS or SAS process, they have received increased attention in recent 
years. However, most of the reported studies deal with batch production of milligram 
quantities of product and of the proof-of-concept. As a result, continuous production 
of particles with desired product characteristics and consistency for the semi­
continuous process requires investigation. Continuous harvesting of particles at high 
yield remains a challenge, especially with submicron size particles. Some useful 
attempts have been made to interpret the effects of process variables on particle size 
and morphology in terms of the dimensionless groups (Reynolds, Weber, and 
Ohnesorge numbers) that characterize the spray dynamics and jet breakup (Dixon et 
al, 1993; Saim et al, 1996; Eggers et al, 1996). At the same time a mathematical 
model of spray process, based on the underlying rate processes (spray dynamics, mass 
transfer, and nucléation process), is required for better understanding of mechanism.
Such an understanding is essential for rational design and scale-up.
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Table 1.4 . E xperim ental resu lts on  th e  supercritica l a n tiso lv en t p recip itation  o f com p ou nd s.
00
Solute Solution SCF* process Solution,
CO, Flow Rate
T(»C) P(bar) Nozzle Diam (p im )/ 
Particle D iam (|im )
References
L-PU\‘ (MW 102 000) 1.5%  (w/v) in CHjCI^ CO, PCA 3 m l/m in, 6.4 kg/h 40 90 ,200 400  /spheres l-IO Bleich et al 1993
L-PLA (MW 100 000) 0 .6%  (w/w) in CHjClj CO, PCA 1 m l/m in, stagnan t 31 76-97 75 /spheres 0 .6 -1 .4 (0 .5 ) ' Randolph et al 1993
0 .3%  (w/w) in CH^CI; CO, PCA 1 m l/m in, 5.34 SCFM 36 76-83 U ltrasonic/spheres 0 .8 -2 .8  (0.3)
L-PLA (MW 94100) 3%  (w/v) in CHjClj CO, PCA - 0 81.6 IO O /< l Bodmeier et al 1995
3%  (w/v) in CHjClj CO, PCA - 2 3 ,3 2 81.6 100/spheres 1-5, fibers
(+ )-C h lo rphen ira tn ine  m aleate  4%  (w/v) in CH^CI  ^
(IO % /3 .7 % )‘
CO, PCA 22 69 100/1-5
(+ )-ln d o m eth ac in  ( IO % /0 .7 % )‘ 4%  (w/v) in CH^CI; CO, PCA ■ 22 69 100/1-5
L-PLA (MW 102 000) (+)-H yosine-CH jClj/M eO H  (85:15) 
butylbrom ide (2 0 % /1 9 .5 , 1 9 .8 % ) '
CO, PCA
C02 Density 0 .5-0 .8  g/m l
33-60 90-200 yield 8 I% (I .6 9 )  
particle size <  20
Bleich et al 1994
L-PLA (MW 102 000) (+ )-H yosine- 2%  (w/w) in CH^CIj 
butylbrom ide (2 0 % /1 9 .5 , 1 9 .8 % ) '
CO, PCA 6 m l/m in, stagnan t 40 9 0 /2 0 0 4 0 0 /1 3 .2  " (2 3 .1 ) ',  1 4 .9"  (26 .4) ‘ Bleich and Muller 1996
(+ )-ln d o m eth ac in  (2 0 % /0 .5 % ) '  2%  (w/w) in CHjClj CO, PCA 6 m l/m in, 6 kg/h 40 200 4 0 0 /8 .2  (15.3)
(+ )-P iro x icam  (2 0 % /6 .8 , 3 .7% ) '  2%  (w/w) in CHjClj CO, PCA 6 m l/m in, 6 kg/h 40 90 ,200 4 0 0 /3 .5  (6 .0 ),2 .8  (3.7)
(+ )-T hym open tine  (5 % /4 .8 , 4 .9% ) '2 %  (w/w) in CH^CIj/MeOH CO, PCA 6 m l/m in, 6 kg/h 40 90,200 4 0 0 /6 .6  (12 .1), 5 .1(8 .7)
L-PLA (MW 115000 +  MW 7000) 3%  (w/w) in CHjClj CO, PCA - 30-45 85 3 0 0 /7  " ( 9 ) ‘ 2 6 "  (36) ‘ Thies and Muller 1996
3%  (w/w) in CHjClj CO, PCA - 40 65-125 3 0 0 /5 0  (55)-IO  (20)
HYAFF-7 " 2 00 -500  ppm  in DMSO CO, PCA 2.5 m l/m in, 5 m l/m in 40 104 1 00 /50 -500 Saim e t al 1996
PLGA' 0 .5  m g/m l in DMSO CO, PCA 2.5 m l/m in, 5 m l/m in 35 104 100/15
Hydrocortisone 20 0 -5 0 0  ppm in DMSO CO, PCA 2.5 m l/m in, 5 m l/m in 35 104 100/0.2-1
Insulin 0 .5 -9 .2  m g/m l in DMSO CO, PCA 0.9-1 .7  m l/m in, 9-26 L/min 28-46 91-142 30 o r 5 0 /  spheres 1-5 " W inters 1996
Lysozyme 2 .2 -6 .8  m g/m l in DMSO CO, PCA 0.2-2 .4  m l/m in, 10-21 L/min 27-45 73-115 30 o r 5 0 /  spheres 1-5 "
Trypsin 0 .1 -4 .0  m g/m l in DMSO CO, PCA 0.5-2.1 m l/m in, 5-20 L/min 27-47 73-136 30 o r 5 0 /  spheres 1-5 "
Polystyrene (MW 200  000) Toluene CO, PCA CO, Density 0 .24-0 .93 g/cm 3 
D > 0 .7  g/cm 3
0-40
< 3 0
39 .6-224 .7 100 / spheres, variety of size 0 .1- 
20 depending upon T and D 
100/0.1
Dixon e t al 1993
Table 1.4 [Continued^
U\VO
Solute Solution SCF process Solution,
C02 Flow Rate
T(Q P(bar) Nozzle Diam (m icron)/ 
Particle Diam(micron)
References
Lactose 10% (W/V) W ater CO; +EtOH 
or MEOH
SEDS 0.035 m l/m in, 5 o r 19 m l/m in 50 
co-solvent flow rate  0.665 
m l/m in
150 p'cle m orphology depends on
th e  CO j  flow rate  
particle size 5-31
Palakodaty et al 1998
Steroids drug 1% (w/w) CHjCI; a n d /o r  
MeOH
CO; ASES 63 m l/m in, stagnan t 40 8.5 3 0 0 /5 Steckel et al 1997
Nicotinic acid HeOH CO; SEDS - 35
120
80
80
particle size 9 .38  (0 .47) 
particle size 3.93 (0 .24)
Rehman et al 1999
Carbam azepine 5%  (w/v) CH;CI;, 
5%  (w/v) MeOH
CO; SEDS 0.5-1 m l/m in, 500  L/hr 45-85 80-150 polym orphs can be formed 
depends on solvent choice, 
supersa tu ration  ra te  and I
Edwards et al 2000
Terbutaline sulphate MeOH/W ater (92:8) CO; SEDS 35-80 90-250 variety of size 1.99-12.15 
depending upon supersa tu ration  
ra te  and D
Rehman et al 2000
Superconductor precursors 5-65 m g/m l in DMSO CO;+DMSO ASES Im l/m in ,6 5 0 0 -l2 0 0 0  m l/m in 40-60 70-160 22/0.1 Reverchon et al 1998
Lysozyme 0 .5 -1%  (w/v) in DMSO CO; SEDS 0.2-0 .6  m l/m in, 18-30 m l/m in 40-50 80-150 0 .2 , 0 .3 /  1-5 a t  low P Moshashaee e t al 2000
C u-lndom ethacin cpx ' 90%  (w/v) in DMF CO; GAS 25-40 59 P'cle m orphology and Partice 
size 10-100 depends on 
expansion ra te  and cone of 
solution
W arwick e t al 2000
'  super critical fluid. poly(L-lactic acid). ‘ (Expected drug load ing / actual drug loading): the am ount of drug in the precip itate (actual) was less than  am ount of drug mixed with th e  polym er p rior to  precipitation 
(expected), due to  partition ing  of the  drug in to  CO; during m icroparticle form ation; eg, (20% /6 .8 ,3 .7% )m eans 6 .8%  drug loading a t  90 bar, 3 .7%  drug loading a t 200 bar. ‘'Hyalurinic acid ethyl ester. '  Poly( dl- 
lactide-glycolide). ^Copper and Indom ethacin complex. ^Relative standard  deviation. ""After sonication. 'Range: IO"*- 9 0 ' percentile.
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1.4 Techniques for characterizing amorphous solids
Various techniques have been proposed for the physical characterization of 
amorphous solids. These techniques include, Differential Scanning Calorimetry 
(DSC), X-ray Diffraction (XRD), Molecular spectroscopy. Isothermal Calorimetry, 
Modulated DSC, Solution Calorimetry, Density, Solubility and Water sorption. 
Buckton and Darcy (1999) reviewed both calorimetric (Isothermal microcalorimetry, 
solution calorimetry) and gravimetric methods, which can be used to characterise 
partially amorphous materials. Darcy and Buckton (1998) employed isothermal 
microcalorimetry to quantify the amorphous content of spray-dried lactose. Taylor 
and Zografi (1998b) used FT-Raman Spectroscopy to quantify the degree of 
crystallinity in milled indomethacin.
1.5 Dissolution studies
Many drugs exhibit poor solubility in water, thus presenting problems with regards to 
dissolution and hence bioavailability. The dissolution rate of drugs in the 
gastrointestinal fluids is often the rate-limiting step in the absorption of drugs rather 
than their diffusion rates across the gut wall.
The in vivo dissolution rate and the bioavailability of drugs for gastrointestinal 
absorption from solid dosage forms are relatively difficult to perform as the study 
involves human volunteers. In vitro dissolution experiments, which are comparatively 
simpler to perform, can be used to approximate the dissolution behaviour of the drugs 
in the body.
1.5.1. Factors affecting the dissolution rate of drugs
1.5.1.1 Solid phase characteristics
Many studies have shown that the crystalline form of a drug usually exhibits lower 
solubility and dissolution rate compared to that of the amorphous form. For example, 
novobiocin, phénobarbital, cortisone acetate, griseofulvin, and chloramphenicol 
(Banakar, 1992).
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1.5.1.2 Polymorphism
The polymorphic forms of drugs and the states of hydration have been shown to affect 
the solubilising characteristics and dissolution rates of drugs. The anhydrous form 
usually has a higher aqueous solubility and faster dissolution rate than the hydrated 
form (Brittain and Grant, 1999). The influence of polymorphism on the dissolution 
rate has been reported for various pharmaceutical drug compounds, which included 
carbamazepine, tolbutamide, phenylbutazone, erythromycin, ampicillin and 
chloramphenicol (Banakar, 1992).
Al-Saieq et al (1982) studied the dissolution behaviour of chlorpropamide (CPM) 
polymorphs. The four metastable forms exhibited higher dissolution rates than that of 
the stable form. Ueda et al (1984) carried out further investigations on the dissolution 
profiles of CPM polymorphs in potassium chloride-hydrochloiide acid buffer system. 
The polymorphic transformation of metastable form II to the stable form was 
observed during dissolution testing. Although the metastable polymorph exhibited a 
faster dissolution rate than the stable form, the use of the metastable form to improve 
the dissolution rates of poorly water soluble drugs is limited in application to 
commercial drug formulations. This limitation was due to the possibility of 
conversion from the highly soluble form to the less soluble crystalline form during 
manufacture and storage of the dosage forms (Horter and Dressman, 1997).
1.5.1.3 Particle size and surface area
The surface area of pharmaceutical solids plays an important role in controlling the 
dissolution. In general, the dissolution rate is directly proportional to the surface area 
of the drug. As a result, a higher dissolution rate can be obtained through a reduction 
in particle size. However, in the case of hydrophobic drugs with poor wettability, 
decreasing the particle size may not enhance the dissolution rate. Loth and 
Hemgesberg (1986) reported that dissolution rates of phenacetin powders micronised 
by jet milling and the Rapid Expansion of Supercritical Solution technique were 
nearly the same, even though they differed considerably in their surface areas. The 
insignificant difference in the dissolution rate was due to the agglomeration of the 
drug particles delaying dissolution medium penetration and subsequent wetting. The 
dissolution rate of micronised phenacetin was enhanced after mixing with hydrophilic
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vehicles, such as mannitol and Aerosil R972. Once the wetting limitation was 
eliminated, the phenacetin micronised by RESS showed a higher dissolution rate than 
that produced via jet milling.
1.6 Thesis aims
The objectives of this work were to study the formation and stabilisation of drugs in 
the amorphous state, as a means of increasing dissolution and hence potentially 
bioavailability. A poorly water soluble drug, indomethacin, was selected as a model. 
Another objective was to construct and design a supercritical fluid based apparatus for 
preparing amorphous particles.
The aims of this study were to prepare amorphous particles using different methods. 
These included spray drying and precipitation using supercritical CO2 as solvent and 
antisolvent. In addition the effect of different additives on the physical form of 
indomethacin would be investigated. A further aim was to understand how processing 
method and presence of additives affects dissolution and physical stability.
The hypothesis was that spray drying and supercritical fluid based techniques should 
make amorphous material, and that changes in production method would yield 
different morphologies and give different physical properties of products, especially 
with respect to dissolution rate.
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2.1 Materials
2.1.1 Drug 
Indomethacin
The drug Indomethacin, having a poor solubility in water, was chosen as a model. 
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) having anti­
inflammatory, analgesic and antipyretic activities (O’Brien et al, 1984; Laurence et al,
1997). NSAIDs are indicated for the treatment of moderate to severe rheumatoid 
arthritis, acute gouty arthritis and for the relief of mild to moderate pain (Mehta, 1993; 
Berkow et al, 1997).
Member drugs of the NSAID group act by inhibiting prostaglandin biosynthesis and 
share several adverse affects which include gastrointestinal bleeding and ulceration 
(Charles and Mogg, 1994). Previous thermodynamic and kinetic examinations of their 
behaviours in aqueous solutions reported a dominant hydrophobicity, weak acidity, 
low solubility and low dissolution rate in water but high partition coefficient in their 
acidic form (Fini et al, 1995). Many NSAIDs with expired patents are being 
developed as generic products with the possible risk of variable bioavailability due to 
differences between formulations. Indomethacin is one of them. There are more than 
one hundred NSAID drugs, which are presently available worldwide.
CO
Figure 2.1. Structural formula of Indomethacin
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Indomethacin (C19H 16CINO4 , l-[p-chlorobenzoyl]-5-methoxy-2-methylindole-3- 
acetic acid} is a pale-yellow to yellow tan crystalline powder with a slightly bitter 
taste. It is odourless or almost odourless, practically insoluble in water (less than I g/1) 
and has a molecular weight of 357.79 g/mole. Table 2.1 shows the equilibrium 
solubilities of indomethacin in different solvents at 25 °C (O’Brien et al, 1984). 
Indomethacin is light sensitive but stable in air and heat under the normal temperature 
conditions.
Table 2.1. Indomethacin solubility in different solvents at 25 C ( adapted from O’Brien et al, 1984).
Solvent Solubility (mg/100 ml)
Water Practically Insoluble
Phosphate Buffer pFI 5.6 3(a)
Phosphate Buffer pH 5.6 5(b)
Phosphate Buffer pH 7 54(a)
Phosphate Buffer pH 7 80(b)
Ethyl alcohol (95%) 200
Chloroform 330
Methanol 320
Benzene 40
(a) Fomn I, (b) Form II
Indomethacin is known to exist in two non-solvated crystalline modifications. There
are consistent melting points, infra-red (IR) and powder X-ray diffraction data for
these two polymorphic forms. Polymorphism is a phenomenon demonstrated by
compounds that are able to crystallise in more than one crystal structure. Due to the
different crystal packing arrangements, polymorphs display different chemical and
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physical properties such as melting point, solubility, heat of fusion, density and 
refractive index (Rustichelli et al., 2000). Yamamoto (1968, through O’Brien et al, 
1984) named the two forms of indomethacin as y-type (melting point at about 162 °C) 
and a-type (melting point at about 155 °C). However, most of the researchers use 
Form I and Form II, respectively. Form I is the highest melting and lowest solubility 
polymorph. It is the thermodynamically stable crystalline form of indomethacin. 
Therefore, this form has been used in the pharmaceutical preparations. In addition to 
the polymorphic forms as described above, indomethacin can form solvates with 
benzene, t-butyl alcohol and other solvents (O’Brien et al, 1984).
Indomethacin (Lot No. 950012-254, Becpharm Ltd., England) of European 
Pharmacopeia quality was used as received.
2.1.2. Polymers 
Polyvinylpyrrolidone (PVP)
Polyvinylpyrrolidone or Povidone {poly[ 1 -(2-oxo-1 -pyrrolidinyl) ethylene]} is a 
synthetic, water soluble polymer consisting of linear 1 -vinylpyrrolidin-2 -one group. 
The molecular weight of polyvinylpyrrolidone (PVP) depends on the degree of 
polymerization, which ranges between 2,500 and 3,000,000 g/mole. PVP is a fine, 
white to creamy coloured, odourless and hygroscopic powder. It is freely soluble in 
acids, chloroform, ethanol, ketones, methanol and water (Wade and Weller, 1994). It 
is stable to a short cycle of heat exposure at around 110-130 “C but it darkens if the 
temperature is higher than 150 °C.
— CH—CH2—
Figure 2.2. Structural formula of Polyvinylpyrrolidone
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PVP has been employed in many preparations especially in solid-dosage forms. PVP 
can be used as binder, disintegrating agent, and dissolution enhancer (Wade and 
Weller, 1994). The main advantages of using PVP are non-toxicity and general 
applicability to most drugs. Many researchers investigated the effect of PVP as an 
excipient on the crystallisation of compounds. Sekikawa et al (1979) reported that 
PVP retarded or inhibited crystallisation of sulfisoxazole, sulfamethizole, and 
sulfamerazine but has no effect in the crystallisation of nalidixic acid and caffeine. 
Corrigan et al (1985) showed that PVP inhibited the crystallization of indomethacin 
following co-spray drying. It has been shown that PVP can act as a stabilising agent 
for the amorphous state of certain materials. The mechanism of action of PVP as a 
stabiliser could be due to the formation of hydrogen bonds with the materials. In 
addition, PVP has an anti-plasticizing effect, and therefore increases the glass 
transition temperature of materials (Shamblin et al, 1998; Shamblin and Zografi, 
1998; Taylor and Zografi, 1997; 1998a). PVP is known as a stabilising agent because 
of its ability to maintain a material in its amorphous state for a period of time.
PVP (MW 44,000Da, BDH Laboratory Supplies, England) was used as polymeric 
carriers for spray drying, precipitation using S C - C O 2  as solvent and as anti-solvent 
process.
Microcrystalline cellulose
Microcrystalline cellulose (MCC) in general has a wide range of uses in oral 
pharmaceutical solid dosage forms. It is basically used in tablet and capsule 
formulations, where it functions as a filler-binder, lubricant and also disintegrant 
(Wallace et al, 1983). The quantity of MCC used in a formulation may also alter 
depending on its functions. Table 2.2 presents the use of MCC and the corresponding 
concentrations (Wade and Weller, 1994). MCC is a white, odourless, and tasteless 
powder. There are several grades of MCC, which are commercially available in 
different particle sizes and moisture contents. It is slightly soluble in 5% w/v sodium 
hydroxide solution, practically insoluble in water, dilute acids, and most organic 
solvents (Wade and Weller, 1994).
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OH CH20HOH CH20H
OHHO
Figure 2.3. Structural formula of microcrystalline cellulose
Table 2.2 The functions and their corresponding concentrations of MCC.
Use Concentration (%w/w)
Adsorbent 20-90
Anti-adfierent 5-20
Capsule filler-binder 20-90
Tablet disintegrant 5-15
Tablet filler-binder 20-90
MCC is a non-toxic and non-irritant material. It is not absorbed readily into the body 
system following oral administration (Wade and Weller, 1994). It was found that 
MCC markedly affected the mechanical, microstructural and release characteristics of 
tablets (Landin et al, 1993). The study of cohesive properties of MCC indicated that 
these properties were related to hydrogen bonding. The hydrogen bond provides 
mechanical strength to the tablet by holding the particles together (Wan and Prasad, 
1988) and the strength increases with increasing amount of cellulose (Pesonen et al, 
1992). However, although MCC has excellent tablet binding characteristics, a rapid 
drug release from samples compressed with MCC is expected as this is due to the 
hydrophillic nature of the cellulose derivative (Shaikh, 1991). It has been documented
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that the uptake of water into the tablet was increased by MCC. In consequence, the 
disintegration time was shortened (Wan and Prasad, 1988; Pesonen et al, 1992). This 
phenomenon occurred due to MCC accelerating the dissolution rate by the mechanism 
of enhancing water penetration into the tablet. As a result, the hydrogen bonds 
between MCC and drug were broken and the tablet structure loosened. It has also 
been shown that MCC absorbed water by capillary action. The molecular swelling is 
insignificant and the structure of MCC is retained even after water absorption (Wan 
and Prasad, 1988).
MCC (Emcocel 50M, mean particle size of 50 pm, Edward Mendell, Reigate, Surrey, 
England) was used as polymeric carriers for spray drying process. It was also used as 
a formulation excipient.
Silicifîed microcrystalline cellulose
Silicified microcrystalline cellulose (SMCC), achieved by silicification of the 
microcrystalline cellulose, resulting in an association between colloidal silica and 
microcrystalline cellulose. This particular grade has a median particle size in the 
region of 2 0 0  pm.
SMCC (ProsolV, LP200, Penwest, England) was used as polymeric carriers for spray 
drying process.
Polyethylene glycol
Polyethylene glycol (PEG) is an addition polymer of ethylene oxide and water. PEG 
grades 200-600 are liquids; grades 1 0 0 0  and above are solids at ambient temperature. 
The liquid grades appear as clear, colourless, viscous liquids. They have a slight, but 
characteristic odour and a bitter, slightly burning taste. The solid grades are white and 
waxy flakes. They have a faint, sweet odour. PEG is widely used in a variety of 
pharmaceutical formulations. All grades of PEG are stable, soluble in water and 
miscible in all proportions with other PEG (after melting, if necessary). PEG 4000 has 
a melting range of 50-58 °C.
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PEG (MW 4,000 Da, BDH, England) was used as a polymeric carrier for 
precipitation using S C - C O 2  as a solvent.
2.1.3 Organic solvents
Organic solvents include acetone, chloroform, dichloromethane, and N,N- 
Dimethylformamide, ethanol, ethanol 96% and anhydrous methanol were used to 
dissolve indomethacin. The properties of the solvents described in the literature 
(British Pharmacopoeia 2002, Pharmaceutical codex, 1994) are summarized as 
follows:
Acetone
Acetone, propan-2-one, CsHôO, is a volatile and flammable liquid. Its boiling point is 
56 °C.
Acetone (BDH, England) was used as a solvent to dissolve indomethacin.
Chloroform
Chloroform, trichloromethane, CHCI3 , contains 0.4 to 1.0% w/w of ethanol. It appears 
as a colourless, heavy, volatile liquid with a characteristic penetrating odour and a 
sweet burning taste. It is non-inflammable but the strongly heated vapour could be 
ignited and bum with production of noxious vapour. The boiling point is 60°C. It is 
soluble in 200 parts of water at 20 °C. It is miscible with dehydrated alcohol, ether, 
most other organic solvents, and fixed and volatile oils.
Chloroform (BDH, England) was used as a solvent to dissolve indomethacin.
Dichloromethane
Dichloromethane, Methylene chloride, CH2CI2 , appears as a volatile, sweet-smelling 
liquid. Its boiling point is 40°C.
Dichloromethane (BDH, England) was used as received. It was also mixed with 
ethanol (at ratio of 1 to 1, v/v). Both were used as solvents to dissolve 
indomethacin.
Dimethylformamide
Dimethylformamide C3H7NO, is a colourless liquid. The boiling point is 153°C.
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Dimethylformamide (Sigma-Aldrich, England) was used as a solvent to dissolve 
indomethacin.
Ethanol
Ethanol (99.7-100% v/v) or absolute alcohol, CH3CH2OH, appears as a clear, 
colourless, mobile, volatile liquid with a characteristic spirituous odour and a burning 
taste. It is readily inflammable. The boiling point is 78 °C. It is miscible with water, 
ether and chloroform. In addition, when mixed with water, contraction of volume and 
rise of temperature occur.
Ethanol (BDH, England) was used as received. It was also mixed with 
dichloromethane (at ratio of 1 to 1, v/v). Both mixtures were used as solvent to 
dissolve indomethacin.
Ethanol 96%
Ethanol 96% is a mixture of ethyl alcohol (ethanol), CH 3 CH 2 OH, and water. Ethanol 
96% (BDH, England) was mixed with water (at ratio of 1 to 2, v/v). It was used as 
solvent to dissolve indomethacin in spray drying process.
Anhydrous methanol
Anhydrous methanol, CH 4 O, contains water not more than 0.03% w/v. It appears as a 
colourless liquid. It is readily inflammable. The boiling point is 64 to 65 °C.
Anhydrous methanol with less than 0.0050% water (Prolabo, England), was used as a 
solvent to dissolve indomethacin in solvent evaporation method.
2.1.4 Excipients 
Sodium starch glycolate
Sodium starch glycolate is a sodium salt of a cross-linked partly o-carboxymethylated 
potato starch. It occurs as a white to off-white, odourless, tasteless, fine and free 
flowing powder. It is very hygroscopic, practically insoluble in methylene chloride. It 
gives a translucent suspension in water. It is cormnonly used in oral pharmaceuticals 
as a disintegrant in solid dosage form. It is widely used in tablets prepared using either 
direct-compression or wet-granulation process. Usually, the concentration employed
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in a formulation is between 2-8%. Disintegration occurs by rapid uptake of water 
followed by immediate swelling.
Sodium starch glycolate (Explotab, Edward Mendell, England) was used as a 
disintegrant for direct-compression indomethacin tablet.
Magnesium stearate
Magnesium stearate is a mixture of magnesium salts of different fatty acids consisting 
chiefly of palmitic acid and stearic acid with minor proportions of other fatty acids. It 
appears as a white, very fine, precipitated or milled, light powder. The powder is 
greasy to the touch and readily adheres to the skin. It has a faint odour of stearic acid 
and a characteristic taste. It is practically insoluble in water and ethanol. Magnesium 
stearate is commonly used in cosmetics, food and pharmaceutical formulations. It is 
widely used as a lubricant in capsule and tablet formulations at concentrations 
between 0.25-5%.
Magnesium stearate (BDH, England) was used as a lubricant for direct-compression 
indomethacin tablet.
2.1.5 Distilled water
Freshly prepared distilled water (measured pH 5.2) was used as an antisolvent for 
Indomethacin precipitation, for preparing dissolution medium and saturated salt 
solution in RH stability studies.
2.1.6 Dissolution medium
A test solution described in the British Pharmacopoeia (BP 2002) was prepared to be 
the dissolution medium.
Phosphate buffer solution pH 7.2 (measured pH 7.2) was prepared by mixing 50 ml of 
0.2 M potassium dihydrogen orthophosphate with 35 ml of 0.2 M sodium hydroxide 
and diluting to 200 ml with water. It was used as the dissolution medium for tablets 
and capsules containing indomethacin.
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Potassium dihydrogen orthophosphate (Fisher, England) and Sodium hydroxide 
pellets (BDH, England) were used for preparing dissolution medium.
2.2 Methods
2.2.1 Scanning electron microscopy
The morphological properties of the indomethacin powder were characterised using a 
scanning electron microscope (Philips XL20, Eidnhoven, Netherlands) at an 
accelerating voltage of between 10 and 15 kV. Prior to examination, samples were 
coated with a thin layer of gold by using a sputter coater (Emitech K550) to render 
them electrically conductive, after the powder had been mounted on double sided 
adhesive tape on aluminium stubs.
2.2.2 Differential scanning calorimetry (DSC)
Differential scanning calorimeter is a thermal analysis instrument. The substance 
under investigation is heated or cooled at a constant rate through a phase transition. 
The DSC provides solid-state transition data, such as melting points, glass transition 
and heat capacity. Determination of purity of materials and compatibility of excipient 
and drugs can be derived from DSC results (Ford and Timmins, 1998).
There are two basic types of DSC, the heat-flux DSC, and the power compensation 
DSC. For the heat flux DSC, the sample and reference are heated by the same furnace. 
The temperature difference, AT, between the materials is measured and recorded 
versus time (or temperature).
A T  =  T s - T r
The area under the curve is related to the enthalpy of reaction, AH
AH = k X area =k x J AT x dt
where k is the calibration constant. The value of k can be determined by measuring 
the area of a known standard. As
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k = AHs xms / As
where AHs is the enthalpy of fusion of the standard and ms is the mass of the 
standard.
For the power compensation DSC, the sample and reference are heated by two 
separate furnaces. The power difference between the materials is plotted against time 
(or temperature) where the temperature difference AT is maintained at zero.
AP= dAq/dt = P x  ( C s- C r)
where P is the heating rate, Cs is the heat capacity of the sample and C r is the heat 
capacity of the reference. In this case, the area under the peak gives the enthalpy 
directly.
The heat capacity, the amount of energy required to raise one gram of sample by 1 
°C, can also be determined from DSC data. The greater the heat capacity (AC?), the 
greater the baseline deflection. Power is related to the heat capacity as in the 
following equation
Power = dq/dt =ACp x dT/dt
To determine the heat capacity of a sample, it must be compared with a known 
standard, for example sapphire (Me Naughton and Mortimer, 1975).
The International Confederation of Thermal Analysis (ICTA) suggested that the data 
obtained with a power-compensation type should show endotherms in an upward 
direction (Figure 2.4).
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Figure 2.4 A typical thermogram generated from power compensation DSC (data 
adapted from Perkin-Elmer training paper).
A differential scanning calorimeter (Perkin Elmer DSC 7, USA) was employed. 
Samples of approximately 5 mg were carefiilly weighed and hermetically sealed in 
aluminium pans. A heating rate of 10 °C /min from 25 to 250 °C under nitrogen gas 
atmosphere was used.
2.2.3 Powder X- ray Diffraction Analysis
The crystalline nature of materials can be investigated using X- ray diffraction 
analysis, i.e. diffraction of x- rays from the planes of a crystal. The condition for 
diffraction of x-ray beams from a crystal is explained by the Bragg equation;
nA = 2 d sinO
where A is the wavelength of the X-ray beam, 0 is the angle of diffraction, d is the 
distance between atomic planes in the crystal, and n is the order of the diffraction
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The scattering power of atoms for X-rays depends on the amount of electrons they 
possess. Hence, the position of the diffraction beams from a crystal depends on the 
size and shape of the unit cell of a crystal and the X-ray beam wavelength. In contrast, 
the intensity of the diffracted beams depends on the type of atoms in the crystal and 
location of these atoms in the unit cell. No two substances would be expected to have 
exactly identical diffraction patterns. For this reason the X-ray pattern is a unique 
result for each crystalline compound.
X-ray diffraction is usually very useful for the initial identification of differences in 
morphology. However, variations in diffraction patterns may result from differences 
in orientation that are not related to differences in crystal structure (Szulzewsky et al, 
1982). The Geometrical relationships among X-ray beam wavelength, diffraction 
angle and the distance of lattice space is shown in Figure 2.5.
Lattice
spacing
Reflected 
X-ray beam
Incident 
X-ray beam
■Crystal plane
.Crystal plane
Crystal plane
Figure 2.5 Geometrical relationships among X-ray beam wavelength, diffraction angle 
and the distance of lattice space.
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If the baseline of spectra is flat between 5° and 50° 20 and the peaks are sharp and 
well defined, the sample can be characterized as crystalline (Figure 2.6(a)). If the base 
line increases in a form of a broad hump at about 2 0 ° 2 0  before dropping again, and 
also has superimposed peaks, it can be explained that the sample may be a mixture of 
crystalline and amorphous material (Figure 2.6(b)). If a spectrum has a smooth hump 
without peaks it means the sample is a totally amorphous material (Figure 2.6(c)).
A Philips PW3710 scanning X-ray powder diffractometer (Philips, Netherlands) was 
used to quantify the presence of crystalline indomethacin in the various samples. The 
radiation used was generated by a copper k<^  filter, with a wavelength of 1.5418 ° A at 
35 kV and 40 mA. Samples were scanned over a range of 20 values from 5° to 50° at 
a scan rate of 2.5°/min.
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Figure 2.6(a) Typical spectra of crystalline material.
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Figure 2.6(b) Typical spectra of partially amorphous material.
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Figure 2.6(c) Typical spectra of amorphous material.
78
Chapter 3 
Spray Drying
Chapter 3________________________________________________________________________________ Spray drying
3.1. Introduction
It has been shown that the spray-drying process can change the physical state of drugs 
with a poor solubility in water and thus increase significantly their in vitro dissolution 
rates. For instance, spray dried indomethacin, phenobarbitone and hydroflumethiazide 
have shown enhanced drug dissolution due to the presence of amorphous content in the 
products (Corrigan et al, 1984; 1985). To change the physical state of poorly water 
soluble drugs and thus to enhance their dissolution and improve their bioavailability, 
polymers and other glass forming solids have been mixed with drugs prior to spray drying 
(Corrigan et al, 1985; Bootsma et al, 1989; Giunchedi and Conte, 1995; Corrigan and 
Crean, 2002).
The aim of this part of the study was to explore the potential of employing the spray- 
drying method in modifying the physical state of indomethacin. Indomethacin and 
polymer mixtures were studied using three different polymers, PVP, MCC and SMCC. 
The spray-dried powders were characterised using DSC and powder X-ray diffraction. In 
addition, the spray-dried samples were prepared in tablet dosage form and their 
dissolution behaviour was investigated.
3.2. Materials and Methods
3.2.1. Materials
Indomethacin, microcrystalline cellulose, polyvinylpyrrolidone, silicified microcrystalline 
cellulose, 96% ethanol, sodium starch glycolate, magnesium stearate, potassium 
dihydrogen orthophosphate, sodium hydroxide pellets, distilled water. The details of these 
materials are given in section 2 .1 .
3.2.2. Preparation of spray dried indomethacin
It was recommended that the Buchi B-190 Minispray dryer should be used only with 
aqueous systems but not used with organic solvents. However, combustible solvents 
could be used if their inflammable/explosion limit is not exceeded. Some examples of 
air/solvent ratio calculations are explained in Appendix. In the present study, a mixture of 
ethanol (96%) and water (2:1, v/v) was used as a solvent for the model drug 
indomethacin. Since increase in humidity content in the spray chamber could reduce
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electrostatic charge build-up, water was added to the spray drying solution. The explosion 
limit of a solvent mixture could also be reduced in the presence of water and thus could 
minimize the potential risk.
Accurately weighed indomethacin of 100 mg was added slowly and dissolved in 360 ml 
of solvent mixture containing ethanol (96%) and water (2:1, v/v). The amount of drug 
dissolved before the supersaturation was recorded and taken as the maximum 
concentration of drug dissolved. Thus, indomethacin solubility in this solvent mixture 
was approximately 1.4% w/v.
Preliminary investigations were carried out to determine the effect of aspirator speed, 
inlet temperature and feed concentration on the physical characteristics and yield of the 
spray dried product. Solutions of indomethacin were prepared in ethanol (96%) and water 
(1:2, v/v) at concentrations of 0.7%w/v and 1.4% w/v. The solutions were spray dried 
using Buchi minispray dryer type 190 (Buchi Laboratory-Techniques Ltd., Switzerland), 
with a 0.7 mm pneumatic nozzle, under different conditions outlined in Table 3.1
Table 3.1 Spray drying parameters investigated for indomethacin
Settings 
Spray drying c o n d itib n s^ ^ (a) (b) (c) (d) (e) (f)
Feed concentration (%w/v) 1.4 1.4 1.4 1.4 0.7 0.7
Aspirator level 18 15 1 0 1 0 1 0 1 0
Pump flow rate (ml/min) 1 0 8.5 5.6 5.6 5.6 5.6
Compressed air flow rate CL/h) 600 600 600 600 600 600
Inlet temperature ) 150 150 150 1 0 0 150 1 0 0
Outlet temperature (®o ) 85-90 80-85 75-80 75-80 75-80 75-80
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Throughout the study, the material was obtained in the collecting vessel and the cyclone 
separator above the collecting vessel. The spray-dried product was desiccated 
immediately after drying at 0%RH over phosphorous pentoxide at 25 °C, to prevent 
uptake of moisture. The percentage yield was calculated using the weight of the materials 
collected from both sites. These preliminary experiments showed that the highest product 
yield was achieved with 1.4% w/v feed concentration, 5.6 ml/min feed input, level 10 (20 
m^hr'^) aspirator speed, 150 °C inlet temperature and 75-80 “C outlet temperature. Hence, 
these were the conditions chosen to produce spray dried materials for further 
investigation in this study.
3.2.3. Preparation of indomethacin and microcrystalline cellulose mixture
Mixtures of indomethacin and MCC at ratios of 8:2,9:1 and 9.5:0.5, were ground for 30 
min using a mortar and pestle. Another set of experiments comprising similar proportions 
of indomethacin and MCC was prepared but without grinding. The physical mixtures 
were dispersed in a solvent mixture consisting of ethanol (96%) and deionised water at 
ratio of 2:1 to produce 1.4 %w/v suspension. The suspension was stirred for 1 hr prior to 
spray drying using the settings as described above.
3.2.4. Preparation of indomethacin and polyvinylpyrrolidone mixture
Indomethacin and polyvinylpyrrolidone were dissolved in ethanol (96%) and deionised 
water solvent mixture at ratio of 2:1 to produce 1.4 %w/v solution. The proportions of 
indomethacin and PVP investigated were, 9.5:0.5, 9:1, 8:2, 7:3, 6:4, 5:5 and 4:6. The 
mixture was spray dried using the settings as described above.
3.2.5. Preparation of indomethacin and PVP mixtures with the inclusion of 
microcrystalline cellulose or silicified microcrystalline cellulose
Indomethacin and polyvinylpyrrolidone ( 8:2) was dissolved in ethanol/water solvent 
mixture at a concentration of 1.4% w/v. Microcrystalline cellulose or silicified 
microcrystalline cellulose was dispersed into the solution at 10%, 20% and 30% w/w of 
the indomethacin and PVP mixture.
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Another set of experiment was prepared comprising fixed amount of indomethacin but 
different ratios of PVP and MCC or SMCC (Table 3.2). Indomethacin and polymer (8:2) 
were dissolved or dispersed in ethanol/water at a concentration of 1.4% w/v. The mixture 
was stirred and spray dried using the settings as described previously.
Table 3.2 The composition of indomethacin and different polymer for spray dried 
solutions.
Sample Compositions
Indomethacin PVP MCC SMCC
8 2 - -
8 1 1 -
8 - 2 -
8 1 - 1
8 - - 2
3.2.6. Thermal Analysis
Characterization method using DSC was described in section 2.2.2.
3.2.7. X-Ray Diffraction Analysis
Characterization method using XRD was described in section 2.2.3.
3.2.8. Preparation of tablets
The spray-dried powders of indomethacin and PVP (8:2), indomethacin, PVP and MCC 
(ratio of 8:2:1), indomethacin, PVP and SMCC (8:2:1) as well as crystalline 
indomethacin alone, were selected for the preparation of tablets. The spray-dried powders 
were mixed with microcrystalline cellulose (diluent), sodium starch glycolate (3%) and 
magnesium stearate (0.2%) for 30 minutes in a mortar and pestle. The powder mixture 
was weighed and fed manually into the die of a single punch tableting machine (F3
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Manesty, England) fitted with a flat surface punch of 13 mm diameter. The powder 
mixture was compressed into tablets with weight of about 700 mg. Each tablet contained 
50 mg of indomethacin.
3.2.9. Dissolution study
Selecting a suitable dissolution medium is an important step in dissolution studies, since 
the choice of medium can affect the dissolution rate of drugs. Indomethacin is a weak 
acid (pKa = 4.5), thus its solubility and dissolution rate can be enhanced when a basic 
medium is used. In this study, phosphate buffer solutions at various pH (pH 6.4-8.0) were 
tested for appropriate dissolution media. At pH 8.0, the rapid dissolution of indomethacin 
was undesirable for the dissolution studies, as it was difficult to distinguish the difference 
between the dissolution profiles of the spray dried indomethacin and that of the original 
material. In order to prolong the dissolution time of indomethacin, dissolution media with 
lower pH were examined. This extended time span allowed more samples to be taken, 
giving more accurate and reliable dissolution profiles. However, if the pH was further 
reduced below 7.2, the dissolution time was unnecessarily long. The phosphate buffer 
solution, pH 7.2 was therefore used as the medium for the dissolution studies.
The dissolution study of tablets was performed using the paddle method (Pharmatest, 
Germany). The dissolution medium comprised 900 ml of phosphate buffer pH 7.2 (BP,
1998). The temperature of the dissolution medium was maintained at 37+0.5 °C with a 
stirring speed of 50 rpm. The samples were collected by automated sampler at preset time 
intervals and analysed spectrophotometrically (Beckman DU-62 Spectrophotometer, 
USA) at the detection wavelength of 320 nm. The percentage drug released was 
calculated and the mean dissolution values versus time profiles were plotted.
3.3. Results and Discussion
Operating conditions for spray drying of indomethacin were preliminarily investigated. 
The aspirator setting alters the velocity of the atomising air which provides the energy for 
atomisation of the feed material, subsequently affecting a degree of separation in the 
cyclone. High aspirator speed results in a high degree of separation in the cyclone. In 
dealing with a combustible solvent, when high aspirator speed was employed, the feed
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rate of solution must be high (calculated within explosion limit), otherwise an explosion 
can occur. In practice, at high aspirator speed (setting n o l8 ) and a liquid feed rate (10 
ml/min), no product was collected, presumably because it was lost in the air stream 
exhaust. Decreasing the aspirator speed to level 15 (feed rate 8.5 ml/min) also produced 
the same problem. Eventually, when an aspirator speed of level 10 was employed (feed 
rate 5.6 ml/min), the powder was obtained in the collecting vessel and the cyclone 
separator. Consequently, an aspirator speed of level 10 was used for further studies in 
settings (d), (e) and (f).
Feed concentration and inlet temperature were investigated at a constant aspirator speed 
and outlet temperature. The yield of the spray drying process was calculated from the 
weight of the dried product collected from the collecting vessel and cyclone separator, as 
a percentage of the initial quantity used in the feed solution (Table 3.3)
Table 3.3 Results of % yield for indomethacin spray dried under different conditions
Drying conditions % Yield
Feed concentration; Inlet temperature (n=l)
0.7%; 100 °C 43.6
0.7%; 150 “C 24.0
1.4%; 100 °C 65.5
1.4%; 150 “C 70.9
The percentage yield obtained was greater for the more concentrated feed solution (1.4% 
w/v). The 0.7% w/v feed solution yielded less product as the inlet temperature was 
increased. As a result of this investigation, a feed concentration of 1.4% w/v and an inlet 
temperature of 150 °C, at a constant outlet temperature were chosen as optimum spray 
drying condition.
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The DSC thermograms of spray-dried indomethacin, spray-dried indomethacin and MCC 
together with spray-dried indomethacin and MCC with grinding are given in Figures 3.1-
3.3. The thermogram of spray-dried indomethacin exhibited two endothermie melting 
peaks, suggesting the presence of both the metastable and stable crystalline forms. It was 
reported previously that spray-dried indomethacin demonstrated a glassy amorphous form 
(Corrigan et al, 1985). However, no evidence of the amorphous form was seen in the 
present study, even though different operating conditions were employed. The 
inconsistency of the present findings might be attributed to the different drying 
parameters. Another contributing factor could be the use of different feed concentrations. 
Corrigan et al (1985) did not explain in detail the conditions used for spray drying.
The spray-dried indomethacin and MCC showed two endothermie melting peaks of 
metastable and stable crystalline forms (Figure 3.2). Similarly, the spray-dried 
indomethacin and MCC with grinding prior to spray drying depicted two endothermie 
peaks (Figure 3.3).
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Figure 3.1 DSC scan of spray-dried Indomethacin in Ethanol/water
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Figure 3.2 DSC scan of spray-dried dispersion of MCC in solution of Indomethacin in 
Ethanol/water
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Figure 3.3 DSC scan of spray-dried ground mixtures of Indomethacin and MCC in 
Ethanol/water
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In addition, the powder X-ray diffraction showed that the spray-dried samples were 
crystalline (Figures 3.4-3.6). The spray drying process did not alter the physical state of 
indomethacin or mixtures of indomethacin and MCC. Nakai et al. (1978a; 1978b) 
reported that MCC could convert crystalline volatile materials into the amorphous state 
by vibrational milling. However, grinding indomethacin with MCC could not produce the 
amorphous form in the present study. Moreover, grinding followed by spray-drying could 
not successfully change indomethacin into the amorphous form.
625
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Figure 3.4 X-ray diffraction pattern of spray-dried Indomethacin in Ethanol/water
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Figure 3.5 X-ray diffraction pattern of spray-dried dispersion on MCC in solution of 
Indomethacin in Ethanol/water.
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Figure 3.6 X-ray diffraction pattern of spray-dried ground mixtures of Indomethacin and 
MCC in Ethanol/water
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A previous study of spray-dried indomethacin-PVP showed the existence of a higher 
energy amorphous drug phase in systems containing 20% PVP and above (Corrigan and 
Holohan, 1985). The DSC scans of spray-dried indomethacin and PVP systems generated 
in the current study are shown in Figures 3.7-3.10. The area under the single endothermie 
peak, which corresponded to melting of the drug at 155 °C, decreased with increasing 
PVP content. The peak disappeared at 20%PVP and above. The X-ray diffraction 
(Figures 3.11-3.14) results further suggested that for spray-dried indomethacin-PVP 
powders, at PVP ratio of 20% and above, indomethacin existed as an amorphous form.
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Figure 3.7 DSC scan of spray-dried Indomethacin with PVP 5%
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Figure 3.8 DSC scan of spray-dried Indomethacin with PVP 10%
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Figure 3.9 DSC scan of spray-dried Indomethacin with PVP 20%
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Figure 3.10 DSC scan of spray-dried Indomethacin with PVP 60%
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Figure 3.11 X-ray diffraction pattern of spray-dried Indomethacin with 5% PVP
92
Chapter 3 Spray drvins
6 2 5
[counts]
4 0 0 .
2 2 5 .
100 -
2 5 .
0. O T—I—I—I—I—I—I—t—I—I—I—I—I—I—I—I—I—I—I—I—I—«—I—I—I—I—I—I—1—I—»—r~3
d o  ' d o  4 0  C '2 0 3  SO
Figure 3.12 X-ray diffraction pattern of spray-dried Indomethacin with 10% PVP
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Figure 3.13 X-ray diffraction pattern of spray-dried Indomethacin with 20% PVP
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Figure 3.14 X-ray diffraction pattern of spray-dried Indomethacin with 60% PVP
Table 3.4. The powder X-ray diffraction results of indomethacin and PVP mixture at 
various compositions.
Sample Compositions
X-ray diffraction resultIndomethacin PVP
9.5 0.5 Crystalline
9 1 Crystalline
8 2 Amorphous
7 3 Amorphous
6 4 Amorphous
5 5 Amorphous
4 6 Amorphous
The x-ray diffraction results of spray-dried indomethacin with varied proportions of PVP 
and MCC are illustrated in Table 3.4.
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Table 3.5. The powder X-ray diffraction results of indomethacin with various amount of 
PVP and MCC or SMCC.
Sample Compositions
X-ray diffraction resultIndomethacin PVP MCC SMCC
8 2 - - Amorphous
8 I I - Crystalline
8 - 2 - Crystalline
8 I - I Crystalline
8 - - 2 Crystalline
The X-ray diffraction results of indomethacin with various amount of PVP and MCC or 
SMCC are shown in Table 3.5. When the PVP content was reduced to less than 20%, 
crystalline indomethacin was obtained. Replacing part of PVP with MCC or SMCC could 
not produce amorphous indomethacin. The results further suggested that the presence of 
PVP and its concentration was crucial for preparing amorphous indomethacin.
The powder X-ray diffraction results of spray-dried indomethacin with 20% PVP with 
varied percentages of MCC and SMCC from 10% to 30% are given in Table 3.6. All 
these systems were amorphous. Furthermore, after 3-months storage at 25 °C with 0% 
relative humidity, all systems remained amorphous, indicating that the inclusion of MCC 
or SMCC was not essential as they did not affect the physical characteristics of spray- 
dried indomethacin with 20% PVP. In the presence of 20%PVP, amorphous 
indomethacin could be produced.
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Table 3.6. The powder X-ray diffraction results of indomethacin and PVP with various 
percentages of MCC or SMCC.
Sample Compositions
X-ray diffraction resultIndomethacin PVP %MCC %SMCC
8 2 - - Amorphous
8 2 1 0 - Amorphous
8 2 2 0 - Amorphous
8 2 30 - Amorphous
8 2 - 1 0 Amorphous
8 2 - 2 0 Amorphous
8 2 - 30 Amorphous
The mean dissolution profiles of tablets prepared from spray dried indomethacin, 
indomethacin and PVP (ratio of 8:2), indomethacin and MCC (ratio of 8:2), 
indomethacin and SMCC (8:2), indomethacin, PVP and MCC (ratio of 8:2:1), 
indomethacin, PVP and SMCC (8:2:1) as well as crystalline indomethacin are shown in 
Figure 3.15. It can be seen that the dissolution rates of all spray-dried powders were 
higher than that of the non-spray dried crystalline indomethacin. With regard to DSC 
results, the spray dried indomethacin produced a mixture of gamma and alpha crystalline 
forms (alpha metastable form was in the majority). The spray dried indomethacin with 20 
% MCC and the spray dried indomethacin with 20% SMCC produced a mixture of 
gamma and alpha crystalline forms (gamma stable form was in the majority). Thus, it can 
be noted that both dissolution rate of the spray dried system containing indomethacin and 
20% MCC and the spray dried system containing indomethacin and 20% SMCC were 
higher than that of the non-spray dried indomethacin but lower than that of the spray- 
dried indomethacin.
On the other hand, the mean dissolution profiles of indomethacin and 20%PVP, 
indomethacin with 20%PVP and 10%MCC or SMCC were superimposable. The 
incorporation of MCC did not seem to alter the drug release. The higher dissolution rate 
of the spray-dried powder was expected as indomethacin was in the amorphous form.
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Figure 3.15 Dissolution profiles o f spray-dried Indomethacin with polymer
3.4 Conclusions
Simple grinding o f indomethacin with MCC did not yield indomethacin in an amorphous 
fomi. Spray dried indomethacin remained crystalline, as did co-spray dried indomethacin 
and MCC. The presence o f PVP at 20% and above produced amorphous indomethacin. 
Adding the third component, either MCC or SMCC, did not affect the physical 
characteristics o f the spray dried product.
The results o f this element o f the study showed that the physical characteristics of 
indomethacin solids spray-dried from non-aqueous solutions depended on the type and 
quantity o f additives. The initial indomethacin dissolution rate o f tablets prepared from 
co-spray dried indomethacin with 20%PVP was higher than that o f  non-spray dried 
tablets. In conclusion, to improve the dissolution rate o f indomethacin, co-spray drying 
with 20% PVP was recommended.
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Chapter 4__________________________________ Precipitation using supercritical CO? as an antisolvent
4.1 Introduction
In this part of the study, a new approach to enhance the dissolution of 
pharmaceuticals is presented, and the focus was particularly on indomethacin, a 
model compound with low water solubility. Precipitation using S C - C O 2  as an 
antisolvent may also be an alternative technique to prepare amorphous materials. 
Although supercritical fluids based methods often result in crystal formation, the fast 
precipitation should not allow the organization of the compound into a crystalline 
form. Consequently, in some cases the processed products show high levels of 
amorphous content. Amorphous sodium chromoglycate has been prepared using 
Solution Enhanced Dispersion by Supercritical Fluids technique (Jarrmo et al, 1997). 
Reverchon et al (1999, 2000) produced amorphous zinc acetate and amorphous 
amoxicillin using the Supercritical Antisolvent method.
The aim of this part of the study was to investigate the characteristics of indomethacin 
precipitated from different types of organic solvents using S C - C O 2  as an antisolvent. 
The method of preparation known as precipitation with compressed anti sol vents 
(PCA) was employed. A small scale PGA apparatus was designed and constructed in 
the laboratory. The influence of process parameters, which included drug 
concentration and solution flow rate on the characteristics of the indomethacin 
powders were examined using SEM, DSC and powder X-ray diffraction.
4.2. Materials and Methods
4.2.1. Materials
Indomethacin, polyvinylpyrrolidone, ethanol, acetone, chloroform, dichloromethane, 
N,N-dimethylformamide, distilled water. The details of these materials are given in 
section 2.1. Industrial grade carbon dioxide (99.95% purity) was supplied by British 
Oxygen Company, England.
4.2.2. Precipitation of indomethacin using water as an antisolvent
Indomethacin solutions of concentrations 5.0, 12.5, 20.0 and 33.3% w/v were
prepared by dissolving in ethanol and heating at approximately 70 °C. Distilled water
at room temperature was added to the indomethacin saturated ethanolic solution. The
precipitated crystals were removed by filtration and dried under vacuum.
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4.2.3. Construction and design of PCA apparatus
The schematic of the experimental apparatus is depicted in Figure 4.1. The liquid feed 
(internal diameter: 0.88 mm) and the CO2 antisolvent feed (internal diameter: 1.75 
mm) were brought together with the concentric nozzle (via a T-piece) into the 
reaction vessel (50 ml internal volume). Solution flow rate was controlled using an 
HPLC pump (model 302, Gilson, France). Liquid CO2 was obtained from a 55 Bar 
liquid withdrawal CO2 cylinder through a heat exchanger into the programmable 
HPLC pump (Model 305, Gilson, France). The pump head (10 ml) and pump inlet 
feed of CO2 were chilled to approximately -10°C using a series of heat exchangers 
(Haake CH and F3, Fisons, Germany). CO2 was warmed above its critical point via a 
coil inside the oven (TC 1900 temperature controller, ICI, Australia) before entering 
the high-pressure reaction vessel (40 ml internal volume). The vessel included a glass 
liner for ease of product recovery. Non-return valves were inserted in the liquid feed 
and CO2 feed to avoid flow inversion in both feeds. The vessel was placed in an oven 
to maintain the temperature of the system. It was necessary to increase the 
supercritical-solution temperature to avoid liquid phase crossing during 
depressurization. A 7 pm stainless steel filter frit was situated at both the bottom of 
the reaction vessel and between the vessel and the back pressure regulator. It trapped 
any precipitated solid but allowed the C0 2 -organic solvent solution to pass through in 
the washing step. The pressure in the whole system was regulated by a manually set 
back pressure regulator (BPR, Tescom, model 26-1762-24-194). Pressure in the CO2 
feed was measured using a pressure gauge. Pressure in the liquid feed was measured 
by a pressure transducer, housed in a custom made stainless steel body and connected 
to a digital read out (RDP electrics, model E705). The powders were collected in the 
vessel. At the end of the precipitation process, the vessel was washed with CO2 to 
eliminate the organic solvent. The organic solvent was collected at the outlet pipe of 
the BPR. A temperature-controlled external heating block was located around the 
BPR to avoid intermittent freezing/blockage of the outlet pipe of the BPR.
The design of the PCA apparatus which included the reaction vessel, HPLC pump for 
liquid feed and adapted HPLC pump for CO2 feed, was shown in Figures 4.2-4.4, 
respectively.
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Filter
Figure 4.2 The reaction vessel required 6  screws at the bottom. The top of the vessel 
was connected with the concentric nozzle. The liquid and CO2 feeds can clearly be 
seen. Notably this design has a glass liner within the vessel to enable the precipitated 
material to be removed without any disturbance.
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Figure 4.3 PCA apparatus. The HPLC pump was used to deliver the drug solution. 
The vessel was placed in the oven.
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Figure 4.4 The adapted HPLC pump that has a chilled head for control of the CO2 
flow rate into the precipitation vessel.
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4.2.4. Procedure
The oven was switched on and the required temperature of 22 °C or 40 “C was 
maintained. The chiller was switched on. Liquid CO 2  was directed from a cylinder 
into a pump at a constant flow rate of 10 ml/min, and delivered to the preheating coil 
which was inside the oven (Figure 4.1 taps T1 and T3 open). The reaction vessel was 
pressurised to the required pressure by adjusting BPR (Figure 4.1 tap T2 close). The 
drug solution pump was switched on. The antisolvent precipitations were started by 
opening the tap T2 to allow a flow of drug solution passing through a nozzle. At the 
end of the precipitation process, the drug solution pum p was switched off and the tap 
T2 was closed. The SC-CO2  continued to flow into the chamber. The product in the 
vessel was washed with 10 ml/min o f supercritical CO 2  for 30 min to eliminate the 
organic solvent. After that, the CO 2  pump was switched off with tap T1 closed. The 
BPR was fully open to remove CO 2  from the system. The pressure was checked to be 
0 bar before opening up the vessel. The product was collected in the vessel and stored 
in a silica gel desiccator at room temperature.
4.2.5. Precipitation of indomcthacin from dichloromethane
Indomethacin solutions of concentrations 0.83, 1.67 and 3.33 %w/w were prepared by 
dissolving in dichloromethane. The SC-CO2  was fed into the reaction vessel at a 
constant flow rate of 10 ml/min. The experim ent started when the operating pressure 
reached 150 bar and the liquid solution was fed into the reactor chamber through the 
nozzle. The drug solution at flow rates between 0.5 and 1.0 ml/min and supercritical 
CO 2  at 10 ml/min were pumped into the reaction vessel. The precipitation process was 
allowed to continue for 30 min. Two different sets of parameters were used. One set 
was at ambient temperature (22 °C), pressure o f  150 bar and CO 2  density o f 0.5 g/ml 
and the other set at 40 °C, pressure of 150 bar and CO 2  density of 0.8 g/ml. A t the end 
of the precipitation process, the product in the vessel was washed with supercritical 
CO 2  as described in section 4.2.4. The product was collected and stored in a silica gel 
desiccator at room  temperature.
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4.2.6. Precipitation of indomethacin from various organic solvents
Accurately weighed indomethacin (100 mg) was added slowly into various organic 
solvents, namely, dichloromethane, acetone, chloroform, dichloromethaneiethanol 
(1:1, v/v), ethanol and dimethyl-formamide. The amount of indomethacin dissolved 
before the drug supersaturate was recorded and taken as the maximum concentration 
of drug dissolved. The system was operated at a temperature of 40 ° C ,  pressure of 150 
bar and C O 2  density of 0.8 g/ml. The S C - C O 2  was initially fed into the reaction vessel 
at a constant flow rate. The experiment started when the operating pressure had been 
reached and the liquid solution was fed into the reactor chamber through the nozzle. 
The drug solution was pumped at flow rates between 0.125 and 1.0 ml/min and 
supercritical CO2 at 10 ml/min into the reaction vessel and allowed to react for 30 
min. At the end of the precipitation process, the product in the vessel was washed 
with S C - C O 2  as described in section 4.2.4. The product was collected and stored in a 
silica gel desiccator at room temperature.
4.2.7. Precipitation of indomethacin and PVP
Mixtures of indomethacin and polyvinylpyrrolidone in various proportions were 
dissolved in dichloromethane to produce a 3.33%w/v solution. The amount of PVP 
utilised in the experiments ranged from 5-60%w/w of the indomethacin content. 
Feeding rates of 0.5 ml/min and 10 ml/min were used to deliver the drug solution and 
S C - C O 2  into the reaction vessel. The experiment was run using similar parameters as 
described earlier.
4.2.8. Scanning electron microscopy
The details were explained in section 2.2.1.
4.2.9. Thermal analysis
The details were explained in section 2.2.2.
4.2.10. X-ray diffraction analysis
The details were explained in section 2.2.3.
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4.3. Results and Discussion
Precipitation o f indomethacin using water as an antisolvent
Prior to the construction of the PCA apparatus, a simple experiment was conducted to 
examine the feasibility of using supercritical CO2 as an antisolvent in the precipitation 
of indomethacin from organic solvents. The experiment employed water as an 
antisolvent to precipitate indomethacin from ethanolic solution. The indomethacin 
precipitated from the organic solvents appeared to be white and fluffy. When the 
powder was viewed under SEM, all the particles were seem to be needle shaped 
irrespective of the concentrations employed. Figure 4.5(a) and (b) show the SEM of 
the original material and indomethacin precipitated from 33.3% indomethacin in 
ethanolic solution using water as an antisolvent, respectively. The DSC profiles 
indicated that indomethacin existed as mixtures of both a  and y crystalline forms 
when precipitates from solution at concentration between 5-20%w/v. The mixture 
contained a higher proportion of a crystalline form as shown from the larger area 
under the melting peak (Figures 4.6-4.7). As seen in Figure 4.8, precipitates from 
solution at a concentration of 33.3%w/v contained only the a crystalline form of 
indomethacin. Figures 4.9 and 4.10 show the PXRD profiles of indomethacin 
prepared from 20% and 33.3% w/v ethanolic solutions, respectively. It can be 
observed that they are both the same profiles. The particular peak at 8.5 “20 identified 
the a polymorphic form. (Figures 4.6-4.7) It is possible that the very small 
endothermie peak at 162 “C was material converted from a form to y form during the 
DSC run.
The physical appearance, SEM, DSC and PXRD results of indomethacin precipitated 
using water as an anti solvent are summarised in Table 4.1.
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(a)
£
Figure 4.5 SEM photograph of indomethacin particles (a) unprocessed indomethacin 
(b) precipitated from 33.3% w/v ethanolic solution using water as an antisolvent.
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Table 4.1 The physical appearance, SEM, DSC and PXRD results of indomethacin 
prepared at different concentrations precipitated using water as an anti-solvent.
Organic
solvents
Maximum
concentration
(%w/v)
Observation SEM DSC & PXRD
Ethanol 33.3 Fluffy white 
powder
Needle shape pure a
2 0 . 0 Fluffy white 
powder
Needle shape a and y
12.5 Fluffy white 
powder
Needle shape a and Y
5.0 Fluffy white 
powder
Needle shape a and y
s-
Î
g
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8 0
7 0
6 0
5 0
4 0
3 0
20
0 200 2505 0 100 150
Temperature (°C)
Figure 4.6 DSC scan of indomethacin recrystallized from 12.5% w/v of ethanolic 
solution using water as an antisolvent.
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Figure 4.7 DSC scan of indomethacin recrystallized from 20% w/v of ethanolic 
solution using water as an anti solvent.
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Figure 4.8 DSC scan of indomethacin recrystallized from 33.33% w/v of ethanolic 
solution using water as an antisolvent.
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Figure 4.9 PXRD scan of indomethacin recrystallized from 20% w/v of ethanolic 
solution using water as an antisolvent.
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Figure 4.10 PXRD scan of indomethacin recrystallized from 33.33 % w/v of ethanolic 
solution using water as an antisolvent.
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Precipitation o f indomethacin using SC-CO2 as antisolvent
Preliminary investigations were carried out to determine the effect of the processing 
temperature on the characteristics of precipitated particles. When the experiment was 
operated at ambient room temperature (22 “C), the temperature was below the critical 
point of CO2 (31.1 °C) and SC-CO2 could not be generated. As a result, the CO2 used 
in the experiment consisted of two phases, namely, liquid and gas. Two types of 
powders having different colours, which stuck together, were obtained at all the 
different concentrations used. One was white and fluffy while the other one was 
yellow with rod-like shape. However, by increasing the temperature to 40 °C, the 
appearance of SCF products was homogeneous. Hence, this temperature was chosen 
to produce material for further investigations.
The SEM of the indomethacin particles prepared using dichloromethane as solvent 
and SC-CO2 as anti solvent showed needle shapes (Figure 4.11). However, the DSC 
profiles of the indomethacin showed the presence of two crystalline peaks, a and y 
crystalline forms (Figure 4.12). It can be noted that the composition of a form was 
higher than the y form. PXRD further confirmed that indomethacin existed in a and y 
crystalline forms (Figure 4.13). It seemed that the characteristics of indomethacin 
were not affected by varying the concentrations of indomethacin in dichloromethane 
solution and its feeding rate. The physical appearance, SEM, DSC and PXRD results 
of indomethacin precipitated from different concentrations and flow rates of drug 
solution using SC-CO2 as anti solvent are given in Table 4.2.
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Figure 4.11 Typical SEM photograph of indomethacin particles prepared using 
dichloromethane as solvent and S C - C O 2  as antisolvent.
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Figure 4.12 Typical DSC scan of indomethacin particles prepared using 
dichloromethane as solvent and S C - C O 2  as antisolvent.
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Figure 4.13 Typical PXRD profile of indomethacin particles prepared using 
dichloromethane as solvent and SC-CO2 as anti solvent.
Table 4.2 The physical appearance, SEM, DSC and PXRD results of indomethacin 
precipitated from different concentrations and flow rates of drug solution.
Concentrations
(%w/v)
Flow rate 
(ml/min)
Observation SEM DSC&PXRD
3.33 0.5 Fluffy
powder
white Needle shape a and Y
1.67 1 . 0 Fluffy
powder
white Needle shape a and Y
1.67 0.5 Fluffy
powder
white Needle shape a and Y
0.83 0.5 Fluffy
powder
white Needle shape a and Y
0.83 1 . 0 Fluffy
powder
white Needle shape a and Y
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The maximum concentrations of indomethacin dissolved in the various organic 
solvents are shown in Table 4.3. Different solution flow rates were employed for 
indomethacin in different organic solvents because at values above those stated in 
Table 4.3, complete precipitation of indomethacin could not occur, which could be 
observed from the colour of the liquid removed through the vent of the back pressure 
regulator. When there was a complete precipitation, clear liquid could be seen through 
the vent. In contrast, if the precipitation process was not complete, yellow liquid 
could be seen, due to the presence of indomethacin in the liquid.
The SEM of indomethacin precipitated from dichloromethane and acetone showed 
needle shapes, indicating the presence of the a  crystalline form. Figure 4.14(a) shows 
a needle shape of indomethacin prepared using acetone. In contrast, non-uniform rod­
like particles were obtained when precipitated using ethanol, chloroform, 
dichloromethaneiethanol (1:1) and DMF. The SEM of indomethacin precipitated from 
chloroform is shown in Figure 4.14(b). The DSC results showed that indomethacin 
precipitated from various organic solvents composed of two crystalline peaks, a  and y 
crystalline forms (Figures 4.15-4.18). It can be noticed that in most samples the a 
form existed in a higher proportion than the y form, especially when precipitated 
using acetone (Figure 4.17). Additionally, in Figure 4.17, the DSC curve of 
indomethacin precipitated from acetone had endo- and exothermic peaks at about 80- 
95 °C, which could be due to desolvation of acetone, and an endothermie peak at 155 
°C which was due to fusion of the a form. Similarly, for Figure 4.18, DSC curve of 
indomethacin precipitated from chloroform had endo- and exothermic peaks at about 
80-110 °C which was due to desolvation of chloroform and endothermie peaks at 
about 155 and 162 °C which could be due to fusion of a  and y form, respectively.The 
PXRD results confirmed that all the samples were composed of two polymophs 
(Figures 4.19-4.21).
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Table 4,3 The maximum concentration, physical apperance, SEM, DSC and PXRD 
results of indomethacin precipitated from various organic solvents using S C - C O 2  as 
anti solvent.
Organic solvents Maximum
concentration
(%w/v)
Flow rate 
(ml/min)
Observation SEM
DSC&
PXRD
Dichloromethane 3.33 0.5 Fluffy white 
powder
Needle
shape
a and 
Y
Acetone 3.75 0.25 Fluffy white 
powder
Needle
shape
a and 
Y
Chloroform 3.75 0.25 Fluffy white 
powder
Non- 
uniform 
rod shape
a and 
Y
Dichloromethane 
lethanol (1 :1 )
8 0.5 Fluffy white 
powder
Non- 
uniform 
rod shape
a and 
Y
Ethanol 1.25 0.5 Fluffy white 
powder
Non- 
uniform 
rod shape
a and
y  *
DMF 1 0 0.125 Fluffy 
yellowish 
powder with 
sticky liquid
NA
* DSC  result only
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Figure 4.14 (a) SEM of indomethacin particles prepared using Acetone as solvent and 
SC-CO2 as antisolvent
(b)
Figure 4.14 (b) SEM of indomethacin particles prepared using chloroform as solvent 
and S C - C O 2  as antisolvent
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Figure 4.15 DSC of indomethacin particle prepared using ethanol as solvent and sc- 
CO2 as antisolvent.
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Figure 4.16 DSC of indomethacin particle prepared using dichloromethane: ethanol
(1:1) as solvent and S C - C O 2  as antisolvent.
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Figure 4.17 DSC of indomethacin particle prepared using acetone as solvent and sc- 
CO2 as antisolvent.
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Figure 4.18 DSC of indomethacin particle prepared using chloroform as solvent and 
S C - C O 2  as antisolvent.
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Figure 4.19 PXRD of indomethacin particle prepared using dichloromethane: ethanol 
(1:1) as solvent and S C - C O 2  as antisolvent.
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Figure 4.20 PXRD of indomethacin particle prepared using acetone as solvent and sc- 
CO2 as antisolvent.
120
Chapter 4 Precipitation usine supercritical C0-> as an antisolvent
625
C o o u n t# ]-
400.
2 2 5 .
100.
"go"' "'' "' ' lo   .
Figure 4.21 PXRD of indomethacin particle prepared using chloroform as solvent and 
SC-CO2 as antisolvent.
A previous study of coprecipitating indomethacin and various proportions of PVP 
employing Solution Enhanced Dispersion by Supercritical fluids (SEDS) showed that 
all samples were non-crystalline, non-cohesive, fine web-like structures, easy-flowing 
powders with good handling properties (Wilkins et al, 1999). In this part of the study, 
unfortunately, coprecipitating indomethacin and PVP for the various ratios of PVP 
could not be obtained using our present PCA apparatus. It was noted that precipitation 
rendered sticky yellow liquid along the glass liner. As such, indomethacin and PVP 
coprecipitate could not be examined. Some of the means that might be able to 
overcome this setback are the use of PVP with higher molecular weight (for instance, 
above 50,000 Da), using a nozzle with a smaller internal diameter and a pump which 
could deliver CO2 at a higher flow rate (for instance, above 1 0  ml/min).
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4.4 Conclusions
The drug concentration and its feeding rate did not affect the characteristics of the 
product. The indomethacin precipitated from various organic solvents using SC-CO2 
(at 40°C and 150 bar) as anti-solvent was a mixture of a  and y crystalline forms. The 
scanning electron micrographs showed only needle or rod-like shape indicating the 
sole presence of a crystalline indomethacin. On the other hand, the DSC result 
showed two melting peaks inferring the presence of both a  and y crystalline forms. 
Obviously, the a crystalline form was present in a markedly higher proportion than y 
crystalline form. Coprecipitation of indomethacin and PVP could not be produced due 
to the limitations of the current apparatus design.
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5.1 Introduction
Supercritical carbon dioxide ( S C - C O 2 )  has been extensively used as an 
environmentally acceptable alternative ‘solvent’ to some conventional hydrocarbon 
solvents. Rapid Expansion of Supercritical Solution (RESS) and Precipitation from 
Gas Saturated Solution or Suspension (FOSS) are both applying S C - C O 2  as a solvent. 
The RESS process involves solvating sample in the S C - C O 2  and immediately 
depressurising this solution through a nozzle, causing a rapid nucléation of the sample 
into a highly dispersed material. The advantages of this process are fine particles with 
a narrow size distribution can be produced via this technique without the need for 
additional solvents or surfactants. The use of low critical temperature solvents also 
makes this technique attractive for the precipitation of thermally labile materials. 
Unfortunately, its application is limited to products that have a considerable solubility 
in S C - C O 2  (nonpolar compounds). During the last decade, many publications are 
related to atomisation of pharmaceutical products, either to obtain microparticles, or 
microcapsules of an active into an excipient. On the other hand, the FOSS process 
basically dissolves a supercritical fluid into the melted or liquid-suspended 
substance(s). Then, it was rapidly depressurised through a nozzle causing the 
formation of solid particles. Farticularly, this method allows forming of particles from 
substances that need not be soluble in S C - C O 2 .  Moreover, this method also can be 
used for suspensions of active substrate(s) in a polymer leading to the production of 
composite microspheres.
In Chapter 4, S C - C O 2  was used as an antisolvent for precipitation, a-metastable and y- 
stable polymorphic forms of indomethacin were obtained. Coprecipitated 
indomethacin and F VF in the form of powder, for the various ratios of F VF, could not 
be obtained through the precipitation process. In this part of study, S C - C O 2  was used 
as solvent. A simple and unique apparatus was designed applying FOSS basic 
concepts. Instead of constructing a new apparatus, the FCA apparatus was duly 
modified to adapt to this change. The characteristics of processed pure indomethacin 
and coprecipitated indomethacin and F VF were investigated using SEM, DSC and 
powder x-ray diffraction. Moreover, the effect of different proportions of polymer on 
the crystallinity of the products was discussed.
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5.2. Materials and Methods
5.2.1. Materials
Indomethacin, polyvinylpyrrolidone, polyethylene glycol. The details of these 
materials are given in section 2.1. Industrial grade carbon dioxide (99.95% purity) was 
supplied by British Oxygen Company, England. Tween 80 (Merck, England) was used 
as received. Lithium Fluoride (Prolabo, England) was used as received.
5.2.2. Design and construction of apparatus
The design of the apparatus had to be modified when supercritical CO2 was used as a 
solvent. In the present design, which was modified from the PC A apparatus (Chapter 
4), the HPLC pump for liquid feed was removed, as the present method did not 
require organic solvents. The special design of the CO2 pump with a built-in chiller 
was made. Figure 5.1 shows the pump containing both input and output pressure 
meters. The desired output pressure was controlled by adjusting the air pressure. As 
shown in Figure 5.2, The design of the stirred batch reaction vessel was simplified by 
fastening the closure with only one screw to ease product recovery, compared to the 
reaction vessel of the PC A design, which required six screws. The glass liner was 
excluded as the product could be easily recovered directly from the reaction vessel. A 
paddle stirrer was included to improve mixing. The pressure in the vessel could be 
double checked from the pressure gauge which was installed on top of the vessel. 
Instead of employing the hot air oven (HPLC column thermostat) to maintain the 
temperature, a snug fitting aluminium heater block was used.
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Input pressure
Air pressure
Output pressure
Figure 5.1 CO2 pump with a built-in chiller.
126
Chapter 5 Precipitation usins supercritical CO? as solvent
CO 2 inlet
CO2 outlet
Filter
Stirrer controller
Pressure gauge
Reaction vessel
Aluminium 
heater block
Figure 5.2 the stirred batch reaction vessel
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Figure 5.3. Schematic diagram o f an apparatus using CO] as solvent
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The schematic of the experimental apparatus is depicted in Figure 5.3. The vessel was 
placed inside an aluminium heater block connected to the heater controller and 
thermocouple to maintain the temperature. The reaction vessel contained a stirrer 
connected to an electric motor. A non-retumed valve was inserted between the CO2 
pump and the reaction vessel to avoid the flow inversion of CO2 . Cotton wool situated 
at the outlet of the vessel and a Nupro 7 pm stainless steel filter frit installed between 
the vessel and the back-pressure regulator was used to trap solids but allow the CO2 to 
pass through during the depressurizing step. The pressure in the CO2 feed was 
measured by a pressure transducer, housed in a custom made stainless steel body 
connected to a digital readout (RDP electronics, model E705). A temperature- 
controlled external heating block was located around the back-pressure regulator 
(BPR) to avoid intermittent freezing/blockage of the outlet pipe of the BPR.
5.2.3. Procedure
The basic procedures were the same in all cases for the mixtures; however, the 
reactions differed in the conditions of temperature and composition. The typical 
reaction was as follows; Indomethacin and PEG or PVP was accurately weighed and 
mixed in mortar and pestle for 15 min before being transferred into the reaction 
vessel. The vessel was sealed and placed into a snug fitting aluminium heater block. 
Liquid CO2 was withdrawn from the CO2 cylinder at 55 bar into the inlet of the pump. 
Then the liquid CO2 was chilled by a built-in chiller for 30 minutes. The air pressure 
knob was opened prior to pressurized the CO2 until the required output pressure of 
CO2 was stable (Figure 5.1). The liquid CO2 was delivered into the reaction vessel 
(Figure 5.3 Taps T l and T2 open). The CO2 was warmed above its critical point 
inside the reaction vessel. The stirrer controller was switched on. The heater 
controller was switched on and the temperature was raised. Upon reaching the desired 
temperature, the system was maintained for further 2 hr with taps T l, T2 and T3 
closed. Lastly, the heater controller was switched off and the CO2 was released 
steadily over a period of three minutes (T3 was fully opened while T l and T2 were 
closed).
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5.2.4. Investigation of the effect of SC-CO2 on the characteristics of indomethacin
Preliminary investigations were carried out to determine if SC-CO2 could produce 
amorphous indomethacin. The effect of different pressure of SC-CO2 on the 
characteristics of indomethacin at 20“C was investigated. Indomethacin (200 mg) was 
exposed to SC-CO2 in the reaction vessel for 2 hr at 20°C with pressures of 100 and 
200 bar. The sample was collected after depressurizing of SC-CO2 .
5.2.5. Precipitation of indomethacin and PEG
Indomethacin and PEG 4000 (ratio of 1:4) was exposed to S C - C O 2  in the reaction 
vessel for 2 hr at 50 “C and 70 “C with pressures of 80, 100, 150 and 200 bar. The 
mixture was precipitated after depressurizing of S C - C O 2 .  The above settings was 
adapted from the study of Senca-Bozic (1997).
5.2.6. Precipitation of indomethacin and PVP
Preliminary investigations were carried out in order to determine the effect of sc-CO^ 
temperature and pressure and different proportions of PVP on the characteristics of 
coprecipitates.
Mixtures of indomethacin and PVP at various ratios of 1.7:8.3, 4:6, 5:5, 7:3 and 8:2 
were prepared. The mixtures were exposed to S C - C O 2  in the reaction vessel for 2 hr 
using the following parameters;
Pressure (Bar) Temperature (°C)
80 40
150 40
150 75
150 90
2 0 0 75
130
Chapter 5____________________________________________ Precipitation usine supercritical C0-> as solvent
Due to the limitation of the rig, the maximum pressure that could be reached was 260 
bar. Therefore, all the pressure values employed were below 260 bar. As the 
temperature used was below 100 °C, it was lower than the melting point of 
indomethacin.
The mixtures were characterized using SEM (Section 2.2.1), DSC (Section 2.2.2) and 
PXRD (Section 2.2.3)
5.2.7. Scanning electron microscopy
Characterization method using SEM was described in section 2.2.1.
5.2.8 Particle size analysis
The mean size and span (90% undersize-10% undersize/ 50% undersize) of 
indomethacin (Becpharm, England) and indomethacin precipitated under different 
CO2 pressure were measured using a laser diffractometer (Malvern Mastersizer S Ver. 
2.18, UK), with a lens size of 14.3 mm. The instrument’s software expresses particle 
size as the volume median diameter (VMD), i.e. the equivalent sphere diameter above 
and below which 50% of the volume of particles lies.
A saturated indomethacin stock solution was used as suspending medium for laser 
diffraction analysis. The stock solution was prepared by adding an excess of 
indomethacin to distilled water containing 0.01% of Tween 80 to facilitate the powder 
dispersion. It was agitated for 48 h at room temperature, thereafter left undisturbed for 
12 h and then filtered through a 0.22 pm filter (Millipore, UK). To this solution, 
amounts of supercritical CO2 processed indomethacin were added to make 35 mg/50 
ml suspension. De-agglomeration of the particles was performed by ultrasonic 
treatment in a water bath for 1 minute before being loaded into a stirred sample cell.
5.2.9. Thermal analysis
A differential scanning calorimeter (Perkin Elmer DSC 7, USA) was employed. 
Samples of approximately 5 mg were carefully weighed in aluminium pans with a 
pinhole in the lid. The DSC was calibrated using pure samples of indium and Zinc.
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In order to erase previous thermal history of the material and remove any residual 
moisture before the measurements of glass transition temperature (Tg), the samples 
were first heated to 145 °C and then cooled to -60 by an automated liquid nitrogen- 
cooling accessory at 20 “C/min. To check that this procedure did not result in 
degradation, each sample was subjected to a further three heating and cooling cycles 
and the Tg monitored. For all samples, there was no variation of the Tg suggesting that 
no degradation had occurred. Further experiment were conducted. After erasing 
thermal history, the samples were subsequently heated a second time from -60 °C to 
220 “C at 20 “C /min, to check that the components were miscible. All Tg values were 
determined. Each sample was run in triplicate.
5.2.10. X-Ray diffraction analysis
Characterization method using PXRD was described in section 2.2.3.
5.2.11. Statistical analysis
The Tg values of indomethacin-PVP mixture prepared by sc-COi based technique 
were analysed using a one-way analysis of variance. A post-hoc Tukey-HSD test was 
performed when there was a statistically significant difference, which was considered 
at p < 0.05.
5.2.12. Determination of the crystallinity of indomethacin
To estimate the % crystallinity of indomethacin, it was necessary to establish a
powder X-ray diffraction calibration curve for known mixtures of amorphous and
crystalline indomethacin. Since indomethacin can exist in both the a  and y crystalline
forms, binary mixtures of each polymorph with amorphous material were prepared
with 20% w/w of Lithium Fluoride (LiF) added as an internal standard. Figures 5.4
(a) and (b) show plots of the ratio of the peak areas at 20 =8.5“ due to the a  form and
at 20 =38.7“ due to LiF versus the content of the a  form, and that of the peak areas at
20 =11.6“ due to the y form and at 20 =38.7“ due to LiF versus the content of the y
form. Each plot was linear and the degree of crystallinity (Xc) of samples could be
obtained using these calibration plots. Each value of Xc used in the calibration curve
was the average of three independent measurements. This procedure allowed the %
crystallinity due to either a  or y crystalline forms to be measured reproducibly down
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to the level of ±5%. Background diffraction due to PVP was negligible and did not 
interfere with the analysis.
(a)
^  0.8
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0.2  -
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Degree of crystallinity, %(w/w)
100
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0.6  -
60 80 10020 40
Degree of crystallinity, % (w/w)
Figure 5.4 Peak intensity ratio versus degree of crystallinity of a  and y forms of 
indomethacin. (a) physical mixture of a  form and noncrystalline solid (ratio of 
20=8.5° versus 38.7°), (b) physical mixture of y form and noncrystalline solid (ratio of 
20=11.6° versus 38.7°).
133
Chapter 5 Precipitation usins supercritical C0-> as solvent
5.3. Results and Discussion
The SEM image of the y-crystalline indomethacin received from Becpharm 
(Becpharm, England) is shown in Figure 5.5(a). The unprocessed particles are 
crystalline in structure. Indomethacin particles precipitated by this method at various 
conditions have different size and morphology. CO2 pressure is an important 
operation parameter of this process which can influence the properties of the 
precipitated product. This parameter was investigated at a constant temperature.
The particle size data form laser diffraction analysis of unprocessed and two 
independent samples are shown in Table 5.1. The yield of the products was calculated 
from the weight of the precipitated product collected from the vessel, as a percentage 
of the initial weight indomethacin (Table 5.1).
Table 5.1 Results of the particle size analysis for indomethacin precipitated under 
different conditions.
Operation parameter 
Temp.; Pressure
Volume median 
diameter (pm)
Span % Yield 
(n=l)
Unprocessed 2S.17(±0.07) 2.05(±0.02) -
indomethacin
20 °C; 100 bar 2S.09(±0.05) 2.17(±0.02) 84.5
20 “C; 200 bar 3.54(±0.02) 1 .2 2 (±0 .0 2 ) 77.9
n= 3 ± sd
At 20 °C indomethacin precipitated under CO2 pressure of 100 bar, the particle size 
was not changed in comparison with the unprocessed indomethacin. Although the 
values for the median particle size were slightly decreased, there was no significant 
different (p>0.05) in size when the operating CO2 pressure was used at 100 bar. A 
CO2 pressure increased from 1 0 0  bar to 2 0 0  bar in this precipitation process had an 
effect in reducing the size of particles. The median particle size decreased from 28.09 
pm to 3.54 pm at a temperature of 20 °C. The low span value indicated that the
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precipitated indomethacin at 200 bar have a narrow size distribution. The percentage 
yield obtained was lower for the higher CO2 pressure condition. As the size of particle 
is smaller than the diameter of a filter, it could be lost during CO2 depressurising step.
(a)
(b)
(c)
Figure 5.5 SEM images of indomethacin (a) original material and the precipitates 
obtained by SCF method at 20 °C (b) P=200 bar; (c) P=100 bar.
1 3 5
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The SEM images of processed particles illustrated in Figures 5.5 (b) and (c) revealed 
that particles were irregular in shape and existed as aggregates. Thus, these results 
indicate that the micronisation of indomethacin using this apparatus is feasible. At 20 
°C , the pressure influenced the particle size of products. The DSC profiles and PXRD 
scans indicated that indomethacin precipitated under CO2 pressure of 100 and 2 0 0  bar 
were pure y- stable crystalline form.
It has been reported that PEG 4000 could modify the characteristics of nifedipine, a 
poorly water soluble drug, using the Precipitation from Gas Saturated Solution 
(PGSS) technique (Sencar-Bozic et al., 1997). Sencar-Bozic et al (1997) found that 
addition of certain amounts of hydrophilic polymer, PEG 4000 to nifedipine resulted 
in a melting point decrease. They also reported the advantage of using PEG 4000 as it 
could lower the mixing temperature in PGSS process and hence avoid degradation of 
drug.
Since indomethacin is also a compound with low water solubility, it was thought that 
PEG 4000 could modify the physical state of indomethacin and potentially enhance 
the dissolution rate. Hence, similar drug to polymer ratio and process parameters were 
adopted in the present study as used by Sencar-Bozic et al (1997). However, the 
mixtures were obtained as yellow stone-like solid mass, consisting of indomethacin 
and PEG 4000, upon eventual loss of all CO2 from the polymer matrix. This solid 
mass was stuck in the reaction vessel. The change in pressure between 200 and 80 bar 
at temperatures of 50 °C and 70 °C produced products of similar characteristics. The 
difficulty in product recovery and also different product characteristics from those 
reported by Sencar-Bozic et al (1997) could be due to the limitation of the present 
apparatus. In the study of Sencar-Bozic et al. (1997), the drug/polymer solution was 
sprayed via a heated nozzle into a separate chamber in which the final product was 
recovered.
The parameters of 150 bar and 40 °C which were used in the PC A method were 
selected for the precipitation of indomethacin and PVP initially. The y crystalline 
form of indomethacin was obtained for all the ratios studied. Fine powdered mixtures 
were obtained. The SEM image of indomethacin and PVP mixture at ratio of 1.7:8 .3
136
Chapter 5___________________________________________ Precipitation usine supercritical CO 7 as solvent
under SC-CO2 150 bar and 40 °C is shown in Figure 5.6. The round shapes of PVP and 
indomethacin crystals show that under this condition no reaction happened between 
indomethacin and PVP. Thus, under this condition SC-CO2 could not plasticize PVP 
and could not assisted PVP and indomethacin mixing.
Figure 5.6 SEM images of indomethacin and PVP mixture at ratio 1.7: 8.3 prepared 
using SC-CO2 as solvent ( T=40 “C and P= 150 bar).
When the temperature was increased to 75 °C at the same pressure, the amorphous 
form of indomethacin was obtained at a PVPiindomethacin ratio of 8:2 and above. At 
lower proportions of PVP, only partially amorphous indomethacin was obtained. 
Under this condition, SC-CO2 plasticized PVP and lowered its viscosity. Thus, SC-CO2 
could assist indomethacin and PVP blending.
The use of higher pressures (150 bar to 200 bar) yielded identical results with the 
same proportion of PVP being required to yield amorphous indomethacin. Similarly, 
temperatures higher than 75 °C produced similar results. Consequently, a pressure of 
150 bar and a temperature of 75 °C were used for further studies.
1 3 7
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The various proportions of indomethacin and PVP produced porous structures when 
viewed under the scanning electron microscope. This was presumably a consequence 
of foaming in the SC-CO2 . A typical scanning electron micrograph of indomethacin 
and PVP mixture at a ratio of 1.7:8.3 under different magnification is shown in 
Figures 5.7 (a) and (b).
(a)
(b)
Figures 5.7 (a) and (b). SEM images of indomethacin and PVP coprecipitate at ratio
1.7:8.3, prepared using SC-CO2 as solvent (T=75 °C and P= 150 bar), before grinding.
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DSC scans were run for the various coprecipitates over the entire composition range. 
As seen in Figure 5.8 such a scan allowed an estimation of the glass transition 
temperature.
§•
I
§
I
30
20
10
0
0 50 100 150 200 250
Temperature (°C)
Figure 5.8 Typical trace obtained from differential scanning calorimetry of 
indomethacin-PVP coprecipitates using SC-CO2 as solvent.
The PXRD profiles of coprecipitated indomethacin and PVP (0.2-0.83 PVP weight 
fraction) are shown in Figures 5.9-5.14. It can be noticed that there is only the peak at
1 1 . 6  “2 0  confirming that only the y type was present in all coprecipitated 
indomethacin and PVP (0.2-0.6 PVP weight fraction).
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Figure 5.9 XRD pattern of the coprecipitation of indomethacin and 0.2 PVP weight 
fraction prepared using sc-CO] as a solvent.
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0. o so10
Figure 5.10 XRD pattern of the coprecipitation of indomethacin and 0.3 PVP weight
fraction prepared using sc-COi as a solvent.
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Figure 5.11 XRD pattern of the coprecipitation of indomethacin and 0.5 PVP weight 
fraction prepared using SC-CO2 as a solvent.
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Figure 5.12 XRD pattern of the coprecipitation of indomethacin and 0.6 PVP weight
fraction prepared using SC-CO2 as a solvent.
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Figure 5.13 XRD pattern of the coprecipitation of indomethacin and 0.8 PVP weight 
fraction prepared using sc-COz as a solvent.
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Figure 5.14 XRD pattern of the coprecipitation of indomethacin and 0.83 PVP weight
fraction prepared using sc-COz as a solvent.
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Table 5.2 shows the effect of PVP on the Tg and the degree of crystallinity of the 
coprecipitates. The Tg value as a function of PVP weight fraction in the coprecipitates 
is presented in Figure 5.15. A single Tg value was observed over the entire range of 
PVP compositions, suggesting that indomethacin and PVP were miscible. The Tg 
values increased with an increase in the PVP content. When the Tg values were 
analysed statistically using one-way analysis of variance and post-hoc statistical 
analysis, they were significantly different (Tables 5.3 and 5.4).
Table 5.2 Glass transition temperature and degree of crystallinity for indomethacin 
coprecipitates with PVP obtained by Differential Scanning Calorimetry and PXRD, 
respectively.
PVP weight fraction Tg(K ) Degree of crystallinity 
(% w/w)
0 . 2 333.98 55
0.3 344.89 41
0.5 366.78 18
0 . 6 370.84 15
0.83 397.45 0
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Figure 5.15. Plot of glass transition temperature versus weight percent of PVP for 
indomethacin-PVP coprecipitates using supercritical fluid based technique: the 
squares represent experimental data points and the solid line represents the fit to the 
Gordon-Taylor equation.
Table 5.3 One-way analysis of variance (ANOVA) results of Tc
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
7297.473 4 1824.368 1699.764 0.000
Within
Groups
10.733 10 1.073
Totai 7308.206 14
144
Chapter 5 Precipitation usins supercritical CO 7 as solvent
Table 5.4 Tukey HSD test results of TgCC )
N Subset for 
alpha = 
0.05
do do do do
PVP wt 
fraction
1 2 3 4 5
0.20 3 60.9767
0.30 3 71.8867
0.50 3 93.7800
0.60 3 97.8367
0.83 3 124.4467
Sig. 1.000 1.000 1.000 1.000 1.000
Means for groups in homogeneous subsets are displayed above.
The extent to which these mixtures might exhibit deviation from ideal mixing was 
evaluated by comparison of the experimental Tg with those predicted using the 
Gordon-Taylor equation (1952) as shown below;
Tgmix =  (W iT g i +  K W 2 T g 2 )/(W i +  K W 2> (1)
Where W] and W2 are the weight fraction of each component. Tgi and Tg2 are the 
corresponding glass transition values of each component. The constant K is related to 
the ratio of the free volumes of the two components and can be estimated from the 
density, pi and p2 , of each component using the Simha-Boyer rule (1962).
K  =  ( p i T g i ) / (  P2 T g 2 ) (2)
The densities of the amorphous indomethacin and PVP samples used in this study 
were 1.31 (Yoshioka et al, 1994) and 1.20 g/cm^ (Matsumoto and Zografi, 1999), 
respectively. The Tg values of indomethacin and PVP were determined by DSC to be 
315 and 429 K, respectively.
As can be seen in Figure 5.15, the solid line depicted the values of Tg predicted from 
Gordon-Taylor equation. The change in experimental Tg with PVP concentration 
follows the ideal mixing up to 50% PVP. However, experimental Tg values at 60 and 
83% PVP were lower than those predicted indicating that mixing was not ideal at
145
Chapter 5____________________________________________ Precipitation usins supercritical CO 7 as solvent
these concentrations (Summers and Enever, 1977). These deviations could be 
attributed to the possibility of complex formation between indomethacin and PVP 
(Yoshioka et al, 1995; Taylor and Zografi, 1997). In addition, another reason could be 
due to a nonuniform distribution of the free volume between two components with 
very different Tg values (Shamblin et al, 1998). It was also proposed, but not shown, 
that these deviations could be resulted from molecular interactions formed between 
the two components which are fewer in number and/or strength relative to the 
interactions within each component (Hancock and Zografi, 1997).
5.4 Conclusions
Indomethacin could be “micronised” using S C - C O 2  as a solvent. Particles of processed 
indomethacin were found to be smaller than the unprocessed materials. At 20 °C, 
increasing the operating pressure from 100 to 200 bar reduced the particle size. The 
“micronised” indomethacin was found to be the y-crystalline form.
An exploration of the potential of precipitation using S C - C O 2  as a solvent in 
modifying the physical state of indomethacin was continued after spray-drying and 
precipitation using S C - C O 2  as an antisolvent method were investigated. Instead of 
constructing a new rig, the PC A apparatus was modified applying PGSS concepts. 
Coprecipitation of indomethacin and PEG could not be produced due to the 
limitations of the present apparatus design.
Coprecipitated indomethacin and PVP at various weight fractions was successfully 
achieved at 75 °C and 150 bar. The totally amorphous products were obtained at 
relatively high PVP weight fraction of 0.80 and above. As the PVP weight fraction 
decreased, indomethacin displayed increasing degree of crystallinity.
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6.1 Introduction
Poorly water-soluble crystalline drugs, often have low bioavailability when 
administered as oral solid dosage forms. Conversion of this material to the higher 
energy amorphous state can improve dissolution rates and hence bioavailability 
(Yamamoto et al, 1970; Chiou and Reigelman, 1970). However, the amorphous form, 
which is metastable relative to the crystalline form, can spontaneously crystallize 
under certain conditions of temperature and relative humidity during storage and use 
(Imaizumi et al, 1980; Otsuka nd Kaneniwa, 1988; Andronis et al, 1997). Therefore, it 
is necessary to add excipients that could retard the instability over timescales. It has 
been suggested that co-lyophilization or co-precipitation of drugs with excipients can 
form molecular dispersions which have higher glass transition temperatures (Tg) than 
the drug alone. An increase in Tg can be employed as a means of stabilizing 
amorphous material (Chiou and Reigelman, 1971; Simonelli et al, 1976). Principally, 
once the molecular dispersion has a Tg higher than that of the drug alone, the 
molecular mobility of the drug will be decreased and as a result, crystallization can be 
retarded. Polymers particularly with high Tg values, such as polyvinyl pyrrolidone 
(PVP), have been reported to enhance the physical stability of amorphous drugs 
(Imaizumi et al, 1983; Sekizaki et al, 1995; Matsumoto and Zografi, 1999).
In Chapter 5, a novel technique utilizing supercritical CO2 for co-precipitation of 
indomethacin and PVP was described. In chapter 6 , the study was conducted to 
investigate the dissolution rates of indomethacin and PVP mixtures of various 
proportions prepared using the method described in Chapter 5 in comparison with 
mixtures prepared using physical mixing and solid dispersion methods. Additionally, 
the dissolution rate of amorphous indomethacin, a-metastable indomethacin, y 
indomethacin was also investigated. The stability of mixtures of indomethacin 
containing various PVP proportions, as solid dispersions (solvent evaporation 
technique), supercritical fluid based preparations and amorphous indomethacin itself 
were also investigated under different combinations of temperature and relative 
humidity.
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6.2 Materials and Methods
6.2.1 Materials
Indomethacin, polyvinylpyrrolidone, ethanol, anhydrous methanol, potassium 
dihydrogen orthophosphate, sodium hydroxide pellets, distilled water. The details of 
these materials are given in section 2.1. Silica gel, magnesium chloride, sodium 
chloride and potassium sulphate which were supplied by BDH (England) and were 
used as received. Lithium Fluoride (Prolabo, England) was used as received.
6.2.2 Preparation of indomethacin and PVP physical mixtures
Indomethacin and PVP were mixed in a mortar and pestle for 15 min. The ratios of 
indomethacin and PVP mixtures were 8:2, 7:3, 5:5, 4:6 and 1.7:8.3. The samples were 
desiccated over silica gel at -20 °C.
6.2.3 Preparation of indomethacin and PVP solid dispersions
Indomethacin and PVP solid dispersions were prepared using a solvent evaporation 
technique, wherein 5 g of the appropriate ratios of the two components, 
indomethacin:PVP at 8:2, 7:3, 5:5 and 1.7:8.3, were dissolved in 100 ml of anhydrous 
methanol at 50 °C. The solvent was then removed using a rotary evaporator (Buchi 
Rotavapor R114, Switzerland) at 50 °C. The organic solvent residue was dried in a 
vacuum oven at room temperature (25 °C) for 24 hours. The co-precipitates were 
lightly ground in a mortar and desiccated over silica gel at -20 “C. The solid 
dispersions were characterized using PXRD (Section 2.2.3). The Tg of solid 
dispersions was determined as method described in section 5.2.9. Determination of 
the % crystallinity of indomethacin in the solid dispersions was described in section
5.2.12.
6.2.4 Preparation of indomethacin and PVP mixture using supercritical CO2
Mixtures of indomethacin and PVP at various ratios of I.7:8.3, 4:6, 5:5, 7:3 and 8:2 
were prepared. The mixtures were exposed to SC-CO2  in the reaction vessel for 2 hr 
under SC-CO2  pressure 150 bar and 75 “C. The procedure for preparing indomethacin 
and PVP co-precipitates using supercritical CO2 as solvent has been described in 
section 5.2.3. The co-precipitates were lightly ground in a mortar and desiccated over 
silica gel at -20 “C.
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6.2.5 Preparation of amorphous indomethacin
Amorphous indomethacin was prepared by the quenching method. 10 g of 
indomethacin was placed in a crucible and melted in an oven (Memmert, Germany) at 
168-169 °C. Indomethacin was held at this temperature for 5 min and then cooled 
rapidly using liquid nitrogen. The amorphous indomethacin was warmed to room 
temperature under vacuum to prevent atmospheric moisture condensation on the 
sample. Then it was desiccated over silica gel at -20 °C. This temperature was 
previously shown to prevent crystallization of pure amorphous indomethacin for up to 
6 months (Yoshioka et al, 1994). The resulting quenched indomethacin was found 
totally amorphous using PXRD (Section 2.2.3). Andronis et al (2000) reported that no 
change in the purity of the indomethacin glass was observed as a result of the melting 
and quenching. The amorphous sample was not ground before the experiments 
because mechanical activation of the sample during grinding was significant to the 
physical characteristic of the quenched indomethacin (Fukuoka et al, 1986).
6.2.6 Preparation of a-metastabie indomethacin
The a-metastable indomethacin was prepared according to the method of Kaneniwa 
(1985), with modification. 10 g of indomethacin was dissolved in 50 ml of ethanol at 
70 °C. 50 ml of distilled water at room temperature was then added to the 
indomethacin ethanolic solution. The precipitated crystals were removed by filtration 
and dried overnight under vacuum at -50 °C (Micromodulyo, England).
6.2.7 Drug content determination
The drug content of the indomethacin and PVP mixtures prepared using physical 
mixing, supercritical CO2 and solid dispersion methods were determined. The 
indomethacin and PVP mixture at ratios of 8:2, 7:3, 5:5, 4:6 and 1.7:8.3 was 
examined. The quantity of powder mixture, equivalent to 25 mg of indomethacin, was 
dissolved in 500 ml of phosphate buffer pH 7.2 and the drug concentration was 
determined using a UV spectrophotometer (Beckman DU-62 Spectrophotometer, 
USA) at 320 nm. Each experiment was run 3 times.
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6.2.8 Solubility determination
The solubility of the amorphous, a  and y indomethacin was determined. The 
indomethacin powder was added in excess into phosphate buffer pH 7.2. The 
preparations were stirred continuously for 7 days at ambient room temperature of 
approximately 22 °C. Samples were collected at preset time intervals and the drug 
concentrations measured using a UV spectrophotometer (Beckman DU-62 
Spectrophotometer, USA) at 320 nm.
6.2.9 Dissolution study
The dissolution rates of amorphous indomethacin, a  metastable indomethacin, y 
indomethacin, mixtures of indomethacin and PVP at ratios of 8:2, 7:3, 5:5, 4:6 and 
1.7:8.3, prepared from physical mixing, supercritical CO2 and solid dispersion 
methods were investigated. The powders were sieved using a mechanical sieve shaker 
and powders with a particle size range between 93-150 pm were selected for the 
dissolution study. The powders were filled manually into size 0 hard gelatin capsules. 
Each capsule contained a quantity of mixture to give the equivalent of 50 mg 
indomethacin. The dissolution study was undertaken according to the USPXXI 
dissolution test, apparatus II or paddle method (Pharmatest dissolution tester, 
Germany). The dissolution medium consisted of 900 ml of phosphate buffer pH 7.2, 
maintained at temperature of 37 ± 0.5 °C. A paddle rotation speed of 20 rpm was 
employed. The capsules were trapped at the bottom of a vessel with stainless steel 
mesh of 1/8".
The schematic illustration of this apparatus for dissolution study is shown in Figure
6.1. Samples of 5 ml each were collected automatically at predetermined time 
intervals of 5 min for the first hour and thereafter at intervals of 15 min for the 
subsequent 3 hours. The drug concentration in the sample was analysed using a UV 
spectrophotometer at a detection wavelength of 320 nm. The percentage of drug 
release versus time was calculated. The times for 50% (Tso%) of drug released were 
estimated from the percentage of drug release versus time profiles.
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Figure 6.1. Paddle apparatus for dissolution testing.
6.2.10 Statistical analysis
The Tso% values of indomethacin-PVP mixture prepared by physical mix, solid 
dispersion and supercritical CO2 methods were analysed using a one-way analysis of 
variance. A post-hoc Tukey-HSD test was performed when there was a statistically 
significant difference, which was considered at p < 0.05.
6.2.11 Stability study
The effect of temperature and relative humidity on the stability of amorphous 
indomethacin, indomethacin and PVP mixtures prepared using supercritical CO2 and 
solid dispersion methods was also investigated. The indomethacin and PVP mixtures 
at ratios of 8:2, 5:5 and 1.7:8.3 were selected for the study.
For the study of temperature effect, the samples were kept in sealed glass bottles
stored in desiccators containing silica gel at 30, 50 and 70 “C for a period of 3 months
using a hot air oven (Pickstone, England and Memmert, Germany).
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For the effect of relative humidity, the samples were kept at three different relative 
humidities in desiccators containing saturated salt solutions at 20 °C for a period of 3 
months. Three saturated salt solutions, magnesium chloride, sodium chloride and 
potassium sulphate were used to create 35, 76 and 98%RH. (Nyqvist, 1983). The 
relative humidity of the desiccators was monitored by a hygrometer (Haenni, 
Switzerland).
Samples of 100 mg were withdrawn at preset time intervals over the 3 months of 
study period and mixed with 20% LiF (internal standard) before determination of 
crystallinity. The % crystallinity of the samples was determined by powder X-Ray 
diffraction analysis, using a Philips model PW 3710 X-Ray diffractometer as 
described in section 5.2.12. Calibration curves were prepared using known amounts of 
amorphous indomethacin mixed with either the a  or y crystal form to the level of 5%. 
Background diffraction due to PVP was negligible and did not interfere with the 
analysis. In this present study the period of observation was limited to 3 months 
because the higher temperatures chemical instability of indomethacin can arise on 
long term storage (Carstensen et al, 1993).
6.3 Results and Discussion
Solubility and dissolution studies o f amorphous indomethacin, (X-metastable 
indomethacin and y indomethacin.
The solubility profiles of amorphous, a  and y indomethacin in phosphate buffer pH 
7.2 at 22 °C are depicted in Figure 6.2. There was a steady increase in the amount of y 
form dissolved and reached a plateau concentration at about 8 hr. On the other hand, 
the a  metastable form showed a high solubility peak value after about 6 hr followed 
by a decline before reaching a plateau. The plateau level observed in this case was 
higher than that of the y-crystal form. The a  form could exist as a supersaturated 
solution and also it could convert to the y stable form (Hancock and Parks, 1999). The 
quenched amorphous indomethacin showed a maximum in solubility after about 6 hr 
before values of solubility began to fall. The maximum in solubility suggested that the 
amorphous indomethacin existed as a supersaturated solution.
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Imaizumi et al (1980) studied the solubility of amorphous indomethacin in 5 % 
aqueous methanol solution. It was reported that the solubility of the amorphous form 
became almost the same as that of a  form after 2 hours. According to X-ray 
difractometry, a  metastable polymorph was formed from the amorphous at the initial 
stage of dissolution, and the resulting a  form changed gradually to y stable form. 
Hancock and Parks (looo ) studied the solubility of amorphous indomethacin in water.
It was shown that over the duration of the solubility experiments of amorphous 
indomethacin, the starting amorphous material partially converted to a  and y 
crystalline polymorphs.
The increase in solubility attained by both amorphous and a metastable form 
indomethacin may correspond to the solubility of an “activated state”. As activated 
state is a high energy metastable state by definition (Buckton and Beezer, 1992), it 
tends to resume more thermodynamically stable, lower energy states. The actual peak 
solubility value of amorphous and a metastable indomethacin might be higher than 
the measured peak during the experiments, since the change back to a more stable 
crystalline form of indomethacin, by crystallisation process, might compete with the 
dissolution of the amorphous or a indomethacin during the early dissolution phase 
(Rodrigues-Homedo et al., 1992). This might explain the solubility profile of 
amorphous and a metastable indomethacin, where the initial phase of the profile is 
dissolution-dominated until the highest possible level of supersaturation is reached, 
i.e., the peak, while the second phase of the profile is dominated by a transition back 
to a more thermodynamically stable form of indomethacin, shown by a decline from 
the peak value. As can be seen in Figure 6.2, during the relatively short observation 
period of 7 days, slow reduction of solubility values of amorphous and a  
indomethacin were seen.
For comparison, the amorphous form exhibited the highest apparent solubility 
followed by the metastable (a) and lastly the stable form (y). The apparent-saturated 
solubility values at steady state were 309.43, 143.97 and 73.67 mg/100 ml for the 
amorphous, a  and y indomethancin.
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Figure 6.2 Solubility study of amorphous, a  and y form of indomethacin.
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Figure 6.3 The dissolution profiles of amorphous, a  and y indomethacin
Table 6.1(a) ANOVA table of T$o% values of amorphous, a  and y forms of 
indomethacin
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
3142.390 2 1571.195 32.443 0.000
Within
Groups
726.450 15 48.430
Total 3868.840 17
1 5 6
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Table 6.1(b) Tukey HSD test results of Tso% values of amorphous, a  and y form 
indomethacin
Indom ethacin N Subset for 
alpha = 
0.05
do.
1 2
Amorphous 6 14.5167
a form 6 19.2667
Y form 6 44.6167
Sig. 0.481 1.000
Means for groups in homogeneous subsets are displayed above.
Figure 6.3 shows the dissolution profiles of amorphous, a  and y indomethacin. The 
profiles indicated that the amorphous form had the highest dissolution rate, followed 
by the metastable (a) and finally the stable form (y). It can be noted that the y form 
was dissolved to the extent of about 70% at 240 min. The T5o% values were 15.4 
minutes for amorphous, 19.3 minutes for a  and 44.6 minutes for y indomethancin. 
According to Noyes-Whitney equation, the dissolution rate is affected by the 
solubility of the compound in the medium. As such, the rank order of the dissolution 
rate was similar to that of the solubility.
When the Tso% values of amorphous, a and y form indomethacin were analyzed 
statistically using one-way analysis of variance, they were significantly different. 
However, post-hoc statistical analysis showed that the Tso% values of the amorphous 
and the a  forms of indomethacin were not significantly different. The reason 
amorphous and a form were not significantly different in post hoc analysis could be 
attributed to the particle size of a form used in the experiment, which was relatively 
small at around 20 pm, as compared to others at 93-150 pm as described in section 
6.2.9. The fluffy nature of a indomethacin powder made sieving difficult. 
Additionally, the a form had needle shape and hence a high surface area.
The drug content of the indomethacin and PVP mixtures prepared using physical 
mixing, supercritical CO2 and solid dispersion methods.
The drug content of indomethacin and PVP mixtures at various proportions produced 
using different methods is given in Table 6.2. The results showed that physical mixing 
and SCF samples gave nearly the same amount of drug content as expected. Whereas,
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the solid dispersion did not give the drug content as predicted. It can be noted that 
mixing was affected by the method of preparation and composition.
Table 6.2 The indomethacin content in various mixtures of indomethacin and PVP.
Expected % 
indomethacin
Measured % 
indomethacin in 
SCF samples 
Mean ± SD
Measured % 
indomethacin in 
Solid dispersion 
samples Mean ± SD
Measured %
indomethacin in Physical 
mixtures samples 
Mean ± SD
80 79.7(1.3) 78.9(1.8) 81.4(1.6)
70 71.1(0.1) 69.8(1.2) 69.2 (0.8)
50 49.6 (0.2) 53.6 (0.3) 50.6 (0.6)
40 39.5 (0.5) 42.3(1.1) 39.9(1.0)
17 17.2 (0.7) 20.1 (0.1) 17.9 (0.8)
Dissolution studies of indomethacin in mixtures o f various proportions of PVP 
prepared using physical mixing, solid dispersion and supercritical CO2 methods.
The dissolution profiles of physical mixtures of indomethacin and various proportion 
of PVP are presented in Figure 6.4. Increasing PVP content from 20% to 60% 
increased the dissolution rate of indomethacin. The dissolution profiles of both 50% 
and 60%PVP were similar and were almost superimposable. At 83%PVP, however, 
the dissolution rate was slower than at 50 and 60%PVP although higher than the 20 
and 30%PVP. The indomethacin used in the physical mixtures is the stable gamma 
crystalline form (the form with poor dissolution). Incorporation of a hydrophilic 
polymer, such as PVP, enhanced the indomethacin dissolution when compared with 
the dissolution of indomethacin alone. Nevertheless, at high concentration the 
increase in viscosity in the diffusion layer as a result of gel formation of PVP could 
retard the drug release. Indomethacin in the physical mixtures dissolved rapidly in the 
first 15 minutes and then slowed down gradually. In the earlier stage, PVP from the 
physical mixture might lower the surface tension of the dissolution medium, resulted 
in wetting of the indomethacin crystal surface. Subsequently, PVP might increase the 
viscosity of the solution, resulting in slower diffusion and dissolution of the drug. The 
relationship between viscosity and drug diffusion has been discussed by Sarisuta and 
Parrott (1982, 1983) and Doherty and York (1987).
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Figure 6.4 Dissolution profiles of pure indomethacin and physical mixture of 
indomethacin with 20-83% of PVP
Table 6.3(a) ANOVA table of Tso% values of physical mixture of indomethacin with 
20-83% of PVP.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
857.398 4 214.350 17.367 0.000
Within
Groups
308.565 25 12.343
Total 1165.963 29
1 5 9
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Table 6.3(b) Tukey HSD test results of Tso% values of physical mixture of 
indomethacin with 20-83% of PVP.
%PVP N Subset for 
alpha = 
0.05
do. do. do.
1 2 3 4
60 6 24.9333
50 6 26.8333 26.8333
83 6 31.9500 31.9500
20 6 35.0500 35.0500
30 6 39.5833
Sig. 0.880 0.117 0.555 0.200
Means for groups in homogeneous subsets are displayed above.
Indomethacin prepared using solid dispersion and supercritical CO2 methods did not 
show similar trends to the trends noted for physical mixtures.
Table 6.4 shows the Tg and % crystallinity of solid dispersions of indomethacin and 
various proportions of PVP. Indomethacin existed in partially amorphous form at 20 
and 30% PVP. An increase in the PVP content resulted in a decrease of % 
crystallinity. A totally amorphous sample could be obtained at 50% PVP and above. 
In contrast, Matsumoto and Zografi (1999) reported that solid dispersion of 
indomethacin and PVP at 5% and above prepared using solvent evaporation method 
was totally amorphous. According to PXRD data, there was a peak at 8.5° 20 
confirming that only the a type was detected in 20 and 30 % PVP solid dispersion 
samples. Figures 6.5-6.7 show PXRD profiles of solid dispersions of indomethacin 
with 20, 30 and 50% PVP, respectively.
Table 6.4 Glass transition temperature and degree of crystallinity for solid dispersions 
of indomethacin and PVP obtained by Differential Scanning Calorimetry and PXRD, 
respectively.
%PVP Tg(K) Degree of crystallinity (%)
20 341.67 20
30 347.89 13
50 356.78 0
60 372.12 0
83 397.45 0
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Figure 6.5 PXRD pattern of the solid dispersion of indomethacin and 0.2 PVP weight 
fraction prepared using solvent evaporation method.
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Figure 6.6 PXRD pattern of the solid dispersion of indomethacin and 0.3 PVP weight
fraction prepared using solvent evaporation method.
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Figure 6.7 PXRD pattern of the solid dispersion of indomethacin and 0.5 PVP weight 
fraction prepared using solvent evaporation method.
The dissolution profiles of solid dispersions of indomethacin and various proportion 
of PVP are shown in Figure 6.8. The maximum dissolution rate was obtained by the 
dispersion having 20 % PVP and then followed by 30% PVP. Since both samples are 
partially amorphous and only the a-type exists, it may therefore be expected to have a 
fast initial dissolution rate due to the solution of amorphous content. This solution 
may become depleted with time and can be followed by a slow dissolution phase of 
the crystalline material. It should be noted that the release profiles of both 20 and 
30%PVP samples were biphasic, these samples were both partially amorphous. The 
dissolution profiles of both 50% and 60%PVP were noted as being similar. The 
release profile of 83% deviated from those of others due to the high viscosity of PVP 
gel which could retard the drug release. However, at higher % PVP (50, 60 and 
83%PVP), the dissolution rates were found to be lower than those of 20 and 30 
%PVP. This trend could be related to the 2 factors involved, the viscosity/gel
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formation and crystallinity. Should this be the case, the crystallinity effect might not 
be dominant compared to gel formation.
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Figure 6.8 Dissolution profiles of pure indomethacin and solid dispersion (SD) of 
indomethacin with 20-83% of PVP prepared using solvent evaporation method.
Table 6.5(a) ANOVA table of Tso*»/» values of solid dispersion indomethacin with 20- 
83% of PVP prepared using solvent evaporation method.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
2308.071 4 577.018 10.412 0.000
Within
Groups
1385.517 25 55.421
Total 3693.588 29
1 6 3
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Table 6.5(b) Tukey HSD test results of Tso% values of solid dispersion indomethacin 
with 20-83% of PVP prepared using solvent evaporation method.
%PVP N Subset for 
alpha = 
0.05
do. do.
1 2 3
20PVP 6 29.5000
30PVP 6 35.1000 35.1000
60PVP 6 43.0500 43.0500
83PVP 6 49.9667
50PVP 6 52.7833
Sig. 0.692 0.369 0.190
Means for groups in homogeneous subsets are displayed above.
With regard to Table 5.2 (Chapter 5), the coprecipitated indomethacin and 20-60% 
PVP samples prepared using the supercritical fluid method were partially amorphous. 
The PXRD profiles (Figure 5.9-5.14 in Chapter 5) showed that only y-type was 
detected in all the co-precipitated indomethacin. For the dissolution of supercritical 
fluid samples shown in Figure 6.9, the 20%, 60% and 83% PVP samples displayed 
lower dissolution rates than those of 30 and 50% PVP. Referring to Tukey HSD test 
results of T5o% values of coprecipitates indomethacin shown in Table 6.6 (b), it can be 
noted that the 20%, 60% and 83% PVP samples were in one group and 30 and 50% 
PVP in another group. The 20%, 60% and 83% PVP samples displayed lower 
dissolution rate than those of 30 and 50% PVP. The 20% PVP had the highest % 
crystallinity whereas the 83% PVP was totally amorphous. In view of this, the gel 
forming effect of PVP was dominant in retarding drug release at higher content of 
PVP.
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Figure 6.9 Dissolution profiles of pure indomethacin and coprecipitates of 
indomethacin with 20-83% of PVP prepared using supercritical CO2 based technique.
Table 6.6(a) ANOVA table of T5o% values of coprecipitates indomethacin with 20- 
83% of PVP prepared using supercritical CO2 based technique.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
2607.255 4 651.614 9.598 0.000
Within
Groups
1697.738 25 67.910
Total 4304.994 29
1 6 5
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Table 6.6(b) Tukey HSD test results of Tso% values of coprecipitates indomethacin 
with 20-83% of PVP prepared using supercritical CO2 based technique.
% PVP N Subset for 
alpha = 
0.05
do.
1 2
30PVP 6 23.5000
50PVP 6 27.5833
60PVP 6 42.3667
20PVP 6 42.9167
83PVP 6 47.0167
Sig. 0.909 0.863
Means for groups in homogeneous subsets are displayed.
Table 6.7 shows the comparison of values of Tso% using three different methods of 
preparation, and similar ratios of indomethacin and PVP. It should be noted that at 
20% PVP, the Tso% of solid dispersion was lowest. However, at PVP contents of 30 
and 50%, the supercritical fluid samples had the lowest value of Tso%. At the higher 
concentration of PVP, at 60 and 83 % PVP, the physical mixtures had the lowest Tso%, 
The Tso% values of indomethacin prepared using 3 different methods for similar ratio 
of indomethacin and PVP (20-83 %) which were analysed statistically using one-way 
analysis of variance and post-hoc statistical analysis are shown in Tables 6.8-6.12. It 
should be noted that except at 20% PVP, the mean Tso% values of other PVP 
concentrations prepared using physical mix, solvent evaporation and supercritical 
fluids based techniques were significantly different. In other words, the Tso% values 
were not affected by the methods used at 20% PVP. Nevertheless, the Tso% values of 
other PVP concentrations were highly dependent on the methods used.
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Table 6.7 Tso% of mixtures of indomethacin and various proportion of PVP prepared 
using physical mixing, solid dispersion and supercritical fluids based technique. The 
numbers shown in the brackets are the respective standard deviations.
(min)
%PVP
Physical mixing Solid dispersion Super critical fluids
20 35.05(5.90) 29.50(6.37) 42.92(13.57)
30 39.58(4.23) 35.10(4.70) 23.50(5.13)
50 26.83(1.66) 52.78(5.83) 27.58(7.08)
60 24.93(2.36) 43.05(13.10) 42.37(8.09)
83 31.95(0.85) 49.97(2.96) 47.02(3.68)
Table 6.8(a) ANOVA table of Tso% values of indomethacin from indomethacin and 
20% PVP prepared by three different methods.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
545.388 2 272.694 3.153 0.072
Within
Groups
1297.243 15 86.483
Total 1842.631 17
Table 6.8(b) Tukey HSD test results of T5o% values of indomethacin from 
indomethacin and 20% PVP prepared by three different methods.
N Subset for 
alpha = 0.05
1
Solid
dispersion
6 29.5000
Physical
mixture
6 35.0500
SCF 6 42.9167
Sig. 0.060
Vleans for groups in lomogeneous
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Table 6.9 (a) ANOVA table of Tso% values of indomethacin from indomethacin and 
30% PVP prepared by three different methods.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
826.668 2 413.334 18.704 0.000
Within
Groups
331.488 15 22.099
Total 1158.156 17
Table 6.9(b) Tukey HSD test results of Tso% values of indomethacin from 
indomethacin and 30% PVP prepared by three different methods.
N Subset for 
alpha = 0.05
do.
1 2
SCF 6 23.5000
Solid
dispersion
6 35.1000
Physical
mixture
6 39.5833
Sig. 1.000 0.256
Means for groups in lomogeneous subsets are displayed above.
Table 6.10(a) ANOVA table of T5o% values of indomethacin from indomethacin and 
50% PVP prepared by three different methods.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
2618.010 2 1309.005 45.216 0.000
Within
Groups
434.250 15 28.950
Total 3052.260 17
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Table 6.10(b)Tukey HSD test results of T5o% values of indomethacin from 
indomethacin and 50% PVP prepared by three different methods.
N Subset for 
alpha = 0.05
do.
1 2
Physical
mixture
6 26.8333
SCF 6 27.5833
Solid
dispersion
6 52.7833
Sig. .968 1.000
Means for groups in lomogeneous subsets are displayed above.
Table 6.11(a) ANOVA table of Tso% values of indomethacin from indomethacin and 
60% PVP prepared by three different methods.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
1265.203 2 632.602 7.818 0.005
Within
Groups
1213.742 15 80.916
Total 2478.945 17
Table 6.11(b) Tukey HSD test results of Tso% values of indomethacin from 
indomethacin and 60% PVP prepared by three different methods.
N Subset for 
alpha = 0.05
do.
1 2
Physical
mixture
6 24.9333
SCF 6 42.3667
Solid
dispersion
6 43.0500
Sig. 1.000 0.991
Means for groups in lomogeneous subsets are displayed above.
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Table 6.12(a) ANOVA table of T5o% values of indomethacin from indomethacin and 
83 % PVP prepared by three different methods.
Sum of 
Squares
df Mean
Square
F Sig.
Between
Groups
1120.614 2 560.307 73.022 0.000
Within
Groups
115.097 15 7.673
Total 1235.711 17
Table 6.12(b) Tukey HSD test results of Tso% values of indomethacin from 
indomethacin and 83% PVP prepared by three different methods.
N Subset for 
alpha =0.05
do.
1 2
Physical
mixture
6 31.9500
SCF 6 47.0167
Solid
dispersion
6 49.9667
Sig. 1.000 0.189
Means for groups in homogeneous subsets are displayed above.
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Stability o f amorphous indomethacin at different temperatures.
Figures 6.10-6.12 show the plots of percentage crystallinity against time for quenched 
amorphous indomethacin after storage over a 3-month period at 30, 50 and 70 °C, 
respectively. It can be noted that the amorphous indomethacin crystallized at 30 °C 
after an induction period of about 36 hours. This is in accordance with the periods of 
28 hours reported by Otsuka and Kenikewa (1988) and 36 hours by Yoshioka et al 
(1994). It took approximately one month for crystallization to reach a steady state, 
and at this time the indomethacin had 90% crystallinity. At isothermal crystallization 
of 30 “C, the amorphous sample only changed to the y crystal form. The plot in Figure 
6.10(b) indicated that the transition of amorphous indomethacin to the crystalline 
form followed first order kinetic with a rate constant of 0.10 day'\ This was also in 
accordance with the results of 0.12 day'^ reported by Otsuka and Kenikewa (1988) 
and 0.11 day'^ by Yoshioka et al (1994), respectively. Crystallization from the 
amorphous state of indomethacin could occur at 30 °C, a temperature which is below 
the Tg of 50 “C, since at this condition, indomethacin has sufficient rotational mobility 
to form a nucleus of critical size followed by crystal growth (Yoshioka et al, 1994).
Crystallization at 50 °C led to both a and y forms as shown in Figure 6.11. It should 
be noted that the initial rate of appearance of the y form was reduced in comparison 
with that at 30 “C and the a form appeared after a 4-day induction period. Both a and 
y forms existed in almost equal proportions. It should be noted in Figure 6.12 that at 
70 °C, both forms showed relatively higher initial crystallization rate than those of 50 
°C. However, the curves were followed by abrupt plateau and the combination of % 
crystallinity for both forms was nearly 100%. It was found that at lower temperature, 
the condition favoured the crystallization of thermodynamically more stable y form, 
whereas at higher temperature both polymorphs appeared but the a metastable form, 
which was thermodynamically less stable, showed a tendency to dominate. Yoshioka 
et al (1994) suggested that at a storage temperature above Tg, the particular 
polymorphic form existed under a particular set of conditions due to the 
thermodynamic factors, which included mechanisms and rates. From homogeneous 
nucléation theory (Turnbull and Fisher, 1949 through Yoshioka et al, 1994), the 
trends for either of the two polymorphs to crystallize from the amorphous state could 
be explained by a balance between the free energy at the nucleus/amorphous matrix
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interface, and the free energy difference between the particular crystal form and 
amorphous matrix.
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Figure 6.10 (a) percent crystalline phase versus time at 30 °C for the amorphous 
indomethacin
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Figure 6.10 (b) plot of percent amorphous indomethacin remaining after storage at 30 
°C for various time periods (t) after an induction time (f) for the amorphous 
indomethacin.
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Figure 6.11 Percent crystalline phase versus time at 50 °C for the amorphous 
indomethacin
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Figure 6.12 Percent crystalline phase versus time at 70 °C for the amorphous 
indomethacin.
Stability o f coprecipitated indomethacin with PVP at different temperatures.
The stability of coprecipitated indomethacin and PVP at 20%, 50% and 83% prepared 
using solvent evaporation and sc-COz methods was investigated. The degree of 
crystallinity results, determined by PXRD, of all freshly prepared solid dispersion 
(SD) and supercritical fluid (SCF) samples which were used to study the isothermal 
crystallisation at 30, 50 and 70 °C are given in Table 6.13. The appearance of 
crystalline indomethacin, either in the alpha or gamma crystalline form over a 3- 
month period at 3 different storage temperatures was monitored.
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Table 6.13 Degree of crystallinity of indomethacin and PVP coprecipitated using solid 
dispersion and supercritical fluid technique.
Samples % Crystallinity (t = 0 days) Polymorph present
SD20PVP 20 a
SD50PVP 0 -
SD83PVP 0 -
SCF20PVP 55 Y
SCF50PVP 18 Y
SCF83PVP 0 -
Figures 6.13-6.15 show the %crystallinity versus time of SD 20%PVP, SCF 20%PVP 
and SCF 50%PVP, respectively. The a form presented in solid dispersion sample 
whereas the y form presented in supercritical fluid samples. The higher the 
temperature, a more drastic change in % crystallinity was obtained. For SD 50%PVP, 
SD 83%PVP and SCF 83%PVP, there was no change in crystallinity over 3 months at 
30, 50 and 70 °C. From these results, it can be concluded that indomethacin 
coprecipitated with PVP can have a significant inhibiting effect on crystallization 
rates at PVP levels of 50% and 83% for solid dispersion and 83% for supercritical 
fluid coprecipitate.
From Figure 6.13, it can be noted that the crystallinity of SD 20% PVP did not change 
up to 3 months at 30 °C. The percentage crystallinity changed from 20 % to 35% at 50 
°C and to 38% at 70 °C, respectively. This phenomenon could be attributed to the 
seeding effect. As shown in Table 6.13, freshly prepared SD 20% PVP had 20 % 
crystallinity. The presence of a crystal in the coprecipitates could have enhanced 
crystallization.
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From Figures 6.14 and 6.15, SCF 20% PVP was noted to exhibit a greater extent of % 
crystallinity change after a 3-month period. At 70 °C, the percentage crystallinity of 
SCF 20% PVP changed from 54% to 80%, whereas SCF 50%PVP changed from 19% 
to 40%. This phenomenon could be attributed to the seeding effect. As shown in 
Table 6.13, freshly prepared SCF 20% PVP had 54 % crystallinity, whereas SCF 50% 
PVP had 19% crystallinity. The presence of y crystal in the coprecipitates could have 
enhanced crystallization. The more amount of y crystal the higher the extent of 
crystallization.
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Figure 6.13 Percent crystalline phase versus time at 30, 50 and 70 °C for the solid 
dispersion of indomethacin and 20%PVP.
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Figure 6.14 Percent crystalline phase versus time at 30, 50 and 70 “C for the 
coprecipitated indomethacin and 20%PVP prepared using the SCF based technique.
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Figure 6.15 Percent crystalline phase versus time at 30, 50 and 70 “C for the 
coprecipitated indomethacin and 50%PVP prepared using the SCF based technique.
177
Chapter 6__________________________________________________________ Dissolution and stability studies
Previous studies of indomethacin-PVP coprecipitates showed that PVP acted as an 
inhibitor of crystallization (Imaizumi et al, 1983, Yoshioka et al, 1995). As reported 
by Imaizumi et al. (1983), coprecipitated samples at 75% PVP remained amorphous 
for at least 180, 60 and 30 days when stored at 40, 50 and 60 °C, while amorphous 
indomethacin exhibited 14% and 25% crystallinity after 2-day storage at 20 and 30 
“C, respectively. In our present work, solid dispersion samples at 50% PVP, 83 % 
PVP and SCF samples at 83%PVP remained amorphous for at least 3 months, 
whereas amorphous indomethacin alone exhibited 22% crystallinity after storage for 4 
days at 30 °C.
Stability o f amorphous indomethacin at different relative humidity 
Figure 6.16 shows the %crystallinity versus time profiles of amorphous indomethacin 
stored at 35%RH and 76%RH. Only the y form was detected. On the other hand, as 
shown in Figure 6.17, a and y forms appeared at 98%RH. It was well established that 
water, with a reported Tg of 135 K, acts as a plasticizer for amorphous and partially 
amorphous materials (Sugisaki et al 1968, through Hancock and Zografi, 1994). In 
this case, water might be absorbed into amorphous indomethacin and therefore, it can 
lower the glass transition temperature, Tg. Consequently, crystallization occurred. The 
more water absorbed at high % relative humidity, the lower the Tg and thus the 
increase in crystallization rate.
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Figure 6.16 Plot of degree of crystallinity versus time of amorphous indomethacin 
stored at 35% and 76% RH and 25 T . Only y form was found in the samples.
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Figure 6.17 Plot of degree of crystallinity versus time of amorphous indomethacin 
stored at 98% RH and 25 °C. Both a and y form were found in the samples.
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Stability o f  coprecipitated indomethacin with PVP at different relative humidity.
The stability of coprecipitated indomethacin and 20%, 50% and 83% PVP prepared 
using solvent evaporation method and SC-CO2 method was investigated. Figures 6.18- 
6.20 show the %crystallinity versus time of SD 20%PVP, SCF 20%PVP and SCF 
50%PVP, respectively. The a form presented in solid dispersion sample whereas the y 
form presented in supercritical samples. The rate of change in % crystallinity 
increased with an increase in %RH. In Figure 6.20, the SCF 50% PVP sample was 
wet and sticky after kept at 76% RH for 30 days and 98% RH for 8 days. 
Consequently, the % crystallinity could not be determined by PXRD.
Monitoring the appearance of indomethacin coprecipitates, the SD 50%PVP, SD 
83%PVP and SCF 83%PVP samples, revealed that there was no change in terms of 
appearance and also no crystallization occurred over a 3-month period at 35%RH. 
However, at higher %RH, the samples were wet and converted to a sticky mass within 
a month. The durations for the appearance of sticky indomethacin as observed at 
different %RH are given in Table 6.14. From this result, it can be concluded that 
indomethacin coprecipitated with PVP can have significant inhibiting effect on the 
crystallization rates at PVP levels of 50% and 83% for solid dispersion and at 83% for 
supercritical fluid coprecipitate. However, it was observed that the storage conditions 
could have an effect on the final results.
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Figure 6.18 Percent crystallinity versus time at 35%, 76% and 98% RH for the solid 
dispersion of indomethacin and 20%PVP.
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Figure 6.19 Percent crystallinity versus time at 35%, 76% and 98% RH for the 
coprecipitated indomethacin and 20%PVP prepared using SCF based technique. Only 
the 7  form was found in the samples.
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Figure 6.20 Percent crystallinity versus time at 35%, 76% and 98% RH for the 
coprecipitated indomethacin and 50%PVP prepared using SCF based technique. Only 
the y form was found in the samples.
Table 6.14 The time measured for the changing of appearance from powder to sticky 
mass of indomethacin-PVP coprecipitates at various RH at 25 °C.
%RH
Time (days)
SD 50 PVP SD 83 PVP SCF 83 PVP
35 >90 >90 >90
76 30 20 20
98 8 5 5
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6.4 Conclusions
The dissolution rate and solubility studies of amorphous indomethacin, a and y 
indomethacin polymorphs showed that the amorphous form had the highest solubility 
and dissolution rate, followed by the metastable form (a) and lastly the stable form
( y ) -
The dissolution studies of various proportions of indomethacin and PVP mixture 
prepared using S C - C O 2  as solvent, physical mixing and solid dispersion methods 
showed that PVP could enhance the dissolution of indomethacin at low concentration 
but an increase in PVP content could retard the dissolution rate. The results were 
dependent on the amount of PVP in the mixture and additionally the method of 
preparation. It should be noted that the Tgo% results obtained using environmental 
friendly method of employing S C - C O 2  as solvent showed dissolution rate which was 
comparable and in some cases even better than those results of physical mixing and 
solid dispersion.
The stability studies for 3 months were carried out on the coprecipitates and 
amorphous indomethacin. The quenched amorphous indomethacin reached 
approximately 90% crystallinity within a month at a temperature of 30 °C and only 
the y crystalline form was observed. At higher temperatures (50 and 70 °C), 
crystallization rate increased and both a  and y crystalline forms were obtained. 
Coprecipitation of indomethacin with PVP retarded the crystallization process. The 
coprecipitates where indomethacin existed in complete amorphous form did not 
crystallize after storage at 30, 50 and 70 °C for 3 months. Nevertheless, for 
coprecipitates with indomethacin existed in partially amorphous form, crystallization 
occurred at a rate which was dependent on temperature. When the amorphous 
indomethacin was stored at 35%RH and 76%RH, only the y form was detected, but 
both a and y forms appeared at 98%RH. Similarly, coprecipitation of indomethacin 
with PVP also retarded the crystallization process at lower %RH. At higher %RH, the 
powder turned sticky.
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7.1 Introduction
The main objective of this work was to study the preparation and stabilisation of 
poorly water-soluble drugs in the amorphous state, as a means of producing solid oral 
dosage forms with rapid dissolution. Indomethacin, a nonsteroidal anti-inflammatory 
drug (NSAID), was chosen as a model compound because its dissolution rate is 
limited by its poor solubility in water. The coprecipitation with a water-soluble 
polymer, polyvinylpyrrolidone (PVP), was used as the means to alter the physical 
state of indomethacin, i.e. conversion to amorphous content and hence increase in the 
dissolution rate of indomethacin. The spray-drying of non-aqueous solutions of 
indomethacin in the presence of various additives were investigated. Additionally, an 
environmental friendly method using supercritical CO2 as an antisolvent and solvent 
were also employed.
Prior to the coprecipitation using supercritical fluid based technique, the rigs were 
specially designed, fabricated and modified under safety precautions. The feasibility 
of using supercritical CO2 to prepare indomethacin and PVP coprecipitates was then 
investigated. The products were characterized using DSC, SEM and PXRD. Finally, 
the dissolution and stability of coprecipitates of indomethacin and PVP prepared 
using supercritical CO2 was examined.
7.2 General conclusions
Spray drying is a process whereby a solution or suspension is atomised into a fine
spray, mixed with warm air and allowed to evaporate to a dry particulate powder.
Spray drying has the advantage of being a one-stage process. However, it is limited by
low yield and the presence of solvent residue could affect the stability of the final
products. Spray drying often produces amorphous material, but spray dried
indomethacin from non- aqueous solution remained crystalline, as did co-spray dried
indomethacin and microcrystalline cellulose (MCC). Co-spray drying with 20-60%
PVP could produce amorphous indomethacin. Combining the third component, either
the MCC or SMCC did not affect the physical characteristics of the product. It has
been shown that the type and quantity of additives can be instrumental in altering the
physical state of indomethacin. The dissolution rate of a direct compression tablet of
CO spray-dried indomethacin with 20%PVP was higher than that of non-spray dried
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indomethacin. To improve the dissolution rate of indomethacin, co-spray drying with 
20% PVP is recommended.
An alternative method, using supercritical CO2 as an anti solvent was performed. 
Indomethacin precipitated from various organic solvents using supercritical CO2 (at 
40 °C and 150 bar) as antisolvent comprised a mixture of a and y polymorphs. Based 
on DSC, PXRD and SEM analyses, it was observed that the a form was present in a 
higher proportion than the y form. No significant effect on the drug characteristic was 
observed when the drug concentration and its feeding rate were varied within the 
range of operating conditions studied. Due to the limitation of the current 
experimental set-up, coprecipitation of indomethacin and PVP could not be produced.
The feasibility of precipitation of indomethacin using supercritical CO2 as a solvent 
was then assessed after the modification of the previous rig. Application of this 
process to the precipitation of indomethacin resulted in the y crystalline form and 
obviously smaller particle size than that of the original material. At 22 °C, an increase 
in the operation pressure from 100 to 200 bar resulted in a decrease in particle size.
The dissolution rates of poorly water-soluble drugs can also be enhanced by 
coprecipitation with water-soluble polymers such as PVP. Numerous studies have 
demonstrated the feasibility of forming coprecipitates of indomethacin and PVP. 
Coprecipitation not only can enhance the dissolution rate of indomethacin, but also 
minimise the side effects such as gastric irritation, ulcers and stomach bleeding upon 
oral administration. The main objective of this study was to prepare indomethacin- 
PVP coprecipitates using supercritical CO2 . A successful coprecipitate was obtained 
upon mixing indomethacin and PVP under supercritical CO2 . Coprecipitation 
experiments involved studying the effect of pressure and temperature on the 
characteristic of the drug in the mixture. It was found that coprecipitated 
indomethacin at various weight fractions was successfully achieved at 75 °C and 150 
bar. The amorphous products were obtained at PVP weight fraction of 0.80 and 
above. As the PVP weight fraction decreased, indomethacin displayed increasing 
degree of crystallinity. The SEM photographs of the coprecipitates showed a foamy 
and porous structure.
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The dissolution studies of coprecipitates of various proportions of indomethacin and 
PVP mixture prepared using supercritical CO2 as solvent and unprocessed crystalline 
indomethacin in a phosphate buffered solution were determined. The dissolution rate 
of coprecipitates exhibited comparatively higher dissolution rates than that of 
crystalline indomethacin alone. The enhanced dissolution rate of the coprecipitate was 
attributed to the reduction in the degree of crystallinity of the product after processing.
The stability studies for 3 months were carried out on the coprecipitates and 
amorphous indomethacin itself. The powders were stored under different temperature 
and relative humidity. Increasing the temperature or relative humidity enhanced the 
rate of conversion of amorphous indomethacin into crystalline indomethacin. On the 
other hand, coprecipitation of indomethacin with PVP could retard the crystallization 
rate.
In summary, this project has demonstrated clearly that the dissolution rate of poorly 
water-soluble indomethacin was enhanced successfully by the coprecipitation with 
PVP using “the clean technology”, supercritical CO2 based process.
7.3 Recommendations for Future Work
Development and evaluation o f rapid dissolution dosage forms 
The SCF indomethacin-PVP could be used to formulate into tablet or capsule dosage 
form with rapid dissolution. Equipped with a better dissolution, the dose of 
indomethacin could be reduced leading to a decrease in side effects. The final dosage 
form should be evaluated using methods stated in standard monograph such as BP.
Application of SCF onto other poorly soluble drugs and polymers
In the present study, PVP has been used to modify the physical state of indomethacin 
and increase its stability. Amorphous form of indomethacin was produced with higher 
dissolution rate. The incorporation of PVP has further improved the stability of the 
compound. Other hydrophilic polymers such as HPMC, HPC should be investigated.
In addition, other poorly water soluble drugs should also be explored.
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Further improvement o f apparatus
In the present study, some of the components used in the experiments were designed 
manually. There is still room for improvement in terms of the design of the apparatus.
For example, a bigger reaction vessel might be constructed to accommodate a larger 
quantity of samples per batch. Recycling of CO2 might be controlled to reduce 
production cost.
Chemical stability
The chemical stability of indomethacin-PVP mixture should be evaluated to establish 
the shelf life of the compound. As indomethacin exists in the amorphous form in the 
mixture, it will be interesting to know if the presence of PVP could reduce its 
chemical stability without compromising on its physical state.
Exploring more sophisticated and sensitive techniques in measuring amorphous 
compounds
In the present study, DSC and X-ray diffraction are the tools used in establishing the 
amorphous or crystalline form of indomethacin. Other alternative techniques such as 
Isothermal microcalorimetry. Solution calorimetry. Water Absorption and FT-Raman 
Spectroscopy, should be explored.
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Spray Drying with combustible solvents
With regard to the presence of spray drying with combustible solvents, special 
precautions were necessary. Working out the correct proportion of the combustible 
solvent in the air is the best approach to prevent any incidents occurring during spray 
drying with combustible solvents. Additionally, this proportion of air/solvent mix 
must be within the upper and lower explosion limits.
Calculation o f air/solvent ratio (% v/v)
The maximum aspirator flow rate is 40 m  ^ hr  ^ (setting 20). Setting the 
aspirator rate at 10, the aspirator flow rate is therefore calculated value of 20 m  ^hr \  
setting the aspirator rate at 5, the rate is therefore evaluated at 10 m  ^hr^ and so on.
Example 1
Calculate the maximum feed rate of a 50% ethanol content by using inlet 
temperature 100 (The lower explosion limit of ethanol is 3.28 % v/v. Molecular 
weight of ethanol 46 g/mole and 
p 0.79 g/ml)
a) Aspirator at 10
b) Aspirator at 5
Solution
From reference lists, the values of the lower explosion limit for higher safety is 1/5 of 
the lower limit (3.28% v/v), which means 0.656% v/v. Thus, for this calculation 
0.656% v/v is the ratio of vapour solvent / total vapour of ethanol.
(a) For setting aspirator at 10:
The maximum capacity of vapour solvent authorised can be calculated as follow:
20000 1/hr X 0.656% = 131.2 1/hr 
The equivalent of solvent can be calculated from The Law of Perfect Gas
PV = nRT  (1)
where P is the atmospheric pressure, V is the volume of solvent liquid, n is the 
number of solvent mole, R is the molar constant gas and T is the inlet temperature in 
degree Kelvin.
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Equation (1) may be rearranged to facilitate the direct determination of the mole/hr as 
follow:
n = PV/(RT) 
where P = 1 atm, R = 0.0823 atm 1 mol'^ K '\
In the operational condition, the inlet temperature is 100 °C +273= 373 K .
Therefore n = 1 x 131.2/ (0.0823 x 373) = 4.274 mole/ hr.
Since Molecular weight of ethanol = 46 g/mole and p= 0.79 g/ml 
The maximum feed rate of ethanol in ml/hr is
4.274 mole/hr x 46 g/mole = 248.87 ml/hr 
0.79 g/ml
Thus, feed rate of ethanol 248.87 ml/hr can be spray-dried with the aspirator at 10 in 
the safety conditions.
For a solution of 50% ethanol content, this mean that a maximum feed rate is
248.87 X i m  = 497.74 ml/hr 
50
note: the feed pump was set at 8
(b) For setting aspirator at 5, the maximum feed rate of a 50% ethanol content 
solution would be half of the former which is 248.87 ml/hr (the feed pump was set at 
4)
Another mode of calculation can be checked to ascertain that the conditions desired 
are safe.
Example 2
Could a 64% ethanol content solution be spray-dried at the inlet temperature 100 °C 
and feed rate 400 ml/hr with the maximal capacity of the aspirator.
Solution
Ethanol feed rate 400x 64/100 = 256 ml/hr
From the density and molecular weight of ethanol, the rate of ethanol in mole/hr is
256 ml/hr x 0.79 g/ml = 4.4 mole/hr 
46 g/mole
From equation (1) can be rearranged and calculate the rate of vapour in 1/hr as follow.
V= nRT/P
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Therefore V= 4.4 mole/hr x 0.0823 atm 1 mole'^ x 373 K
1 atm
= 135.07 1/hr
air/solvent ratio can be obtained from the rate of vapour and aspirator flow rate
air/solvent ratio = 135.07 x 100 = 0.34% v/v
(135.07+ 40,000)
0.34 % < 0.656%
Since this value is lower than the lower explosion limit of ethanol, it can be concluded 
that the process is safe.
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